

Presbyterian Health Plan Clear Cost Metal Plans Formulary, Therapeutic Class Listing

This list is in order by therapeutic class. To find a specific drug, use the search feature available in Adobe Acrobat Reader (keyboard shortcut: Ctrl+F).

What Is A Formulary?

A drug Formulary, or preferred drug list, is a continually updated list of medications and related products supported by current evidence-based medicine, judgment of physicians, pharmacists and other experts in the diagnosis and treatment of disease and preservation of health.

The primary purpose of the Formulary is to encourage the use of safe, effective and most affordable medications. Presbyterian Health Plan administers a "closed Formulary," which means that non-Formulary drugs are not routinely reimbursed by the plan. Medical exceptions policies provide access to non-Formulary medication when medical necessity is established.

The medications listed on the Formulary are subject to change per the management activities of Presbyterian Health Plan Pharmacy and Therapeutics Committee pursuant to N.M.S.A. 1978, §59A-23-7.13.

How Is the Formulary Managed?

Presbyterian Health Plan Pharmacy Services applies utilization management tools to Formulary drugs such as prior authorization, step therapy and quantity limits.

"Prior authorization" is a clinical evaluation process to determine if the requested healthcare service is medically necessary, a covered benefit, and if it is being delivered in the most appropriate healthcare setting. Our Medical Director, or other clinical professional, will review the requested healthcare service and, if it meets our requirements for coverage and medical necessity, it is authorized (approved) before those services are provided.

The prior authorization process and requirements are regularly reviewed and updated based on various factors including evidence-based practice guidelines, medical trends, practitioner/provider participation, state and federal regulations, and our policies and procedures.

"Step therapy" promotes the appropriate use of equally effective but lower-cost Formulary drugs first. With this program, prior use of one or more "prerequisite" drugs is required before a step-therapy medication will be covered. Prerequisite drugs are Food and Drug Administration (FDA)-approved and treat the same condition as the corresponding step-therapy drugs.

Formulary drugs may also limit coverage of quantities for certain drugs. These limits help your provider and pharmacist check that the medications are used appropriately and promote patient safety. Presbyterian Health Plan uses medical guidelines and FDA-approved recommendations from drug makers to set these coverage limits. Quantity limits include the following:

MPC032520 1 Effective: 09/15/2025

- **Maximum Daily Dose** limits quantities to a maximum number of dosage units (i.e., tablets, capsules, milliliters, milligrams, doses, etc.) in a single day. Limits are based on daily dosages shown to be safe and effective, and that are approved by FDA.
- **Quantity Limits Over Time** limits quantities to number of units (i.e., tablets, capsules, milliliters, milligrams, doses, etc.) in a defined period of time.

For the most up-to-date Formulary drug information, visit your searchable formulary found at https://client.formularynavigator.com/Search.aspx?siteCode=0324498195.

You may obtain more information by calling our local Pharmacy Services team, Monday through Friday, 7 a.m. to 6 p.m. at:

Presbyterian Health Plan Commercial HMO: (505) 923-5678 or 1-800-356-2219

You can also send pharmacy inquires to **AskPharmacy@phs.org**.

Some medications may be excluded as determined by benefit.

Definition of Status

lcon	Status	Definition
T1 Tier 1	Tier 1	Tier 1 Generics.
T2 Tier 2	Tier 2	Tier 2 Preferred Brand.
T3 Tier 3	Tier 3	Tier 3 Non-Preferred Drug.
T4 Tier 4	Tier 4	Tier 4 Preferred Specialty Pharmaceutical.
T5 Tier 5	Tier 5	Tier 5 Non-Preferred Specialty Pharmaceutical
\$0 Zego Dollar Cop sy	\$0	Zero Dollar Copay
MB Medical Banefit	Medical Benefit	A medical drug is any drug administered by a healthcare professional and is typically given in the member's home, provider's office, freestanding (ambulatory) infusion suite, or outpatient facility. Medical drugs may require a prior authorization, and some must be obtained through the Specialty Pharmacy network. For a complete list of medical drugs to determine which require prior authorization, please see the Presbyterian Health Plan Pharmacy Services website at www.phs.org
ME Medical Exception	Medical Exception	A process to request an exception to Formulary/Preferred Drug List (PDL) drug limitations and restrictions such as coverage of a non-Formulary drug, quantity limits and step-therapy requirements. The request can be made by a prescriber, a member or their appointed representative. The prescriber must provide information to support the medical exception request by fax, phone or mail.

lcon	Status	Definition
BE Benefit Exclusion	Benefit Exclusion	Benefit Exclusion not a covered benefit.
NF Non- Formulary	Non-Formulary	Non-Formulary drugs require a medical exception to the Formulary due to allergy, adverse reactions, or no response to all Formulary drugs. Medical exception policies provide access to non-Formulary medications when medical necessity is established.

Definition of Restrictions

Icon	Restriction	Definition
AL Age Umit	Age Restriction	A coverage limit based on minimum or maximum age of the member in order to ensure safety and effectiveness of treatments and drug dosages.
BH Behavioral Health	Behavioral Health	Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero cost share. *High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.
STI Security Securities Third des	Sexually Transmitted Infections	Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. *High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.
DX Diagnosis Code	Diagnosis Code	Diagnosis Code.
G Generic	Generic Indicator	A generic drug is approved by the FDA as having the same active ingredient and may be substituted for the brand name drug. Generally, generic drugs cost less than brand name drugs.
CB Capped Benefit	Insulin for Diabetes Cost Sharing Cap	The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total of \$25.00* per 30-day supply. *High Deductible Health Plan copays/coinsurances will be applied toward the deductible <i>but your copay</i> will not exceed a total \$25* per 30-day supply.
Limited Access	Limited Access	Limited Access.

lcon	Restriction	Definition	
NEDS	Non-Extended Day Supply	This drug is limited to a one-month supply.	
\$0 Zago Dollar Copay	\$0	Zero Dollar Copay	
Notes	Note	Note	
PA Prior Auth	Prior Authorization	Prior Authorization is a clinical evaluation process to determine if the requested health care service is medically necessary, a covered benefit, and if it is being delivered in the most appropriate health care setting. Our Medical Director or other clinical professional will review the requested health care service and, if it meets our requirements for coverage and medical necessity, it is authorized (approved) before those services are provided.	
QL Quartey Limit	Quantity Limit	Formulary drugs may also limit coverage of quantities for certain drugs. These limits help your doctor and pharmacist check that the medications are used appropriately and promote patient safety. Presbyterian Health Plan and Presbyterian Insurance Company uses medical guidelines and FDA-approved recommendations from drug makers to set these coverage limits. Quantity limits include the following: • Maximum Daily Dose limits quantities to a maximum number of dosage units (i.e., tablets, capsules, milliliters, milligrams, doses, etc.) in a single day. Limits are based on	
QL Questity Limit	Quantity Limit (Over Time)	daily dosages shown to be safe and effective, and that are approved by the FDA. Quantity Limits Over Time limits quantities to number of units (i.e., tablets, capsules, milliliters, milligrams, doses, etc.) in a	
SL	Schedule II Max Day	defined period of time. Schedule II maximum of 30-day supply.	
Schedule II Limit S P Specialty Pharmacy	Specialty Pharmacy	Most specialty pharmaceuticals require prior authorization and must be obtained through the Specialty Pharmacy network. Specialty pharmaceuticals are often high cost, typically greater than \$600 for up to a 30-day supply. Specialty pharmaceuticals are not available through the retail or mail order option and are limited to a 30-day supply. Certain specialty pharmaceuticals are limited to an initial fill up to a 15-day supply to ensure patients can tolerate the new medication.	
SFNS Split Fil- New Starts	Split Fill - New Starts	Certain specialty pharmaceuticals are limited to an initial fill up to a 15-day supply to ensure patients can tolerate the new medication.	
ST Stap Therdpy	Step Therapy	Step therapy promotes the appropriate use of equally effective but lower-cost Formulary drugs first. With this program, prior use of one or more "prerequisite" drugs is required before a step therapy medication will be covered. Prerequisite drugs are FDA-	

lcoı	n Restriction	Definition
		approved and treat the same condition as the corresponding step-therapy drug.

Can the Formulary change during the year?

The Formulary can change throughout the year. Some reasons why it can change include:

- New drugs are approved
- Existing drugs are removed from the market
- Prescription drugs are removed from the market
- Prescription drugs may become available over the counter (without a prescription)
- Brand-name drugs lose patent protection and generic versions become available
- Changes based on new clinical guidelines

If we remove drugs from our Formulary, add quantity limits, prior authorization, and/or step therapy restrictions on a drug; or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 60 days before the change becomes effective.

What if my drug is not covered?

You or your doctor can ask us to make an exception (**prior authorization**) to our coverage rules. We will work with your prescriber to get additional information to support your request. There are several types of exceptions that you can ask us to make.

- You can ask us to cover your drug even if it is not on our Formulary.
- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, we limit the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover more.

Our review of a prior authorization request will determine if the proposed care involves a covered service, is medically necessary and whether an alternative type of prescription medication should be pursued instead of, or before, the requested prescription medication. Our decisions concerning medical necessity and Formulary alternatives will be guided by current clinical guidelines and will be made by an appropriate medical professional. Prior authorization does not guarantee payment. We are not required to pay for an authorized service if your coverage ends before you receive the service.

Prior Authorization Request Processing Times

Standard Pharmacy Prior Authorization Requests:

When all necessary information is provided with the Drug Prior Authorization request, standard requests are processed as expeditiously as the member's health requires, within **72 hours** after the request is received.

Expedited Pharmacy Prior Authorization Requests:

When a member or their provider believes that waiting for a decision under the standard time frame could place the member's life, health or ability to regain maximum function in jeopardy, a prior

authorization can be expedited. These requests are processed within **24 hours** after the request is received.

If additional information is required in order to decide on a prior authorization, Presbyterian Pharmacy Services team will contact your prescriber by phone and, if necessary, by fax.

Once a decision has been made, you will receive a notification with either an approval or adverse determination.

Learn more about Presbyterian's Nondiscrimination Notice and Interpreter Services at https://www.phs.org/nondiscrimination.

Disclaimers

Please be sure a prescription drug benefit is part of your specific coverage before consulting this list. If you do not know which list is correct, you may obtain more information by calling our local Pharmacy Services team, Monday through Friday, 7 a.m. to 6 p.m. at:

Presbyterian Insurance Company Commercial: (505) 923 -6980 or 1-800-923-6980 Presbyterian Health Plan Commercial HMO: (505) 923-5678 or 1-800-356-2219

You can also send your pharmacy inquires to **AskPharmacy@phs.org**.

Coverage for some drugs may be limited to specific dosage forms and/or strengths. Your benefit design determines what is covered for you and what your copayment will be. Please refer to your benefit materials for your specific coverage information.

This list is not all-inclusive, nor does it imply a guarantee of coverage. In addition, coverage for some drugs listed may be limited to specific dosage forms and/or strengths. Substitution of a generic product for a brand-name drug is mandatory when a generic equivalent is available. If a member requests the brand-name drug in this situation, a pharmacy exception (prior authorization) may be required, and the member must pay the difference in cost between the generic and branded versions. Non-Formulary medications are not considered for coverage unless trial and failure of Formulary alternatives are documented.

Please see your Subscriber and Guide to Your Managed Care Plan (GSA) for further details.

CURRENT AS OF 9/15/2025

Drug Name	Tier	Notes		
ADHD/ANTI-NARCOLEPSY/ANTI- OBESITY/ANOREXIANTS				
*ADHD AGENT - SELECTIVE ALPHA ADRENERGIC AGONISTS***				
guanfacine hcl er oral tablet extended release 24 hour 1 mg, 2 mg, 3 mg, 4 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)		
*ADHD AGENT - SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR***				
atomoxetine hcl oral capsule 10 mg, 100 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)		
*AMPHETAMINE MIXTURES***				
amphetamine-dextroamphet er oral capsule extended release 24 hour 10 mg, 15 mg, 5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years)		

MPC032520 1 Effective: 09/15/2025

Drug Name	Tier	Notes
amphetamine-dextroamphet er oral capsule extended release 24 hour 20 mg, 25 mg, 30 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 6 Years)
amphetamine-dextroamphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 3 Years)
amphetamine-dextroamphetamine oral tablet 30 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 3 Years)
*AMPHETAMINES***		
dextroamphetamine sulfate er oral capsule extended release 24 hour 10 mg, 15 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days); AL (Min 6 Years and Max 18 Years)

MPC032520 2 Effective: 09/15/2025

Drug Name	Tier	Notes		
dextroamphetamine sulfate er oral capsule extended release 24 hour 5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL		
		(Min 6 Years and Max 18 Years)		
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.		
dextroamphetamine sulfate oral tablet 10 mg, 5 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 3 Years)		
lisdexamfetamine dimesylate oral capsule 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg	3	QL (30 EA per 30 days); AL (Min 6 Years); NDS		
		PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.		
methamphetamine hcl oral tablet 5 mg	3	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (150 EA per 30 days); AL (Min 6 Years and Max 18 Years)		
*ANALEPTICS***				
CAFCIT INTRAVENOUS SOLUTION 60 MG/3ML	MB			
caffeine citrate intravenous solution 60 mg/3ml	1			
caffeine citrate oral solution 20 mg/ml	1			
*ANOREXIANTS NON-AMPHETAMINE***	*ANOREXIANTS NON-AMPHETAMINE***			
benzphetamine hcl oral tablet 25 mg, 50 mg	3	PA; QL (90 EA per 30 days)		
diethylpropion hcl er oral tablet extended release 24 hour 75 mg	3	PA; QL (30 EA per 30 days)		
diethylpropion hcl oral tablet 25 mg	3	PA; QL (90 EA per 30 days)		
phendimetrazine tartrate er oral capsule extended release 24 hour 105 mg	3	PA; QL (30 EA per 30 days)		
phendimetrazine tartrate oral tablet 35 mg	3	PA; QL (180 EA per 30 days)		
phentermine hcl oral capsule 15 mg, 30 mg, 37.5 mg	3			

MPC032520 3 Effective: 09/15/2025

Drug Name	Tier	Notes		
ANTI-OBESITY AGENT COMBINATIONS**				
CONTRAVE ORAL TABLET EXTENDED RELEASE 12 HOUR 8-90 MG	3	QL (120 EA per 30 days)		
*DOPAMINE AND NOREPINEPHRINE REUPTAKE INHIBITORS (DNRIS)***				
SUNOSI ORAL TABLET 150 MG, 75 MG	5	PA; QL (30 EA per 30 days); AL (Min 18 Years)		
*HISTAMINE H3-RECEPTOR ANTAGONIST/INVERSE AGONISTS***				
WAKIX ORAL TABLET 17.8 MG	5	PA; LA; QL (60 EA per 30 days); AL (Min 6 Years)		
WAKIX ORAL TABLET 4.45 MG	5	PA; LA; QL (14 EA per 7 days); AL (Min 6 Years)		
*STIMULANTS - MISC.***				
armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg	1	PA; QL (30 EA per 30 days)		
dexmethylphenidate hcl er oral capsule extended release 24 hour 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 5 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years)		
dexmethylphenidate hcl oral tablet 10 mg, 2.5 mg, 5 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 6 Years)		
methylphenidate hcl er (cd) oral capsule extended release 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg	1	QL (30 EA per 30 days); AL (Min 6 Years)		
methylphenidate hcl er (osm) oral tablet extended release 18 mg, 27 mg, 54 mg	1	QL (30 EA per 30 days); AL (Min 6 Years)		
methylphenidate hcl er (osm) oral tablet extended release 36 mg	1	QL (60 EA per 30 days); AL (Min 6 Years)		
methylphenidate hcl er oral tablet extended release 10 mg	1	QL (60 EA per 30 days); AL (Min 6 Years)		
methylphenidate hcl er oral tablet extended release 20 mg	1	QL (90 EA per 30 days); AL (Min 6 Years)		

MPC032520 4 Effective: 09/15/2025

Drug Name	Tier	Notes
methylphenidate hcl er oral tablet extended release 24 hour 18 mg, 27 mg, 54 mg	1	QL (30 EA per 30 days); AL (Min 6 Years)
methylphenidate hcl er oral tablet extended release 24 hour 36 mg	1	QL (60 EA per 30 days); AL (Min 6 Years)
methylphenidate hcl oral solution 10 mg/5ml	1	PA; QL (450 ML per 30 days); AL (Min 6 Years and Max 12 Years)
methylphenidate hcl oral solution 5 mg/5ml	1	PA; QL (180 ML per 30 days); AL (Min 6 Years and Max 12 Years)
methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg	1	QL (90 EA per 30 days); AL (Min 3 Years)
methylphenidate hcl oral tablet chewable 10 mg, 2.5 mg, 5 mg	3	QL (90 EA per 30 days); AL (Min 3 Years)
modafinil oral tablet 100 mg, 200 mg	1	QL (30 EA per 30 days)
AMINOGLYCOSIDES		
*AMINOGLYCOSIDES***		
amikacin sulfate injection solution 50 mg/ml	MB	
gentamicin in saline intravenous solution 0.8-0.9 mg/ml-%	MB	
neomycin sulfate oral tablet 500 mg	1	
paromomycin sulfate oral capsule 250 mg	3	
tobramycin inhalation nebulization solution 300 mg/5ml	5	NDS; SP
tobramycin sulfate injection solution 1.2 gm/30ml, 10 mg/ml, 80 mg/2ml	МВ	
ANALGESICS - ANTI-INFLAMMATORY		
*ANTIRHEUMATIC - JANUS KINASE (JAK) INHIBITORS***		
RINVOQ LQ ORAL SOLUTION 1 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (360 ML per 30 days); NDS; SP
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 15 MG, 30 MG	4	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 45 MG	4	PA; DX (Diagnosis Validation Required); QL (90 EA per 365 days); NDS; SP
XELJANZ ORAL SOLUTION 1 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (300 ML per 30 days); AL (Min 2 Years and Max 12 Years); NDS; SP
XELJANZ ORAL TABLET 10 MG, 5 MG	4	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP

MPC032520 5 Effective: 09/15/2025

Drug Name	Tier	Notes
XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HOUR 11 MG	4	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP
XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HOUR 22 MG	4	PA; DX (Diagnosis Validation Required); QL (112 EA per 6 days); NDS; SP
*ANTI-TNF-ALPHA - MONOCLONAL ANTIBODIES***		
AMJEVITA SUBCUTANEOUS SOLUTION AUTO- INJECTOR 40 MG/0.4ML, 80 MG/0.8ML	4	PA; DX (Diagnosis Validation Required); QL (1.6 ML per 28 days); NDS; SP
AMJEVITA SUBCUTANEOUS SOLUTION AUTO- INJECTOR 40 MG/0.8ML	4	PA; DX (Diagnosis Validation Required); QL (3.2 EA per 28 days); NDS; SP
AMJEVITA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.4ML	4	PA; DX (Diagnosis Validation Required); QL (1.6 ML per 28 days); NDS; SP
AMJEVITA-PED 10KG TO <15KG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.2ML	4	PA; DX (Diagnosis Validation Required); QL (0.4 ML per 28 days); NDS; SP
AMJEVITA-PED 15KG TO <30KG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/0.2ML	4	PA; DX (Diagnosis Validation Required); QL (0.4 ML per 28 days); NDS; SP
AMJEVITA-PED 15KG TO <30KG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/0.4ML	4	PA; DX (Diagnosis Validation Required); QL (0.8 EA per 28 days); NDS; SP
HUMIRA (1 PEN) SUBCUTANEOUS AUTO- INJECTOR KIT 80 MG/0.8ML	4	PA; DX (Diagnosis Validation Required); QL (2 EA per 28 days); NDS; SP
HUMIRA (2 PEN) SUBCUTANEOUS AUTO- INJECTOR KIT 40 MG/0.4ML	4	PA; DX (Diagnosis Validation Required); QL (2 EA per 28 days); NDS; SP
HUMIRA (2 PEN) SUBCUTANEOUS AUTO- INJECTOR KIT 40 MG/0.8ML	4	DX (Diagnosis Validation Required); QL (2 EA per 28 days); NDS; SP
HUMIRA (2 PEN) SUBCUTANEOUS AUTO- INJECTOR KIT 80 MG/0.8ML	4	PA; DX (Diagnosis Validation Required); QL (1 EA per 28 days); NDS; SP
HUMIRA (2 PEN) SUBCUTANEOUS PEN- INJECTOR KIT 40 MG/0.4ML, 40 MG/0.8ML	4	PA; QL (2 EA per 28 days); NDS; SP
HUMIRA (2 PEN) SUBCUTANEOUS PEN- INJECTOR KIT 80 MG/0.8ML	4	PA; QL (1 EA per 28 days); NDS; SP
HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML	4	PA; DX (Diagnosis Validation Required); QL (2 EA per 28 days); NDS; SP
HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 40 MG/0.8ML	4	PA; QL (2 EA per 28 days); NDS; SP

MPC032520 6 Effective: 09/15/2025

Drug Name	Tier	Notes
HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 80 MG/0.8ML	4	PA; DX (Diagnosis Validation Required); QL (2 EA per 28 days); NDS; SP
HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML, 80 MG/0.8ML	4	PA; QL (2 EA per 28 days); NDS; SP
HUMIRA-PED<40KG CROHNS STARTER SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML & 40MG/0.4ML	4	PA; QL (1 EA per 30 days); NDS; SP
HUMIRA-PED>/=40KG CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML	4	PA; QL (1 EA per 30 days); NDS; SP
HUMIRA-PED>/=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 80 MG/0.8ML	4	PA; QL (2 EA per 28 days); NDS; SP
HUMIRA-PED>/=40KG UC STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML	4	PA; QL (2 EA per 28 days); NDS; SP
HUMIRA-PSORIASIS/UVEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 80 MG/0.8ML & 40MG/0.4ML	4	PA; DX (Diagnosis Validation Required); QL (2 EA per 28 days); NDS; SP
HUMIRA-PSORIASIS/UVEIT STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML & 40MG/0.4ML	4	PA; QL (2 EA per 28 days); NDS; SP
*CYCLOOXYGENASE 2 (COX-2) INHIBITORS***		
celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg	1	QL (60 EA per 30 days)
*GOLD COMPOUNDS***		
RIDAURA ORAL CAPSULE 3 MG	2	
*INTERLEUKIN-6 RECEPTOR INHIBITORS***		
KEVZARA SUBCUTANEOUS SOLUTION AUTO- INJECTOR 150 MG/1.14ML, 200 MG/1.14ML	4	PA; DX (Diagnosis Validation Required); QL (2.28 ML per 28 days); NDS; SP
KEVZARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/1.14ML, 200 MG/1.14ML	4	PA; DX (Diagnosis Validation Required); QL (2.28 ML per 28 days); NDS; SP
TYENNE INTRAVENOUS SOLUTION 200 MG/10ML, 400 MG/20ML, 80 MG/4ML	MB	PA; DX (Diagnosis Validation Required); STI (05/2025: 2026 Addition); SP
TYENNE SUBCUTANEOUS SOLUTION AUTO- INJECTOR 162 MG/0.9ML	4	PA; DX (Diagnosis Validation Required); STI (05/2025: 2026 Addition); QL (3.6 ML per 28 days); NDS; SP

MPC032520 7 Effective: 09/15/2025

Drug Name	Tier	Notes
TYENNE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 162 MG/0.9ML	4	PA; DX (Diagnosis Validation Required); STI (05/2025: 2026 Addition); QL (3.6 ML per 28 days); NDS; SP
*NONSTEROIDAL ANTI-INFLAMMATORY AGENT COMBINATIONS***		
diclofenac-misoprostol oral tablet delayed release 50- 0.2 mg, 75-0.2 mg	3	
*NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS)***		
diclofenac sodium er oral tablet extended release 24 hour 100 mg	1	
diclofenac sodium oral tablet delayed release 25 mg, 50 mg, 75 mg	1	
etodolac er oral tablet extended release 24 hour 400 mg, 500 mg, 600 mg	1	
etodolac oral capsule 200 mg, 300 mg	1	
etodolac oral tablet 400 mg, 500 mg	1	
fenoprofen calcium oral tablet 600 mg	2	
flurbiprofen oral tablet 100 mg, 50 mg	1	
ibuprofen oral tablet 400 mg, 600 mg, 800 mg	1	
indomethacin er oral capsule extended release 75 mg	1	
indomethacin oral capsule 25 mg, 50 mg	1	
ketoprofen oral capsule 50 mg, 75 mg	1	
ketorolac tromethamine intramuscular solution 30 mg/ml	МВ	
ketorolac tromethamine oral tablet 10 mg	1	QL (20 EA per 30 days)
meclofenamate sodium oral capsule 100 mg, 50 mg	2	
meloxicam oral tablet 15 mg, 7.5 mg	1	
nabumetone oral tablet 500 mg, 750 mg	1	
naproxen dr oral tablet delayed release 375 mg, 500 mg	1	
naproxen oral tablet 250 mg, 375 mg, 500 mg	1	
naproxen sodium oral tablet 275 mg, 550 mg	1	
oxaprozin oral tablet 600 mg	1	
piroxicam oral capsule 10 mg, 20 mg	1	
sulindac oral tablet 150 mg, 200 mg	1	
tolmetin sodium oral capsule 400 mg	2	
tolmetin sodium oral tablet 600 mg	2	

MPC032520 8 Effective: 09/15/2025

Drug Name	Tier	Notes	
*PHOSPHODIESTERASE 4 (PDE4) INHIBITORS***			
OTEZLA ORAL TABLET 30 MG	4	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP	
OTEZLA ORAL TABLET THERAPY PACK 10 & 20 & 30 MG	4	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP	
*PYRIMIDINE SYNTHESIS INHIBITORS***			
leflunomide oral tablet 10 mg, 20 mg	1		
*SELECTIVE COSTIMULATION MODULATORS***			
ORENCIA CLICKJECT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 125 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (4 ML per 28 days); NDS; SP	
ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 125 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (4 ML per 28 days); NDS; SP	
ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 50 MG/0.4ML	4	PA; DX (Diagnosis Validation Required); QL (1.6 ML per 28 days); NDS; SP	
ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 87.5 MG/0.7ML	4	PA; DX (Diagnosis Validation Required); QL (2.8 ML per 28 days); NDS; SP	
*SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR AGENTS***			
ENBREL MINI SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (4 ML per 28 days); NDS; SP	
ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML	4	PA; DX (Diagnosis Validation Required); QL (2 ML per 28 days); NDS; SP	
ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML	4	PA; DX (Diagnosis Validation Required); QL (2 ML per 28 days); NDS; SP	
ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 50 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (4 ML per 28 days); NDS; SP	
ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (4 ML per 28 days); NDS; SP	
ANALGESICS - NONNARCOTIC			
*ANALGESICS-SEDATIVES***			
butalbital-acetaminophen oral tablet 50-325 mg	1	QL (6 EA per 1 day)	
butalbital-apap-caffeine oral tablet 50-325-40 mg	1	QL (6 EA per 1 day)	

MPC032520 9 Effective: 09/15/2025

Drug Name	Tier	Notes
*SALICYLATES***		
aspirin ec oral tablet delayed release 325 mg, 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
aspirin low dose oral tablet 81 mg	1	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
aspirin low dose oral tablet delayed release 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
aspirin oral tablet 325 mg, 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
aspirin oral tablet delayed release 325 mg, 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
aspirtab oral tablet delayed release 324 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
BAYER ASPIRIN ORAL TABLET 325 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
BAYER ASPIRIN ORAL TABLET DELAYED RELEASE 325 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
BAYER ASPIRIN REGIMEN ORAL TABLET DELAYED RELEASE 325 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
childrens aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
cvs aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
cvs aspirin oral tablet delayed release 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
cvs childrens aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
diflunisal oral tablet 500 mg	1	
ec-81 aspirin oral tablet delayed release 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
eq aspirin low dose oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
eq aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
eq aspirin oral tablet delayed release 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
eq aspirin oral tablet delayed release 500 mg	1	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
eq childrens aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
eql aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
eql childrens aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)

MPC032520 10 Effective: 09/15/2025

Drug Name	Tier	Notes
gnp aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
gnp aspirin oral tablet delayed release 325 mg, 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
hm aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
hm aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
MEDI-FIRST ASPIRIN ORAL TABLET 325 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
MEDIQUE ASPIRIN ORAL TABLET 325 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
mm aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
NORWICH ASPIRIN ORAL TABLET 325 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
px aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
px aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
px enteric aspirin oral tablet delayed release 325 mg, 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
qc aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
qc aspirin oral tablet delayed release 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
qc childrens aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
ra aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
ra aspirin oral tablet 500 mg	1	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
ra childrens aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
salsalate oral tablet 500 mg, 750 mg	1	
sb aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
sb aspirin oral tablet delayed release 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
sb childrens aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
sm aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
sm childrens aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)

MPC032520 11 Effective: 09/15/2025

Drug Name	Tier	Notes
ST JOSEPH ADULT ORAL TABLET CHEWABLE 75 MG	1	AL (Min 45 Years and Max 79 Years)
ST JOSEPH ASPIRIN ORAL TABLET CHEWABLE 81 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
ST JOSEPH ASPIRIN ORAL TABLET DELAYED RELEASE 81 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
tgt aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
tgt aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
tgt aspirin oral tablet delayed release 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
tgt childrens aspirin oral tablet chewable 81 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
th aspirin oral tablet 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
th enteric aspirin oral tablet delayed release 325 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 45 Years)
ANALGESICS - OPIOID		
*CODEINE COMBINATIONS***		
acetaminophen-codeine #2 oral tablet 300-15 mg	1	PA; QL (13 EA per 1 day); AL (Min 12 Years)
acetaminophen-codeine #3 oral tablet 300-30 mg	1	PA; QL (13 EA per 1 day); AL (Min 12 Years)
acetaminophen-codeine #4 oral tablet 300-60 mg	1	PA; QL (13 EA per 1 day); AL (Min 12 Years)
acetaminophen-codeine oral solution 120-12 mg/5ml, 300-30 mg/12.5ml	1	PA; QL (166 ML per 1 day); AL (Min 12 Years)
acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg, 300-60 mg	1	PA; QL (13 EA per 1 day); AL (Min 12 Years)
butalbital-apap-caff-cod oral capsule 50-325-40-30 mg	1	PA; QL (6 EA per 1 day); AL (Min 12 Years)
butalbital-asa-caff-codeine oral capsule 50-325-40-30 mg	1	PA; QL (6 EA per 1 day); AL (Min 12 Years)
*HYDROCODONE COMBINATIONS***		
hydrocodone-acetaminophen oral solution 2.5-108 mg/5ml	1	QL (180 ML per 30 days)
hydrocodone-acetaminophen oral solution 5-217 mg/10ml, 7.5-325 mg/15ml	1	QL (180 ML per 1 day)
hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg	1	QL (12 EA per 1 day)
hydrocodone-acetaminophen oral tablet 10-650 mg, 10-660 mg	1	QL (6 EA per 1 day)
hydrocodone-acetaminophen oral tablet 2.5-500 mg	1	QL (8 EA per 1 day)
*OPIOID AGONISTS***		

MPC032520 12 Effective: 09/15/2025

Drug Name	Tier	Notes
codeine sulfate oral tablet 15 mg, 30 mg	1	PA; QL (180 EA per 30 days); AL (Min 12 Years)
codeine sulfate oral tablet 60 mg	2	PA; QL (180 EA per 30 days); AL (Min 12 Years)
fentanyl citrate (pf) injection solution 100 mcg/2ml, 1000 mcg/20ml, 250 mcg/5ml, 2500 mcg/50ml, 500 mcg/10ml	MB	
fentanyl citrate (pf) injection solution cartridge 100 mcg/2ml	MB	
fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr	1	QL (10 EA per 30 days)
hydrocodone bitartrate er oral tablet er 24 hour abusedeterrent 30 mg, 40 mg, 60 mg	3	ST; QL (30 EA per 30 days)
hydromorphone hcl er oral tablet er 24 hour abusedeterrent 12 mg, 16 mg, 8 mg	3	ST; QL (30 EA per 30 days)
hydromorphone hcl er oral tablet extended release 24 hour 12 mg, 16 mg, 8 mg	3	
hydromorphone hcl injection solution 1 mg/ml	MB	
hydromorphone hcl oral tablet 2 mg, 4 mg, 8 mg	1	QL (180 EA per 30 days)
KADIAN ORAL CAPSULE EXTENDED RELEASE 24 HOUR 200 MG	3	ST; QL (30 EA per 30 days)
levorphanol tartrate oral tablet 2 mg	3	QL (180 EA per 30 days)
meperidine hcl injection solution 10 mg/ml	MB	
meperidine hcl oral solution 50 mg/5ml	2	QL (2000 ML per 30 days)
methadone hcl oral solution 10 mg/5ml, 5 mg/5ml	2	QL (900 ML per 30 days)
methadone hcl oral tablet 10 mg, 5 mg	1	QL (180 EA per 30 days)
morphine sulfate (concentrate) oral solution 100 mg/5ml, 20 mg/ml	1	QL (180 ML per 30 days)
morphine sulfate er beads oral capsule extended release 24 hour 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg	3	ST; QL (30 EA per 30 days)
morphine sulfate er oral capsule extended release 24 hour 10 mg, 100 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg	3	ST; QL (60 EA per 30 days)
morphine sulfate er oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg	1	QL (180 EA per 30 days)
morphine sulfate intravenous solution 25 mg/ml	MB	
morphine sulfate oral solution 10 mg/5ml, 20 mg/5ml	1	QL (1000 ML per 30 days)
morphine sulfate oral tablet 15 mg, 30 mg	1	QL (180 EA per 30 days)
NUCYNTA ER ORAL TABLET EXTENDED RELEASE 12 HOUR 100 MG, 150 MG, 200 MG, 250 MG, 50 MG	3	PA; QL (60 EA per 30 days)
oxycodone hcl oral concentrate 100 mg/5ml	1	QL (180 ML per 30 days)
oxycodone hcl oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg	1	QL (180 EA per 30 days)

MPC032520 13 Effective: 09/15/2025

Drug Name	Tier	Notes
oxymorphone hcl er oral tablet extended release 12 hour 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg	3	ST; QL (60 EA per 30 days)
oxymorphone hcl oral tablet 10 mg	3	ST; QL (360 EA per 30 days)
oxymorphone hcl oral tablet 5 mg	3	ST; QL (180 EA per 30 days)
tramadol hcl er oral tablet extended release 24 hour 100 mg	3	PA; QL (90 EA per 30 days); AL (Min 12 Years)
tramadol hcl er oral tablet extended release 24 hour 200 mg	3	PA; QL (30 EA per 30 days); AL (Min 12 Years)
tramadol hcl oral tablet 50 mg	1	PA; QL (240 EA per 30 days); AL (Min 12 Years)
*OPIOID COMBINATIONS***		
ENDOCET ORAL TABLET 2.5-325 MG	1	QL (12 EA per 1 day)
oxycodone-acetaminophen oral capsule 5-500 mg	1	QL (8 EA per 1 day)
oxycodone-acetaminophen oral solution 5-325 mg/5ml	1	QL (60 ML per 30 days)
oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg	1	QL (12 EA per 1 day)
oxycodone-acetaminophen oral tablet 10-650 mg	1	QL (6 EA per 1 day)
oxycodone-acetaminophen oral tablet 7.5-500 mg	1	QL (8 EA per 1 day)
oxycodone-aspirin oral tablet 4.8355-325 mg	1	QL (180 EA per 30 days)
ROXICET ORAL TABLET 5-325 MG	1	QL (12 EA per 1 day)
XARTEMIS XR ORAL TABLET EXTENDED RELEASE 7.5-325 MG	3	PA; QL (120 EA per 30 days)
*OPIOID PARTIAL AGONISTS***		
BRIXADI (WEEKLY) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 16 MG/0.32ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan
FREI IEEED STRINGE TO MIGIO. 32MIE		copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.28 ML per 28 days)
BRIXADI (WEEKLY) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 24 MG/0.48ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
	7	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.92 ML per 28 days)

MPC032520 14 Effective: 09/15/2025

Drug Name	Tier	Notes
BRIXADI (WEEKLY) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 32 MG/0.64ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2.56 ML per 28 days)
BRIXADI (WEEKLY) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 8 MG/0.16ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.64 ML per 28 days)
BRIXADI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 128 MG/0.36ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.36 ML per 28 days)
BRIXADI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 64 MG/0.18ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.18 ML per 28 days)
BRIXADI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 96 MG/0.27ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.27 ML per 28 days)

MPC032520 15 Effective: 09/15/2025

Drug Name	Tier	Notes
buprenorphine hcl sublingual tablet sublingual 2 mg	3	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to
		deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (3 EA per 1 day); AL (Min 16 Years)
		PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
buprenorphine hcl sublingual tablet sublingual 8 mg	3	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (4 EA per 1 day); AL (Min 16 Years)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
buprenorphine hcl-naloxone hcl sublingual film 12-3 mg	3	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 16 Years)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
buprenorphine hcl-naloxone hcl sublingual film 2-0.5 mg, 4-1 mg, 8-2 mg	3	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 16 Years)

MPC032520 16 Effective: 09/15/2025

Drug Name	Tier	Notes
buprenorphine hcl-naloxone hcl sublingual tablet sublingual 2-0.5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 16 Years)
buprenorphine hcl-naloxone hcl sublingual tablet sublingual 8-2 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days); AL (Min 16 Years)
butorphanol tartrate nasal solution 10 mg/ml	3	QL (10 ML per 30 days)
nalbuphine hcl injection solution 10 mg/ml	1	
SUBLOCADE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.5ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.5 ML per 30 days)
SUBLOCADE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300 MG/1.5ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.5 ML per 30 days); NDS; SP
TALWIN INJECTION SOLUTION 30 MG/ML	MB	
*PENTAZOCINE COMBINATIONS***		
pentazocine-acetaminophen oral tablet 25-650 mg	1	QL (6 EA per 1 day)
*TRAMADOL COMBINATIONS***		

MPC032520 17 Effective: 09/15/2025

*ANDROGENS-*** *ANDROGENS*** *ANDROGENS*** *ANDRODERM TRANSDERMAL PATCH 24 HOUR 2 *ANDROY ORAL TABLET 10 MG danazol oral capsule 100 mg, 200 mg, 50 mg testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml testosterone enanthate intramuscular solution 200 mg/ml, 200 mg/ml testosterone transdermal gel 1,62 %, 20.25 mg/act (1,62%), 40.5 mg/2.5gm (1,62%) testosterone transdermal gel 10 mg/act (2%) testosterone transdermal gel 10 mg/act (1%), 50 mg/sgm (1%) testosterone transdermal gel 20.25 mg/act (1%), 50 testosterone transdermal gel 20.25 mg/act (1%), 50 testosterone transdermal gel 20.25 mg/act (1%) *ANORECTAL AND RELATED PRODUCTS* **INTRARECTAL STEROIDS*** **CORTIFOAM RECTAL FOAM 10 % **APROCTOFOAM HC EXTERNAL FOAM 1-1 % ilidocaine-hydrocortisone ace rectal cream 3-0.5 % 1	Drug Name	Tier	Notes
*ANDROGENS*** ANDRODERM TRANSDERMAL PATCH 24 HOUR 2 3 PA; QL (60 EA per 30 days) MG/24HR, 4 MG/24HR 3 PA; QL (120 EA per 30 days) ANDROX PORAL TABLET 10 MG 3 PA; QL (120 EA per 30 days) danazol oral cepsule 100 mg, 200 mg, 50 mg 1 lestosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml lestosterone enanthate intramuscular solution 200 mg/ml lestosterone transdermal gel 1.62 %, 20.25 mg/act (1.62%), 40.5 mg/2.5gm (1.62%) 3 QL (150 GM per 30 days) lestosterone transdermal gel 10 mg/act (2%) 3 QL (120 GM per 30 days) lestosterone transdermal gel 12.5 mg/act (1%), 50 mg/5gm (1%) lestosterone transdermal gel 20.25 mg/1.25gm 3 QL (75 GM per 30 days) lestosterone transdermal gel 20.25 mg/1.25gm 3 QL (75 GM per 30 days) lestosterone transdermal gel 25 mg/2.5gm (1%) lestosterone transdermal gel 25 mg/2.5gm (1%) *ANORECTAL AND RELATED PRODUCTS* *INTRARECTAL STEROIDS*** CORTIFOAM RECTAL FOAM 10 % 3 hydrocortisone rectal enema 100 mg/60ml *RECTAL ANESTHETIC/STEROIDS** hydrocortisone ace premoxine rectal cream 3-0.5 % 1 lidocaine-hydrocort (perianal) external cream 3-0.5 % 1 lidocaine-hydrocortisone ace rectal cream 3-0.5 % 1 lidocaine-hydrocortisone ace rectal cream 3-0.5 % 1 PROCTOFOAM HC EXTERNAL FOAM 1-1 % 2 PROCTOFOAM HC EXTERNAL FOAM 1-1 % 2 PROCTOFOAM HC RECTAL FOAM 1-1 % 3 *RECTAL LOCAL ANESTHETICS*** pramoxine hci rectal foam 1 % 1 PROCTOFOAM EXTERNAL FOAM 1-1 % 2 *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 hydrocortisone rectal cream 2.5 % 1 hydrocortisone rectal cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	tramadol-acetaminophen oral tablet 37.5-325 mg	1	PA; QL (300 EA per 30 days); AL (Min 12 Years)
ANDRODERM TRANSDERMAL PATCH 24 HOUR 2 3	*ANDROGENS-ANABOLIC*	-	•
MG/24HR, 4 MG/24HR ANDROXY ORAL TABLET 10 MG danazol oral capsule 100 mg, 200 mg, 50 mg testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml testosterone enanthate intramuscular solution 200 mg/ml, 200 mg/ml testosterone transdermal gel 1.62 %, 20.25 mg/act (1.62%), 40.5 mg/2.5gm (1.62%) testosterone transdermal gel 1.62 %, 20.25 mg/act (1.62%), 40.5 mg/2.5gm (1.62%) testosterone transdermal gel 10 mg/act (2%) testosterone transdermal gel 12.5 mg/act (1%), 50 mg/5gm (1%) testosterone transdermal gel 20.25 mg/1.25gm 3 QL (300 GM per 30 days) testosterone transdermal gel 20.25 mg/1.25gm 3 QL (75 GM per 30 days) testosterone transdermal gel 25 mg/2.5gm (1%) testosterone transdermal gel 25 mg/2.5gm (1%) *ANORECTAL AND RELATED PRODUCTS* **INTRARECTAL STEROIDS*** corniforam Rectal croam 100 mg/60ml *RECTAL ANESTHETIC/STEROIDS*** hydrocortisone ace-pramoxine rectal cream 3-0.5 % 1 lidocaine-hydrocort (perianal) external cream 3-0.5 % 1 PROCTOFOAM HC EXTERNAL FOAM 1-1 % 2 PROCTOFOAM HC RETAL ANESTHETICS*** pramoxine hcl rectal foam 1 % *RECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % 1 PROCTOFOAM EXTERNAL FOAM 1-1 % 2 PROCTOFOAM EXTERNAL FOAM 1-1 % 3 *RECTAL STEROIDS*** hydrocortisone ace testal cream 2.5 % 1 hydrocortisone rectal cream 2.5 %	*ANDROGENS***		
danazol oral capsule 100 mg, 200 mg, 50 mg	ANDRODERM TRANSDERMAL PATCH 24 HOUR 2 MG/24HR, 4 MG/24HR	3	PA; QL (60 EA per 30 days)
testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml testosterone enanthate intramuscular solution 200 mg/ml testosterone transdermal gel 1.62 %, 20.25 mg/act (1.62%), 40.5 mg/2.5gm (1.62%)	ANDROXY ORAL TABLET 10 MG	3	PA; QL (120 EA per 30 days)
### testosterone enanthate intramuscular solution 200 ### testosterone transdermal gel 1.62 %, 20.25 mg/act (1.62%), 40.5 mg/2.5gm (1.62%) ### testosterone transdermal gel 1.62 %, 20.25 mg/act (1.62%), 40.5 mg/2.5gm (1.62%) ### testosterone transdermal gel 10 mg/act (2%) ### testosterone transdermal gel 12.5 mg/act (1%), 50 mg/5gm (1%) ### testosterone transdermal gel 20.25 mg/1.25gm ### testosterone transdermal gel 20.25 mg/1.25gm ### testosterone transdermal gel 20.25 mg/1.25gm ### testosterone transdermal gel 25 mg/2.5gm (1%) ### ANORECTAL AND RELATED ### PRODUCTS* ### INTRARECTAL STEROIDS*** ### CORTIFOAM RECTAL FOAM 10 % ### hydrocortisone rectal enema 100 mg/60ml ### RECTAL ANESTHETIC/STEROIDS*** ### hydrocortisone ace-pramoxine rectal cream 3-0.5 % ### Ilidocaine-hydrocort (perianal) external cream 3-0.5 % ### Ilidocaine-hydrocortisone ace rectal cream 3-0.5 % ### PROCTOFOAM HC EXTERNAL FOAM 1-1 % ### PROCTOFOAM HC EXTERNAL FOAM 1-1 % ### PROCTOFOAM EXTERNAL FOAM 1-1 % ### PROCTOFOAM EXTERNAL FOAM 1-1 % #### In PROCTOFOAM EXTERNAL FOAM 1-1 % #### In PROCTOFOAM EXTERNAL FOAM 1-1 % ##### In PROCTOFOAM EXTERNAL FOAM 1-1 % ######### In PROCTOFOAM EXTERNAL FOAM 1-1 % ####################################	danazol oral capsule 100 mg, 200 mg, 50 mg	1	
### Table 1	testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml	1	
(1.62%), 40.5 mg/2.5gm (1.62%) 3	testosterone enanthate intramuscular solution 200 mg/ml	2	
testosterone transdermal gel 12.5 mg/act (1%), 50 mg/5gm (1%) 1 QL (300 GM per 30 days) 1 testosterone transdermal gel 20.25 mg/1.25gm 3 QL (75 GM per 30 days) 1 testosterone transdermal gel 25 mg/2.5gm 3 QL (75 GM per 30 days) 1 QL (75 GM per 30 d	testosterone transdermal gel 1.62 %, 20.25 mg/act (1.62%), 40.5 mg/2.5gm (1.62%)	3	QL (150 GM per 30 days)
testosterone transdermal gel 20.25 mg/1.25gm (1.62%) 1 QL (75 GM per 30 days) testosterone transdermal gel 25 mg/2.5gm (1%) 1 QL (75 GM per 30 days) testosterone transdermal gel 25 mg/2.5gm (1%) 1 QL (75 GM per 30 days) testosterone transdermal gel 25 mg/2.5gm (1%) 1 QL (75 GM per 30 days) TANORECTAL AND RELATED PRODUCTS* *INTRARECTAL STEROIDS**** CORTIFOAM RECTAL FOAM 10 % 1 *RECTAL ANESTHETIC/STEROIDS*** hydrocortisone ace-pramoxine rectal cream 1-1 % 1 lidocaine-hydrocort (perianal) external cream 3-0.5 % 1 lidocaine-hydrocortisone ace rectal cream 3-0.5 % 1 PROCTOFOAM HC EXTERNAL FOAM 1-1 % 2 PROCTOFOAM HC RECTAL FOAM 1-1 % 2 PROCTOFOAM EXTERNAL FOAM 1-1 % 2 PROCTOFOAM EXTERNAL FOAM 1 % 3 TRECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % 1 PROCTOFOAM EXTERNAL FOAM 1 % 3 *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 hydrocortisone rectal cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	testosterone transdermal gel 10 mg/act (2%)	3	QL (120 GM per 30 days)
(1.62%) testosterone transdermal gel 25 mg/2.5gm (1%) *ANORECTAL AND RELATED PRODUCTS* *INTRARECTAL STEROIDS*** CORTIFOAM RECTAL FOAM 10 % *RECTAL ANESTHETIC/STEROIDS*** hydrocortisone rectal enema 100 mg/60ml *RECTAL ANESTHETIC/STEROIDS*** hydrocortisone ace-pramoxine rectal cream 1-1 % Ilidocaine-hydrocort (perianal) external cream 3-0.5 % IPROCTOFOAM HC EXTERNAL FOAM 1-1 % *RECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % 1 PROCTOFOAM EXTERNAL FOAM 1 % *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 PROCTOFOAM EXTERNAL FOAM 1 % *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 PROCTOFOAM EXTERNAL FOAM 1 % *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	testosterone transdermal gel 12.5 mg/act (1%), 50 mg/5gm (1%)	1	QL (300 GM per 30 days)
ANORECTAL AND RELATED PRODUCTS *INTRARECTAL STEROIDS*** *CORTIFOAM RECTAL FOAM 10 % 3 hydrocortisone rectal enema 100 mg/60ml 1 *RECTAL ANESTHETIC/STEROIDS*** hydrocortisone ace-pramoxine rectal cream 1-1 % 1 lidocaine-hydrocort (perianal) external cream 3-0.5 % 1 lidocaine-hydrocortisone ace rectal cream 3-0.5 % 1 PROCTOFOAM HC EXTERNAL FOAM 1-1 % 2 PROCTOFOAM HC RECTAL FOAM 1-1 % 2 *RECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % 1 PROCTOFOAM EXTERNAL FOAM 1 % 3 *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 hydrocortisone rectal cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	testosterone transdermal gel 20.25 mg/1.25gm (1.62%)	3	QL (75 GM per 30 days)
*INTRARECTAL STEROIDS*** *CORTIFOAM RECTAL FOAM 10 % 3	testosterone transdermal gel 25 mg/2.5gm (1%)	1	QL (75 GM per 30 days)
CORTIFOAM RECTAL FOAM 10 % hydrocortisone rectal enema 100 mg/60ml *RECTAL ANESTHETIC/STEROIDS*** hydrocortisone ace-pramoxine rectal cream 1-1 % lidocaine-hydrocort (perianal) external cream 3-0.5 % PROCTOFOAM HC EXTERNAL FOAM 1-1 % PROCTOFOAM HC RECTAL FOAM 1-1 % 2 *RECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % PROCTOFOAM EXTERNAL FOAM 1 % 3 *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	*ANORECTAL AND RELATED PRODUCTS*		
hydrocortisone rectal enema 100 mg/60ml *RECTAL ANESTHETIC/STEROIDS*** hydrocortisone ace-pramoxine rectal cream 1-1 % lidocaine-hydrocort (perianal) external cream 3-0.5 % lidocaine-hydrocortisone ace rectal cream 3-0.5 % 1 PROCTOFOAM HC EXTERNAL FOAM 1-1 % 2 PROCTOFOAM HC RECTAL FOAM 1-1 % 2 *RECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % 1 PROCTOFOAM EXTERNAL FOAM 1 % 3 *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	*INTRARECTAL STEROIDS***		
*RECTAL ANESTHETIC/STEROIDS*** hydrocortisone ace-pramoxine rectal cream 1-1 % 1 lidocaine-hydrocort (perianal) external cream 3-0.5 % 1 lidocaine-hydrocortisone ace rectal cream 3-0.5 % 1 PROCTOFOAM HC EXTERNAL FOAM 1-1 % 2 PROCTOFOAM HC RECTAL FOAM 1-1 % 2 *RECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % 1 PROCTOFOAM EXTERNAL FOAM 1 % 3 *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 hydrocortisone rectal cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	CORTIFOAM RECTAL FOAM 10 %	3	
hydrocortisone ace-pramoxine rectal cream 1-1 % lidocaine-hydrocort (perianal) external cream 3-0.5 % lidocaine-hydrocortisone ace rectal cream 3-0.5 % PROCTOFOAM HC EXTERNAL FOAM 1-1 % PROCTOFOAM HC RECTAL FOAM 1-1 % 2 *RECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % 1 PROCTOFOAM EXTERNAL FOAM 1 % 3 *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	hydrocortisone rectal enema 100 mg/60ml	1	
lidocaine-hydrocort (perianal) external cream 3-0.5 % 1 PROCTOFOAM HC EXTERNAL FOAM 1-1 % 2 PROCTOFOAM HC RECTAL FOAM 1-1 % 2 *RECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % 1 PROCTOFOAM EXTERNAL FOAM 1 % 3 *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	*RECTAL ANESTHETIC/STEROIDS***		
Ilidocaine-hydrocortisone ace rectal cream 3-0.5 % PROCTOFOAM HC EXTERNAL FOAM 1-1 % PROCTOFOAM HC RECTAL FOAM 1-1 % *RECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % PROCTOFOAM EXTERNAL FOAM 1 % *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % PROCTOCARE-HC RECTAL CREAM 2.5 % 1	hydrocortisone ace-pramoxine rectal cream 1-1 %	1	
PROCTOFOAM HC EXTERNAL FOAM 1-1 % PROCTOFOAM HC RECTAL FOAM 1-1 % *RECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % PROCTOFOAM EXTERNAL FOAM 1 % *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % hydrocortisone rectal cream 2.5 % PROCTOCARE-HC RECTAL CREAM 2.5 % 1	lidocaine-hydrocort (perianal) external cream 3-0.5 %	1	
PROCTOFOAM HC RECTAL FOAM 1-1 % *RECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % PROCTOFOAM EXTERNAL FOAM 1 % *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % hydrocortisone rectal cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	lidocaine-hydrocortisone ace rectal cream 3-0.5 %	1	
*RECTAL LOCAL ANESTHETICS*** pramoxine hcl rectal foam 1 % 1 PROCTOFOAM EXTERNAL FOAM 1 % 3 *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 hydrocortisone rectal cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	PROCTOFOAM HC EXTERNAL FOAM 1-1 %	2	
pramoxine hcl rectal foam 1 % PROCTOFOAM EXTERNAL FOAM 1 % *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % hydrocortisone rectal cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	PROCTOFOAM HC RECTAL FOAM 1-1 %	2	
PROCTOFOAM EXTERNAL FOAM 1 % 3 *RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 hydrocortisone rectal cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	*RECTAL LOCAL ANESTHETICS***		
*RECTAL STEROIDS*** hydrocortisone (perianal) external cream 2.5 % 1 hydrocortisone rectal cream 2.5 % 1 PROCTOCARE-HC RECTAL CREAM 2.5 % 1	pramoxine hcl rectal foam 1 %	1	
hydrocortisone (perianal) external cream 2.5 % hydrocortisone rectal cream 2.5 % PROCTOCARE-HC RECTAL CREAM 2.5 % 1	PROCTOFOAM EXTERNAL FOAM 1 %	3	
hydrocortisone rectal cream 2.5 % PROCTOCARE-HC RECTAL CREAM 2.5 % 1	*RECTAL STEROIDS***		
PROCTOCARE-HC RECTAL CREAM 2.5 % 1	hydrocortisone (perianal) external cream 2.5 %	1	
	hydrocortisone rectal cream 2.5 %	1	
PROCTO-MED HC EXTERNAL CREAM 2.5 %	PROCTOCARE-HC RECTAL CREAM 2.5 %	1	
	PROCTO-MED HC EXTERNAL CREAM 2.5 %	1	

MPC032520 18 Effective: 09/15/2025

Drug Name	Tier	Notes
PROCTOSOL HC EXTERNAL CREAM 2.5 %	1	
PROCTOSOL HC RECTAL CREAM 2.5 %	1	
PROCTOZONE-HC EXTERNAL CREAM 2.5 %	1	
PROCTOZONE-HC RECTAL CREAM 2.5 %	1	
ANTHELMINTICS		
*ANTHELMINTICS***		
albendazole oral tablet 200 mg	4	
BILTRICIDE ORAL TABLET 600 MG	3	
EMVERM ORAL TABLET CHEWABLE 100 MG	5	PA; QL (6 EA per 21 days)
ivermectin oral tablet 3 mg	3	QL (30 EA per 90 days)
ANTIANGINAL AGENTS		
*ANTIANGINALS-OTHER***		
ranolazine er oral tablet extended release 12 hour 1000 mg, 500 mg	3	ST
*NITRATES***		
DILATRATE-SR ORAL CAPSULE EXTENDED RELEASE 40 MG	2	
isosorbide dinitrate er oral tablet extended release 40 mg	2	
isosorbide dinitrate oral tablet 10 mg, 20 mg, 5 mg	1	
isosorbide dinitrate oral tablet 30 mg	2	
isosorbide dinitrate sublingual tablet sublingual 2.5 mg	1	
isosorbide mononitrate er oral tablet extended release 24 hour 120 mg, 30 mg, 60 mg	1	
isosorbide mononitrate oral tablet 10 mg, 20 mg	1	
MINITRAN TRANSDERMAL PATCH 24 HOUR 0.6 MG/HR	1	
NITRO-BID TRANSDERMAL OINTMENT 2 %	2	
nitroglycerin er oral capsule extended release 2.5 mg	2	
nitroglycerin er oral capsule extended release 6.5 mg, 9 mg	1	
nitroglycerin sublingual tablet sublingual 0.3 mg, 0.4 mg	1	
nitroglycerin sublingual tablet sublingual 0.6 mg	2	
nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr	1	
ANTIANXIETY AGENTS		
*ANTIANXIETY AGENTS - MISC.***		

MPC032520 19 Effective: 09/15/2025

Drug Name	Tier	Notes
buspirone hcl oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
droperidol injection solution 2.5 mg/ml	MB	
hydroxyzine hcl intramuscular solution 25 mg/ml, 50 mg/ml	MB	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
hydroxyzine hcl oral solution 10 mg/5ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
hydroxyzine hcl oral syrup 10 mg/5ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 20 Effective: 09/15/2025

Drug Name	Tier	Notes
hydroxyzine pamoate oral capsule 100 mg, 25 mg, 50 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
meprobamate oral tablet 200 mg, 400 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*BENZODIAZEPINES***		
alprazolam er oral tablet extended release 24 hour 0.5 mg, 1 mg, 2 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
alprazolam er oral tablet extended release 24 hour 3 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days)

MPC032520 21 Effective: 09/15/2025

Drug Name	Tier	Notes
alprazolam oral tablet 2 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (135 EA per 30 days)
alprazolam xr oral tablet extended release 24 hour 0.5 mg, 1 mg, 2 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
alprazolam xr oral tablet extended release 24 hour 3 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)
clorazepate dipotassium oral tablet 15 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days)

MPC032520 22 Effective: 09/15/2025

Drug Name	Tier	Notes
clorazepate dipotassium oral tablet 3.75 mg, 7.5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
ciorazepate dipotassium oral tablet 3.75 mg, 7.5 mg		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days)
diazonom injection colution 5 mg/ml	MD	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
diazepam injection solution 5 mg/ml	MB	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
diazepam oral tablet 10 mg, 2 mg, 5 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
lorazepam injection solution 2 mg/ml, 4 mg/ml	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2.5 ML per 1 day)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
lorazepam oral concentrate 2 mg/ml	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (150 ML per 30 days)

MPC032520 23 Effective: 09/15/2025

Tier	Notes
1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days)
2	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)
1	
1	
1	
MB	
1	
1	
1	
1	
1	
MB	
3	
3	PA; QL (60 EA per 30 days)
5	PA; QL (120 EA per 30 days); NDS; SP
	1 1 1 1 1 1 1 1 1 1 MB 3 3 3 3 3 3

Drug Name	Tier	Notes
*ADRENERGIC COMBINATIONS***	•	
ANORO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 62.5-25 MCG/ACT	2	QL (60 EA per 30 days)
BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-25 MCG/INH	3	ST; QL (30 EA per 30 days)
COMBIVENT RESPIMAT INHALATION AEROSOL SOLUTION 20-100 MCG/ACT	3	QL (8 GM per 30 days)
DULERA INHALATION AEROSOL 100-5 MCG/ACT, 200-5 MCG/ACT, 50-5 MCG/ACT	3	ST; QL (13 GM per 30 days)
DUONEB INHALATION SOLUTION 0.5-2.5 (3) MG/3ML	МВ	
fluticasone-salmeterol inhalation aerosol powder breath activated 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act	3	QL (60 EA per 30 days)
fluticasone-salmeterol inhalation aerosol powder breath activated 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose	3	ST; QL (60 EA per 30 days)
fluticasone-salmeterol inhalation aerosol powder breath activated 113-14 mcg/act, 232-14 mcg/act, 55- 14 mcg/act	2	QL (1 EA per 30 days)
ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml	1	
STIOLTO RESPIMAT INHALATION AEROSOL SOLUTION 2.5-2.5 MCG/ACT	2	QL (4 GM per 30 days)
SYMBICORT INHALATION AEROSOL 160-4.5 MCG/ACT, 80-4.5 MCG/ACT	2	QL (10.2 GM per 30 days)
TRELEGY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/ACT, 200-62.5-25 MCG/ACT	2	PA; QL (60 EA per 30 days)
WIXELA INHUB INHALATION AEROSOL POWDER BREATH ACTIVATED 100-50 MCG/ACT, 250-50 MCG/ACT, 500-50 MCG/ACT	3	QL (60 EA per 30 days)
WIXELA INHUB INHALATION AEROSOL POWDER BREATH ACTIVATED 100-50 MCG/DOSE, 250-50 MCG/DOSE, 500-50 MCG/DOSE	3	ST; QL (60 EA per 30 days)
*ANTI-IGE MONOCLONAL ANTIBODIES***		
XOLAIR SUBCUTANEOUS SOLUTION AUTO- INJECTOR 150 MG/ML, 300 MG/2ML, 75 MG/0.5ML	MB	PA; NDS; SP
XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 300 MG/2ML, 75 MG/0.5ML	МВ	PA; NDS; SP
*ANTI-INFLAMMATORY AGENTS***		
cromolyn sodium inhalation nebulization solution 20 mg/2ml	1	
*BETA ADRENERGICS***		
albuterol sulfate er oral tablet extended release 12 hour 4 mg, 8 mg	1	

MPC032520 25 Effective: 09/15/2025

Drug Name	Tier	Notes
albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act	1	
albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, (5 mg/ml) 0.5%, 0.63 mg/3ml, 1.25 mg/3ml	1	
albuterol sulfate oral syrup 2 mg/5ml	1	
albuterol sulfate oral tablet 2 mg, 4 mg	1	
BROVANA INHALATION NEBULIZATION SOLUTION 15 MCG/2ML	MB	
isoproterenol hcl injection solution 0.2 mg/ml	MB	
levalbuterol tartrate inhalation aerosol 45 mcg/act	3	QL (30 GM per 30 days)
metaproterenol sulfate oral syrup 10 mg/5ml	2	
metaproterenol sulfate oral tablet 10 mg, 20 mg	2	
SEREVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 50 MCG/DOSE	2	
terbutaline sulfate injection solution 1 mg/ml	1	
terbutaline sulfate oral tablet 2.5 mg, 5 mg	1	
VENTOLIN HFA INHALATION AEROSOL SOLUTION 108 (90 BASE) MCG/ACT	2	
XOPENEX CONCENTRATE INHALATION NEBULIZATION SOLUTION 1.25 MG/0.5ML	MB	
*BRONCHODILATORS - ANTICHOLINERGICS***		
ATROVENT HFA INHALATION AEROSOL SOLUTION 17 MCG/ACT	2	
ipratropium bromide inhalation solution 0.02 %	1	
SPIRIVA HANDIHALER INHALATION CAPSULE 18 MCG	2	
SPIRIVA RESPIMAT INHALATION AEROSOL SOLUTION 1.25 MCG/ACT, 2.5 MCG/ACT	2	
*LEUKOTRIENE RECEPTOR ANTAGONISTS***		
montelukast sodium oral tablet 10 mg	1	QL (30 EA per 30 days)
montelukast sodium oral tablet chewable 4 mg, 5 mg	1	QL (30 EA per 30 days)
zafirlukast oral tablet 10 mg, 20 mg	1	
*SELECTIVE PHOSPHODIESTERASE 4 (PDE4) INHIBITORS***		
roflumilast oral tablet 500 mcg	2	PA; QL (30 EA per 30 days)
*STEROID INHALANTS***		
ALVESCO INHALATION AEROSOL SOLUTION 160 MCG/ACT	3	ST; QL (12.2 GM per 30 days)

Drug Name	Tier	Notes
ALVESCO INHALATION AEROSOL SOLUTION 80 MCG/ACT	3	ST; QL (6.1 GM per 30 days)
ARNUITY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100 MCG/ACT, 200 MCG/ACT, 50 MCG/ACT	2	QL (30 EA per 30 days)
budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml	1	QL (120 ML per 30 days)
fluticasone propionate diskus inhalation aerosol powder breath activated 100 mcg/act, 250 mcg/act, 50 mcg/act	2	
fluticasone propionate hfa inhalation aerosol 110 mcg/act, 220 mcg/act, 44 mcg/act	2	
PULMICORT FLEXHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 180 MCG/ACT, 90 MCG/ACT	3	
QVAR REDIHALER INHALATION AEROSOL BREATH ACTIVATED 40 MCG/ACT	3	QL (10.6 GM per 30 days)
QVAR REDIHALER INHALATION AEROSOL BREATH ACTIVATED 80 MCG/ACT	3	QL (21.2 GM per 30 days)
*XANTHINES***		
aminophylline intravenous solution 25 mg/ml	MB	
ELIXOPHYLLIN ORAL ELIXIR 80 MG/15ML	3	
THEOCHRON ORAL TABLET EXTENDED RELEASE 12 HOUR 200 MG	1	
theophylline er oral tablet extended release 12 hour 100 mg, 200 mg, 450 mg	1	
theophylline er oral tablet extended release 12 hour 300 mg	2	
theophylline er oral tablet extended release 24 hour 400 mg, 600 mg	1	
theophylline in d5w intravenous solution 0.8-5 mg/ml- %	МВ	
ANTICOAGULANTS		
*COUMARIN ANTICOAGULANTS***		
warfarin sodium oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg	1	
*DIRECT FACTOR XA INHIBITORS***		
ELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK 5 MG	2	QL (74 EA per 365 days)
ELIQUIS ORAL TABLET 2.5 MG, 5 MG	2	QL (60 EA per 30 days)
XARELTO ORAL SUSPENSION RECONSTITUTED 1 MG/ML	2	QL (600 ML per 30 days)
XARELTO ORAL TABLET 10 MG, 15 MG, 20 MG	2	QL (30 EA per 30 days)
XARELTO ORAL TABLET 2.5 MG	2	QL (60 EA per 30 days)

MPC032520 27 Effective: 09/15/2025

Tier	Notes		
2	QL (102 EA per 365 days)		
*HEPARINS AND HEPARINOID-LIKE AGENTS***			
1			
MB			
1			
1			
1			
1			
3			
МВ			
1			
1			
_			
1	PA		
1	PA		
1	PA		
5	PA; QL (30 ML per 30 days)		
5	PA; QL (30 ML per 30 days)		
5	PA		
	1 MB 1 1 1 3 MB 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		

MPC032520 28 Effective: 09/15/2025

Drug Name	Tier	Notes
*THROMBIN INHIBITORS - HIRUDIN TYPE***		
ANGIOMAX INTRAVENOUS SOLUTION RECONSTITUTED 250 MG	MB	
*THROMBIN INHIBITORS - SELECTIVE DIRECT & REVERSIBLE***		
argatroban intravenous solution 250 mg/2.5ml	MB	
dabigatran etexilate mesylate oral capsule 110 mg	3	PA; QL (2 EA per 1 day)
dabigatran etexilate mesylate oral capsule 150 mg	3	PA; QL (60 EA per 30 days)
dabigatran etexilate mesylate oral capsule 75 mg	3	PA; QL (30 EA per 30 days)
ANTICONVULSANTS	•	
*ANTICONVULSANTS - BENZODIAZEPINES***		
clobazam oral suspension 2.5 mg/ml	3	ST; QL (8 ML per 1 day)
clobazam oral tablet 10 mg, 20 mg	3	ST; QL (2 EA per 1 day)
clonazepam oral tablet 0.5 mg, 1 mg, 2 mg	1	QL (90 EA per 30 days)
clonazepam oral tablet dispersible 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg	1	QL (90 EA per 30 days)
diazepam rectal gel 10 mg, 2.5 mg, 20 mg	2	ST; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (5 EA per 30 days)
NAYZILAM NASAL SOLUTION 5 MG/0.1ML	5	ST; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (10 EA per 30 days)
VALTOCO 10 MG DOSE NASAL LIQUID 10 MG/0.1ML	5	ST; QL (10 EA per 30 days); AL (Min 2 Years)
VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 2 X 7.5 MG/0.1ML	5	ST; QL (5 packs per 30 days); AL (Min 2 Years)
VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 7.5 MG/0.1ML	5	PA; QL (5 packs per 30 days); AL (Min 2 Years)
VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 10 MG/0.1ML	5	PA; QL (5 packs per 30 days); AL (Min 2 Years)

MPC032520 29 Effective: 09/15/2025

Drug Name	Tier	Notes
VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 2 X 10 MG/0.1ML	5	ST; QL (5 packs per 30 days); AL (Min 2 Years)
VALTOCO 5 MG DOSE NASAL LIQUID 5 MG/0.1ML	5	ST; QL (10 EA per 30 days); AL (Min 2 Years)
*ANTICONVULSANTS - MISC.***		
carbamazepine er oral capsule extended release 12 hour 100 mg, 200 mg, 300 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
		plans.)
carbamazepine er oral tablet extended release 12 hour 100 mg, 200 mg, 400 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
carbamazepine oral suspension 100 mg/5ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
carbamazepine oral tablet 200 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 30 Effective: 09/15/2025

Drug Name	Tier	Notes
carbamazepine oral tablet chewable 100 mg, 200 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to
		deductible first. Coverage at no cost share is subject to applicable benefit plans.)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
gabapentin oral capsule 100 mg, 300 mg, 400 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
gabapentin oral solution 250 mg/5ml		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
gabapentin oral tablet 600 mg, 800 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
lacosamide oral solution 10 mg/ml	5	ST; QL (1200 ML per 30 days)
lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg	5	QL (60 EA per 30 days)
lamotrigine er oral tablet extended release 24 hour		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
100 mg, 25 mg, 50 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)

MPC032520 31 Effective: 09/15/2025

Drug Name	Tier	Notes
lamotrigine er oral tablet extended release 24 hour 200 mg, 250 mg, 300 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
lamotrigine oral tablet chewable 25 mg, 5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
levetiracetam er oral tablet extended release 24 hour 500 mg, 750 mg	3	QL (120 EA per 30 days)
levetiracetam intravenous solution 500 mg/5ml	MB	
levetiracetam oral solution 100 mg/ml	1	
levetiracetam oral tablet 1000 mg, 250 mg, 500 mg, 750 mg	1	
oxcarbazepine oral suspension 300 mg/5ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 32 Effective: 09/15/2025

Drug Name	Tier	Notes
oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
POTIGA ORAL TABLET 200 MG, 300 MG, 400 MG, 50 MG	3	PA; QL (90 EA per 30 days)
pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days)
pregabalin oral capsule 225 mg, 300 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
primidone oral tablet 250 mg, 50 mg	1	
ROWEEPRA XR ORAL TABLET EXTENDED RELEASE 24 HOUR 500 MG, 750 MG	3	QL (120 EA per 30 days)
topiramate oral capsule sprinkle 15 mg, 25 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 33 Effective: 09/15/2025

Drug Name	Tier	Notes
topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan
		copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
zonisamide oral capsule 100 mg, 25 mg, 50 mg	1	
*CARBAMATES***		
felbamate oral suspension 600 mg/5ml	3	QL (900 ML per 30 days)
felbamate oral tablet 400 mg	3	QL (90 EA per 30 days)
felbamate oral tablet 600 mg	5	QL (180 EA per 30 days)
*GABA MODULATORS***		
tiagabine hcl oral tablet 12 mg, 16 mg, 2 mg, 4 mg	3	
*HYDANTOINS***		
DILANTIN INFATABS ORAL TABLET CHEWABLE 50 MG	3	
DILANTIN ORAL CAPSULE 30 MG	3	
fosphenytoin sodium injection solution 100 mg pe/2ml, 500 mg pe/10ml	МВ	
phenytoin oral suspension 125 mg/5ml	1	
phenytoin sodium extended oral capsule 100 mg, 200 mg, 300 mg	1	
phenytoin sodium injection solution 50 mg/ml	MB	
*SUCCINIMIDES***		
ethosuximide oral capsule 250 mg	1	
ethosuximide oral solution 250 mg/5ml	1	
*VALPROIC ACID***	,	,
divalproex sodium er oral tablet extended release 24 hour 250 mg, 500 mg		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
divalproex sodium oral capsule sprinkle 125 mg	1	

MPC032520 34 Effective: 09/15/2025

Drug Name	Tier	Notes
divalproex sodium oral tablet delayed release 125 mg, 250 mg, 500 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
valproic acid oral capsule 250 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost
		share is subject to applicable benefit plans.)
valproic acid oral syrup 250 mg/5ml	1	
ANTIDEPRESSANTS		
*ALPHA-2 RECEPTOR ANTAGONISTS (TETRACYCLICS)***		
mirtazapine oral tablet 15 mg, 30 mg, 45 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost
		share is subject to applicable benefit plans.); QL (30 EA per 30 days) BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance
mirtazapine oral tablet dispersible 15 mg, 30 mg, 45 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*ANTIDEPRESSANTS - MISC.***		

MPC032520 35 Effective: 09/15/2025

Drug Name	Tier	Notes
bupropion hcl er (sr) oral tablet extended release 12 hour 100 mg, 150 mg, 200 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
bupropion hcl er (xl) oral tablet extended release 24 hour 150 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days)
bupropion hcl er (xl) oral tablet extended release 24 hour 300 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
bupropion hcl oral tablet 100 mg, 75 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
maprotiline hcl oral tablet 25 mg, 50 mg, 75 mg *MONOAMINE OXIDASE INHIBITORS	2	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 36 Effective: 09/15/2025

Drug Name	Tier	Notes
EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24HR, 6 MG/24HR, 9 MG/24HR	5	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
phenelzine sulfate oral tablet 15 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
tranylcypromine sulfate oral tablet 10 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*N-METHYL-D-ASPARTIC ACID (NMDA) RECEPTOR ANTAGONISTS***		
SPRAVATO (56 MG DOSE) NASAL SOLUTION THERAPY PACK 28 MG/DEVICE	МВ	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
SPRAVATO (84 MG DOSE) NASAL SOLUTION THERAPY PACK 28 MG/DEVICE	МВ	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 37 Effective: 09/15/2025

Drug Name	Tier	Notes	
*SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)***			
citalopram hydrobromide oral solution 10 mg/5ml, 20 mg/10ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (600 ML per 30 days)	
citalopram hydrobromide oral tablet 10 mg, 20 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)	
citalopram hydrobromide oral tablet 40 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)	
escitalopram oxalate oral solution 5 mg/5ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (600 ML per 30 days)	
escitalopram oxalate oral tablet 10 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (45 EA per 30 days)	

MPC032520 38 Effective: 09/15/2025

Drug Name	Tier	Notes
escitalopram oxalate oral tablet 20 mg, 5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
fluoxetine hcl oral capsule 10 mg, 20 mg, 40 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
fluoxetine hcl oral solution 20 mg/5ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
fluvoxamine maleate oral tablet 100 mg, 25 mg, 50 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
paroxetine hcl er oral tablet extended release 24 hour 12.5 mg, 25 mg, 37.5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 39 Effective: 09/15/2025

Drug Name	Tier	Notes
paroxetine hcl oral suspension 10 mg/5ml	3	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan
		copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (900 ML per 30 days)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
paroxetine hcl oral tablet 10 mg, 20 mg, 30 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
paroxetine hcl oral tablet 40 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (45 EA per 30 days)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
sertraline hcl oral concentrate 20 mg/ml	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
sertraline hcl oral tablet 100 mg, 25 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)

MPC032520 40 Effective: 09/15/2025

Drug Name	Tier	Notes
sertraline hcl oral tablet 50 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (45 EA per 30 days)
*SEROTONIN MODULATORS***		
nefazodone hcl oral tablet 100 mg, 150 mg, 200 mg, 250 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
trazodone hcl oral tablet 100 mg, 150 mg, 300 mg, 50 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
vilazodone hcl oral tablet 10 mg, 20 mg, 40 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
*SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)***		

MPC032520 41 Effective: 09/15/2025

Drug Name	Tier	Notes
desvenlafaxine succinate er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
duloxetine hcl oral capsule delayed release particles 20 mg, 30 mg, 60 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
venlafaxine hcl er oral capsule extended release 24 hour 150 mg, 37.5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
venlafaxine hcl er oral capsule extended release 24 hour 75 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days)
venlafaxine hcl er oral tablet extended release 24 hour 150 mg, 37.5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero cost share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2 EA per 1 day)

MPC032520 42 Effective: 09/15/2025

Drug Name	Tier	Notes
venlafaxine hcl er oral tablet extended release 24 hour 75 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero cost share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (3 EA per 1 day)
venlafaxine hcl oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*TRICYCLIC AGENTS***	•	
amitriptyline hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg	2	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
clomipramine hcl oral capsule 25 mg, 50 mg, 75 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 43 Effective: 09/15/2025

Drug Name	Tier	Notes
desipramine hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
doxepin hcl oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
doxepin hcl oral concentrate 10 mg/ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
imipramine hcl oral tablet 10 mg, 25 mg, 50 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
nortriptyline hcl oral capsule 10 mg, 25 mg, 50 mg, 75 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
ANTIDIABETICS		
*ALPHA-GLUCOSIDASE INHIBITORS***		

MPC032520 44 Effective: 09/15/2025

Drug Name	Tier	Notes
acarbose oral tablet 100 mg, 25 mg, 50 mg	1	
*ANTIDIABETIC - AMYLIN ANALOGS***		
SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR 2700 MCG/2.7ML	3	PA
SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN- INJECTOR 1500 MCG/1.5ML	3	PA
*BIGUANIDES***		
metformin hcl er oral tablet extended release 24 hour 500 mg, 750 mg	1	
metformin hcl oral tablet 1000 mg, 500 mg, 850 mg	1	
*DIABETIC OTHER***		
BAQSIMI ONE PACK NASAL POWDER 3 MG/DOSE	2	
BAQSIMI TWO PACK NASAL POWDER 3 MG/DOSE	2	
GVOKE HYPOPEN 1-PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 0.5 MG/0.1ML, 1 MG/0.2ML	2	
GVOKE HYPOPEN 2-PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 0.5 MG/0.1ML, 1 MG/0.2ML	2	
GVOKE KIT SUBCUTANEOUS SOLUTION 1 MG/0.2ML	2	
GVOKE PFS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 0.5 MG/0.1ML, 1 MG/0.2ML	2	
*DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS***		
alogliptin benzoate oral tablet 12.5 mg, 25 mg, 6.25 mg	2	ST; QL (30 EA per 30 days)
JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG	2	ST; QL (30 EA per 30 days)
saxagliptin hcl oral tablet 2.5 mg, 5 mg	3	PA; QL (30 EA per 30 days)
*DIPEPTIDYL PEPTIDASE-4 INHIBITOR-BIGUANIDE COMBINATIONS***		
alogliptin-metformin hcl oral tablet 12.5-1000 mg, 12.5-500 mg	2	ST; QL (60 EA per 30 days)
JANUMET ORAL TABLET 50-1000 MG, 50-500 MG	2	ST; QL (60 EA per 30 days)
JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100-1000 MG	2	ST; QL (30 EA per 30 days)
JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 50-1000 MG, 50-500 MG	2	ST; QL (60 EA per 30 days)
saxagliptin-metformin er oral tablet extended release 24 hour 2.5-1000 mg	3	PA; QL (60 EA per 30 days)
saxagliptin-metformin er oral tablet extended release 24 hour 5-1000 mg, 5-500 mg	3	PA; QL (30 EA per 30 days)

MPC032520 45 Effective: 09/15/2025

Drug Name	Tier	Notes
*DPP-4 INHIBITOR-THIAZOLIDINEDIONE COMBINATIONS***		
alogliptin-pioglitazone oral tablet 12.5-15 mg, 12.5-30 mg, 12.5-45 mg, 25-15 mg, 25-30 mg, 25-45 mg	2	ST; QL (30 EA per 30 days)
OSENI ORAL TABLET 25-45 MG	2	ST; QL (30 EA per 30 days)
*HUMAN INSULIN***		
APIDRA INJECTION SOLUTION 100 UNIT/ML	3	ST; QL (50 ML per 30 days)
HUMALOG INJECTION SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
HUMALOG KWIKPEN SUBCUTANEOUS SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
HUMALOG KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML	2	ST; CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
HUMALOG MIX 50/50 KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (50-50) 100 UNIT/ML	3	ST; QL (45 ML per 30 days)
HUMALOG MIX 50/50 SUBCUTANEOUS SUSPENSION (50-50) 100 UNIT/ML	3	ST; QL (50 ML per 30 days)

MPC032520 46 Effective: 09/15/2025

Drug Name	Tier	Notes
HUMALOG MIX 75/25 KWIKPEN SUBCUTANEOUS SUSPENSION (75-25) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
HUMALOG MIX 75/25 KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (75-25) 100 UNIT/ML	2	ST; CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
HUMALOG MIX 75/25 PEN SUBCUTANEOUS SUSPENSION (75-25) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
HUMALOG MIX 75/25 PEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (75-25) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)

MPC032520 47 Effective: 09/15/2025

Drug Name	Tier	Notes
HUMALOG MIX 75/25 SUBCUTANEOUS SUSPENSION (75-25) 100 UNIT/ML	2	ST; CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
HUMALOG PEN SUBCUTANEOUS SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
HUMALOG PEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
HUMALOG SUBCUTANEOUS SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
HUMALOG SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML	3	ST; QL (50 ML per 30 days)
HUMULIN 70/30 KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML	3	ST; QL (45 ML per 30 days)

MPC032520 48 Effective: 09/15/2025

Drug Name	Tier	Notes
HUMULIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML	3	ST; QL (50 ML per 30 days)
HUMULIN N KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML	3	ST; QL (45 ML per 30 days)
HUMULIN N SUBCUTANEOUS SUSPENSION 100 UNIT/ML	3	QL (50 ML per 30 days)
HUMULIN R INJECTION SOLUTION 100 UNIT/ML	3	ST; QL (50 ML per 30 days)
HUMULIN R U-500 (CONCENTRATED) SUBCUTANEOUS SOLUTION 500 UNIT/ML	3	PA; QL (20 ML per 30 days)
HUMULIN R U-500 KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 500 UNIT/ML	3	PA; QL (18 ML per 30 days)
insulin asp prot & asp flexpen subcutaneous suspension pen-injector (70-30) 100 unit/ml	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
insulin aspart flexpen subcutaneous solution pen- injector 100 unit/ml	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
insulin aspart injection solution 100 unit/ml	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
insulin aspart penfill subcutaneous solution cartridge 100 unit/ml	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)

MPC032520 49 Effective: 09/15/2025

Drug Name	Tier	Notes
insulin aspart prot & aspart subcutaneous suspension (70-30) 100 unit/ml	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
insulin aspart subcutaneous solution 100 unit/ml	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
insulin glargine-yfgn subcutaneous solution 100 unit/ml	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
insulin glargine-yfgn subcutaneous solution pen- injector 100 unit/ml	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)

Drug Name	Tier	Notes
insulin lispro (1 unit dial) subcutaneous solution pen- injector 100 unit/ml	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
insulin lispro injection solution 100 unit/ml	2	ST; CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
insulin lispro subcutaneous solution 100 unit/ml	3	ST; QL (50 EA per 30 days)
LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)

MPC032520 51 Effective: 09/15/2025

Drug Name	Tier	Notes
LANTUS SUBCUTANEOUS SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
LEVEMIR FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
LEVEMIR FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
LEVEMIR SUBCUTANEOUS SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
NOVOLIN 70/30 FLEXPEN RELION SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)

Drug Name	Tier	Notes
NOVOLIN 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
NOVOLIN 70/30 PENFILL SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
NOVOLIN 70/30 RELION SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
NOVOLIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
NOVOLIN N FLEXPEN RELION SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)

Drug Name	Tier	Notes
NOVOLIN N FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
NOVOLIN N PENFILL SUBCUTANEOUS SUSPENSION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
NOVOLIN N RELION SUBCUTANEOUS SUSPENSION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
NOVOLIN N SUBCUTANEOUS SUSPENSION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
NOVOLIN R FLEXPEN INJECTION SOLUTION PEN- INJECTOR 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)

Drug Name	Tier	Notes
NOVOLIN R FLEXPEN RELION INJECTION SOLUTION PEN-INJECTOR 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
NOVOLIN R INJECTION SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
NOVOLIN R PENFILL INJECTION SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
NOVOLIN R RELION INJECTION SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
NOVOLOG 70/30 FLEXPEN RELION SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)

MPC032520 55 Effective: 09/15/2025

Drug Name	Tier	Notes
NOVOLOG FLEXPEN RELION SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
NOVOLOG INJECTION SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)

Drug Name	Tier	Notes
NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
NOVOLOG MIX 70/30 RELION SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
NOVOLOG MIX 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)

Drug Name	Tier	Notes
NOVOLOG RELION INJECTION SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
NOVOLOG RELION SUBCUTANEOUS SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
NOVOLOG SUBCUTANEOUS SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
REZVOGLAR KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. *High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)

MPC032520 58 Effective: 09/15/2025

Drug Name	Tier	Notes
TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML, 200 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (45 ML per 30 days)
TRESIBA SUBCUTANEOUS SOLUTION 100 UNIT/ML	2	CB (The copay amount for a preferred Formulary prescription insulin covered at an amount not to exceed a total \$25.00* per thirty-day supply. * High Deductible Health Plan copays/coinsurances are subject to deductible first.); QL (50 ML per 30 days)
*INCRETIN MIMETIC AGENTS (GIP & GLP-1 RECEPTOR AGONISTS)***		
MOUNJARO SUBCUTANEOUS SOLUTION AUTO- INJECTOR 10 MG/0.5ML, 12.5 MG/0.5ML, 15 MG/0.5ML, 2.5 MG/0.5ML, 5 MG/0.5ML, 7.5 MG/0.5ML	2	PA; QL (2 ML per 28 days); NDS
MOUNJARO SUBCUTANEOUS SOLUTION PEN- INJECTOR 10 MG/0.5ML, 12.5 MG/0.5ML, 15 MG/0.5ML, 2.5 MG/0.5ML, 5 MG/0.5ML, 7.5 MG/0.5ML	2	PA; QL (2 ML per 28 days); NDS
*INCRETIN MIMETIC AGENTS (GLP-1 RECEPTOR AGONISTS)***		
TRULICITY SUBCUTANEOUS SOLUTION AUTO- INJECTOR 0.75 MG/0.5ML, 1.5 MG/0.5ML, 3 MG/0.5ML, 4.5 MG/0.5ML	2	PA; QL (2 ML per 28 days); NDS
TRULICITY SUBCUTANEOUS SOLUTION PEN- INJECTOR 0.75 MG/0.5ML, 1.5 MG/0.5ML, 3 MG/0.5ML, 4.5 MG/0.5ML	2	PA; QL (2 ML per 28 days); NDS
*MEGLITINIDE ANALOGUES***		
nateglinide oral tablet 120 mg, 60 mg	1	
repaglinide oral tablet 0.5 mg, 1 mg, 2 mg	3	
*MEGLITINIDE-BIGUANIDE COMBINATIONS***		
repaglinide-metformin hcl oral tablet 1-500 mg, 2-500 mg	3	
*SGLT2 INHIBITOR - DPP-4 INHIBITOR COMBINATIONS***		
STEGLUJAN ORAL TABLET 15-100 MG, 5-100 MG	2	ST; QL (30 EA per 30 days)

MPC032520 59 Effective: 09/15/2025

Drug Name	Tier	Notes
*SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS***		
FARXIGA ORAL TABLET 10 MG, 5 MG	2	ST; QL (30 EA per 30 days)
STEGLATRO ORAL TABLET 15 MG, 5 MG	2	ST; QL (30 EA per 30 days)
*SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITOR-BIGUANIDE COMB***		
SEGLUROMET ORAL TABLET 2.5-1000 MG, 2.5- 500 MG, 7.5-1000 MG, 7.5-500 MG	2	ST; QL (60 EA per 30 days)
XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 10-500 MG, 5-500 MG	2	ST; QL (30 EA per 30 days)
XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 2.5-1000 MG, 5-1000 MG	2	ST; QL (60 EA per 30 days)
*SULFONYLUREA-BIGUANIDE COMBINATIONS***		
glipizide-metformin hcl oral tablet 2.5-250 mg, 2.5-500 mg, 5-500 mg	1	
glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg	1	
*SULFONYLUREAS***		
chlorpropamide oral tablet 100 mg, 250 mg	2	
glimepiride oral tablet 1 mg, 2 mg, 4 mg	1	
glipizide er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg	1	
glipizide oral tablet 10 mg, 5 mg	1	
glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg	1	
glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg	1	
tolazamide oral tablet 250 mg, 500 mg	2	
tolbutamide oral tablet 500 mg	2	
*SULFONYLUREA-THIAZOLIDINEDIONE COMBINATIONS***		
pioglitazone hcl-glimepiride oral tablet 30-2 mg, 30-4 mg	1	ST
*THIAZOLIDINEDIONE-BIGUANIDE COMBINATIONS***		
pioglitazone hcl-metformin hcl oral tablet 15-500 mg, 15-850 mg	1	ST
*THIAZOLIDINEDIONES***		
AVANDIA ORAL TABLET 2 MG, 4 MG, 8 MG	3	ST
pioglitazone hcl oral tablet 15 mg, 30 mg, 45 mg	1	QL (30 EA per 30 days)
ANTIDIARRHEAL/PROBIOTIC AGENTS		
*ANTIPERISTALTIC AGENTS***		

MPC032520 60 Effective: 09/15/2025

Drug Name	Tier	Notes
diphenoxylate-atropine oral liquid 2.5-0.025 mg/5ml	2	
diphenoxylate-atropine oral tablet 2.5-0.025 mg	1	
ANTIDOTES AND SPECIFIC ANTAGONISTS		
*ANTIDOTES AND SPECIFIC ANTAGONISTS***		
ACETADOTE INTRAVENOUS SOLUTION 200 MG/ML	МВ	
ANDEXXA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 200 MG	MB	
calcium disodium versenate injection solution 1 gm/5ml	МВ	
DESFERAL INJECTION SOLUTION RECONSTITUTED 500 MG	МВ	
fomepizole intravenous solution 1.5 gm/1.5ml	MB	
PROTOPAM CHLORIDE INTRAVENOUS SOLUTION RECONSTITUTED 1 GM	МВ	
*OPIOID ANTAGONISTS***		
naloxone hcl injection solution 0.4 mg/ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to
		deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2 ML per 30 days)
naloxone hcl injection solution 1 mg/ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to
		deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (4 ML per 30 days)
naloxone hcl injection solution prefilled syringe 2		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
mg/2ml	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 61 Effective: 09/15/2025

Drug Name	Tier	Notes
naloxone hcl nasal liquid 4 mg/0.1ml	2	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost
		share is subject to applicable benefit plans.)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
naltrexone hcl oral tablet 50 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
ANTIEMETICS		
*5-HT3 RECEPTOR ANTAGONISTS***		
ANZEMET ORAL TABLET 100 MG, 50 MG	3	PA; QL (4 EA per 30 days)
granisetron hcl intravenous solution 1 mg/ml, 4 mg/4ml	МВ	
granisetron hcl oral tablet 1 mg	1	ST; QL (20 EA per 30 days)
ondansetron hcl injection solution 4 mg/2ml, 40 mg/20ml	MB	
ondansetron hcl injection solution prefilled syringe 4 mg/2ml	MB	
ondansetron hcl oral solution 4 mg/5ml	1	AL (Max 4 Years)
ondansetron hcl oral tablet 4 mg, 8 mg	1	QL (90 EA per 30 days)
ondansetron oral tablet dispersible 4 mg, 8 mg	1	QL (90 EA per 30 days)
palonosetron hcl intravenous solution 0.25 mg/2ml	MB	QL (2 ML per 5 days)
palonosetron hcl intravenous solution 0.25 mg/5ml	MB	QL (5 ML per 5 days)
*ANTIEMETICS - ANTICHOLINERGIC***		_
meclizine hcl oral tablet 25 mg	1	
scopolamine transdermal patch 72 hour 1 mg/3days	3	
TIGAN INTRAMUSCULAR SOLUTION 100 MG/ML	MB	
trimethobenzamide hcl oral capsule 300 mg	1	
*ANTIEMETICS - MISCELLANEOUS***		
CESAMET ORAL CAPSULE 1 MG	MB	
*SUBSTANCE P/NEUROKININ 1 (NK1) RECEPTOR ANTAGONISTS***		
aprepitant oral capsule 125 mg, 40 mg	3	PA; QL (1 EA per 30 days)
L		

Drug Name	Tier	Notes
aprepitant oral capsule 80 & 125 mg, 80 mg	3	PA; QL (3 EA per 30 days)
CINVANTI INTRAVENOUS EMULSION 130 MG/18ML	MB	PA
EMEND ORAL SUSPENSION RECONSTITUTED 125 MG/5ML	5	PA; QL (6 EA per 28 days)
fosaprepitant dimeglumine intravenous solution reconstituted 150 mg	MB	PA; QL (4 EA per 30 days)
ANTIFUNGALS		
*ANTIFUNGAL - GLUCAN SYNTHESIS INHIBITORS (ECHINOCANDINS)***		
caspofungin acetate intravenous solution reconstituted 50 mg, 70 mg	МВ	
ERAXIS INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 50 MG	MB	
micafungin sodium intravenous solution reconstituted 50 mg	MB	
*ANTIFUNGALS***		
ABELCET INTRAVENOUS SUSPENSION 5 MG/ML	MB	
AMPHOTEC INTRAVENOUS SUSPENSION RECONSTITUTED 100 MG, 50 MG	МВ	
amphotericin b injection solution reconstituted 50 mg	MB	
bio-statin oral capsule 500000 unit	2	
griseofulvin microsize oral suspension 125 mg/5ml	1	
griseofulvin ultramicrosize oral tablet 125 mg	3	
GRIS-PEG ORAL TABLET 250 MG	3	
nystatin oral tablet 500000 unit	1	
terbinafine hcl oral tablet 250 mg	1	QL (90 EA per 365 days)
*IMIDAZOLES***		
ketoconazole oral tablet 200 mg	1	
*TRIAZOLES***		
fluconazole in sodium chloride intravenous solution 200-0.9 mg/100ml-%	MB	
fluconazole oral suspension reconstituted 10 mg/ml, 40 mg/ml	1	

MPC032520 63 Effective: 09/15/2025

Drug Name	Tier	Notes
fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
itraconazole oral capsule 100 mg	3	ST; QL (168 EA per 365 days)
VFEND IV INTRAVENOUS SOLUTION RECONSTITUTED 200 MG	MB	
voriconazole intravenous solution reconstituted 200 mg	МВ	
voriconazole oral suspension reconstituted 40 mg/ml	5	PA; QL (150 ML per 14 days)
voriconazole oral tablet 200 mg	3	PA; QL (60 EA per 30 days)
voriconazole oral tablet 50 mg	1	PA; QL (60 EA per 30 days)
ANTIHISTAMINES		
*ANTIHISTAMINES - ETHANOLAMINES***		
carbinoxamine maleate oral tablet 4 mg	3	
diphenhydramine hcl injection solution 50 mg/ml	MB	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
diphenhydramine hcl oral elixir 12.5 mg/5ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*ANTIHISTAMINES - NON-SEDATING***		
desloratadine oral tablet 5 mg	3	
levocetirizine dihydrochloride oral solution 2.5 mg/5ml	3	
levocetirizine dihydrochloride oral tablet 5 mg	3	

MPC032520 64 Effective: 09/15/2025

Drug Name	Tier	Notes
*ANTIHISTAMINES - PHENOTHIAZINES***		
promethazine hcl injection solution 25 mg/ml, 50 mg/ml	1	
promethazine hcl oral solution 6.25 mg/5ml	1	
promethazine hcl oral syrup 6.25 mg/5ml	1	
promethazine hcl oral tablet 12.5 mg, 25 mg, 50 mg	1	
promethazine hcl rectal suppository 12.5 mg, 25 mg	1	
*ANTIHISTAMINES - PIPERIDINES***		
cyproheptadine hcl oral syrup 2 mg/5ml	1	
cyproheptadine hcl oral tablet 4 mg	1	
ANTIHYPERLIPIDEMICS		
*ANTIHYPERLIPIDEMICS - MISC.***		
omega-3-acid ethyl esters oral capsule 1 gm	3	QL (120 EA per 30 days)
*BILE ACID SEQUESTRANTS***		
cholestyramine light oral packet 4 gm	1	
cholestyramine light oral powder 4 gm/dose	1	
cholestyramine oral packet 4 gm	1	
cholestyramine oral powder 4 gm/dose	1	
colesevelam hcl oral packet 3.75 gm	5	QL (30 EA per 30 days)
colesevelam hcl oral tablet 625 mg	1	
colestipol hcl oral tablet 1 gm	3	
PREVALITE ORAL PACKET 4 GM	1	
PREVALITE ORAL POWDER 4 GM/DOSE	1	
*FIBRIC ACID DERIVATIVES***		
fenofibrate micronized oral capsule 134 mg, 200 mg, 67 mg	1	
fenofibrate oral tablet 145 mg, 160 mg, 48 mg, 54 mg	1	
gemfibrozil oral tablet 600 mg	1	
*HMG COA REDUCTASE INHIBITORS***		
atorvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 80 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (30 EA per 30 days)
fluvastatin sodium oral capsule 20 mg, 40 mg	3	
lovastatin oral tablet 10 mg, 20 mg, 40 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
pitavastatin calcium oral tablet 1 mg, 2 mg, 4 mg	3	ST
pravastatin sodium oral tablet 10 mg, 20 mg, 40 mg, 80 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
rosuvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 5 mg	1	

MPC032520 65 Effective: 09/15/2025

Drug Name	Tier	Notes
simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg, 80 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
*INTEST CHOLEST ABSORP INHIB-HMG COA REDUCTASE INHIB COMB***		
ezetimibe-simvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg	3	
*INTESTINAL CHOLESTEROL ABSORPTION INHIBITORS***		
ezetimibe oral tablet 10 mg	1	
*NICOTINIC ACID DERIVATIVES***		
niacin er (antihyperlipidemic) oral tablet extended release 1000 mg, 500 mg, 750 mg	1	
*PCSK9 INHIBITORS***		
REPATHA PUSHTRONEX SYSTEM SUBCUTANEOUS SOLUTION CARTRIDGE 420 MG/3.5ML	2	PA; QL (3.5 ML per 28 days); NDS
REPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 140 MG/ML	2	PA; QL (2 ML per 28 days); NDS
REPATHA SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140 MG/ML	2	PA; QL (2 ML per 28 days); NDS
ANTIHYPERTENSIVES		
*ACE INHIBITOR & CALCIUM CHANNEL BLOCKER COMBINATIONS***		
amlodipine besy-benazepril hcl oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg	1	
*ACE INHIBITORS & THIAZIDE/THIAZIDE- LIKE***		
benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg	1	
captopril-hydrochlorothiazide oral tablet 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg	2	
enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5- 12.5 mg	1	
fosinopril sodium-hctz oral tablet 10-12.5 mg, 20-12.5 mg	1	
lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg	1	
moexipril-hydrochlorothiazide oral tablet 15-12.5 mg, 15-25 mg, 7.5-12.5 mg	1	
quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg	1	
*ACE INHIBITORS***		
benazepril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg	1	

MPC032520 66 Effective: 09/15/2025

Drug Name	Tier	Notes
captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg	1	
enalapril maleate oral solution 1 mg/ml	3	PA; AL (Max 12 Years)
enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg	1	
fosinopril sodium oral tablet 10 mg, 20 mg, 40 mg	1	
lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg	1	
moexipril hcl oral tablet 15 mg, 7.5 mg	1	
perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg	3	
QBRELIS ORAL SOLUTION 1 MG/ML	5	PA
quinapril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg	1	
ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg	1	
trandolapril oral tablet 1 mg, 2 mg, 4 mg	1	
*AGENTS FOR PHEOCHROMOCYTOMA***		
phenoxybenzamine hcl oral capsule 10 mg	3	
phentolamine mesylate injection solution reconstituted 5 mg	MB	
*ANGIOTENSIN II RECEPTOR ANTAG & THIAZIDE/THIAZIDE-LIKE***		
candesartan cilexetil-hctz oral tablet 16-12.5 mg, 32- 12.5 mg, 32-25 mg	3	
irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg	1	
losartan potassium-hctz oral tablet 100-12.5 mg, 100- 25 mg, 50-12.5 mg	1	
olmesartan medoxomil-hctz oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg	3	
valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg	1	
*ANGIOTENSIN II RECEPTOR ANTAGONISTS***		
candesartan cilexetil oral tablet 16 mg, 32 mg, 4 mg, 8 mg	3	
eprosartan mesylate oral tablet 600 mg	3	ST
irbesartan oral tablet 150 mg, 300 mg, 75 mg	1	
losartan potassium oral tablet 100 mg, 25 mg, 50 mg	1	
olmesartan medoxomil oral tablet 20 mg, 40 mg, 5 mg	3	QL (30 EA per 30 days)
telmisartan oral tablet 20 mg, 40 mg, 80 mg	3	ST; QL (30 EA per 30 days)
valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg	3	QL (60 EA per 30 days)
*ANTIADRENERGICS - CENTRALLY ACTING***		

MPC032520 67 Effective: 09/15/2025

Drug Name	Tier	Notes
clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg	1	
clonidine hcl transdermal patch weekly 0.1 mg/24hr, 0.2 mg/24hr, 0.3 mg/24hr	1	
clonidine transdermal patch weekly 0.1 mg/24hr, 0.2 mg/24hr, 0.3 mg/24hr	1	
guanfacine hcl oral tablet 1 mg, 2 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
methyldopa oral tablet 250 mg, 500 mg	1	
*ANTIADRENERGICS - PERIPHERALLY ACTING***		
doxazosin mesylate oral tablet 1 mg, 2 mg, 4 mg, 8 mg	1	
prazosin hcl oral capsule 1 mg, 2 mg, 5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
terazosin hcl oral capsule 1 mg, 10 mg, 2 mg, 5 mg	1	
*BETA BLOCKER & DIURETIC COMBINATIONS***		
atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg	1	
bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg	1	
metoprolol-hydrochlorothiazide oral tablet 100-25 mg, 100-50 mg, 50-25 mg	1	
propranolol-hctz oral tablet 40-25 mg, 80-25 mg	2	
TENORETIC 100 ORAL TABLET 100-25 MG	1	
TENORETIC 50 ORAL TABLET 50-25 MG	1	
*DIRECT RENIN INHIBITORS & THIAZIDE/THIAZIDE-LIKE COMB***		
TEKTURNA HCT ORAL TABLET 150-12.5 MG, 150- 25 MG, 300-12.5 MG, 300-25 MG	3	PA; QL (30 EA per 30 days)

MPC032520 68 Effective: 09/15/2025

Drug Name	Tier	Notes
*DIRECT RENIN INHIBITORS***		
aliskiren fumarate oral tablet 150 mg	3	PA; QL (30 EA per 30 days)
TEKTURNA ORAL TABLET 150 MG, 300 MG	3	PA; QL (30 EA per 30 days)
*SELECTIVE ALDOSTERONE RECEPTOR ANTAGONISTS (SARAS)***		
eplerenone oral tablet 25 mg, 50 mg	3	
*VASODILATORS***		
hydralazine hcl injection solution 20 mg/ml	MB	
hydralazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg	1	
minoxidil oral tablet 10 mg, 2.5 mg	1	
ANTI-INFECTIVE AGENTS - MISC.		
*ANTI-INFECTIVE AGENTS - MISC.***		
baciim intramuscular solution reconstituted 50000 unit	3	
metronidazole oral tablet 250 mg, 500 mg	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
pentamidine isethionate inhalation solution reconstituted 300 mg	3	QL (1 EA per 28 days)
pentamidine isethionate injection solution reconstituted 300 mg	3	
trimethoprim oral tablet 100 mg	1	
vancomycin hcl intravenous solution reconstituted 5000 mg	1	
XIFAXAN ORAL TABLET 200 MG	5	PA; QL (9 EA per 30 days)
XIFAXAN ORAL TABLET 550 MG	5	PA; QL (60 EA per 30 days)
*ANTI-INFECTIVE MISC COMBINATIONS***		

MPC032520 69 Effective: 09/15/2025

Drug Name	Tier	Notes
erythromycin-sulfisoxazole oral suspension reconstituted 200-600 mg/5ml	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
sulfamethoxazole-trimethoprim oral suspension 200- 40 mg/5ml	1	
sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg	1	
*ANTIPROTOZOAL AGENTS***		
atovaquone oral suspension 750 mg/5ml	1	
*CARBAPENEM COMBINATIONS***		•
PRIMAXIN IV INTRAVENOUS SOLUTION RECONSTITUTED 250-250 MG	MB	
*CARBAPENEMS***		
INVANZ INJECTION SOLUTION RECONSTITUTED 1 GM	MB	
MERREM INTRAVENOUS SOLUTION RECONSTITUTED 500 MG	MB	
*CHLORAMPHENICALS***		•
chloramphenicol sod succinate intravenous solution reconstituted 1 gm	MB	
*GLYCOPEPTIDES***		
vancomycin hcl in dextrose intravenous solution 1-5 gm/200ml-%, 500-5 mg/100ml-%	MB	
vancomycin hcl in nacl intravenous solution 1-0.9 gm/200ml-%, 500-0.9 mg/100ml-%, 750-0.9 mg/150ml-%	MB	
vancomycin hcl intravenous solution reconstituted 1000 mg	1	
vancomycin hcl intravenous solution reconstituted 500 mg	5	
vancomycin hcl oral capsule 125 mg	3	QL (56 EA per 14 days)
vancomycin hcl oral capsule 250 mg	3	PA; QL (80 EA per 30 days)
vancomycin hcl oral solution reconstituted 25 mg/ml, 50 mg/ml	2	QL (300 ML per 14 days)
VIBATIV INTRAVENOUS SOLUTION RECONSTITUTED 750 MG	MB	
*LEPROSTATICS***		

MPC032520 70 Effective: 09/15/2025

Drug Name	Tier	Notes
dapsone oral tablet 100 mg, 25 mg	2	
*LINCOSAMIDES***		
clindamycin hcl oral capsule 150 mg, 300 mg	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
clindamycin palmitate hcl oral solution reconstituted 75 mg/5ml	1	
lincomycin hcl injection solution 300 mg/ml	MB	
*MONOBACTAMS***		
CAYSTON INHALATION SOLUTION RECONSTITUTED 75 MG	5	PA; QL (84 ML per 56 days); SP
*OXAZOLIDINONES***		
linezolid intravenous solution 2 mg/ml	MB	PA
linezolid oral suspension reconstituted 100 mg/5ml	3	PA
linezolid oral tablet 600 mg	3	PA
*POLYMYXINS***		
colistimethate sodium (cba) injection solution reconstituted 150 mg	МВ	
*STREPTOGRAMIN COMBINATIONS***		•
SYNERCID INTRAVENOUS SOLUTION RECONSTITUTED 150-350 MG	МВ	
*URINARY ANTI-INFECTIVES***		•
fosfomycin tromethamine oral packet 3 gm	3	
methenamine hippurate oral tablet 1 gm	1	
methenamine mandelate oral tablet 0.5 gm	2	
methenamine mandelate oral tablet 1 gm	1	
nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg	1	
nitrofurantoin monohyd macro oral capsule 100 mg	1	
nitrofurantoin oral suspension 25 mg/5ml	3	QL (560 ML per 7 days); AL (Max 12 Years)
ANTIMALARIALS		
*ANTIMALARIAL COMBINATIONS***		
atovaquone-proguanil hcl oral tablet 62.5-25 mg	3	
MPC032520	71	Effective: 00/15/2025

Drug Name	Tier	Notes
*ANTIMALARIALS***		·
chloroquine phosphate oral tablet 250 mg, 500 mg	1	
hydroxychloroquine sulfate oral tablet 200 mg	1	
primaquine phosphate oral tablet 26.3 (15 base) mg, 26.3 mg	2	
ANTIMYASTHENIC/CHOLINERGIC AGENTS		
*ANTIMYASTHENIC/CHOLINERGIC AGENTS***		
FIRDAPSE ORAL TABLET 10 MG	5	PA; LA; QL (240 EA per 30 days); SP
MESTINON ORAL SYRUP 60 MG/5ML	3	
neostigmine methylsulfate intravenous solution 5 mg/10ml	MB	
pyridostigmine bromide oral solution 60 mg/5ml	3	
pyridostigmine bromide oral tablet 60 mg	1	
ANTIMYCOBACTERIAL AGENTS		
*ANTI TB COMBINATIONS***		
RIFAMATE ORAL CAPSULE 150-300 MG	5	
*ANTIMYCOBACTERIAL AGENTS***		
ethambutol hcl oral tablet 100 mg, 400 mg	1	
isoniazid oral syrup 50 mg/5ml	2	
isoniazid oral tablet 100 mg	1	
isoniazid oral tablet 300 mg	2	
PASER ORAL PACKET 4 GM	1	
PRIFTIN ORAL TABLET 150 MG	3	
pyrazinamide oral tablet 500 mg	2	
rifabutin oral capsule 150 mg	5	
rifampin oral capsule 150 mg, 300 mg	1	
TRECATOR ORAL TABLET 250 MG	3	
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES		
*ALKYLATING AGENTS***		
busulfan intravenous solution 6 mg/ml	MB	DX (Diagnosis Validation Required)
carboplatin intravenous solution 50 mg/5ml	MB	DX (Diagnosis Validation Required)
cisplatin intravenous solution 100 mg/100ml, 50 mg/50ml	MB	DX (Diagnosis Validation Required)
HEXALEN ORAL CAPSULE 50 MG	4	PA; DX (Diagnosis Validation Required); NDS; SP

MPC032520 72 Effective: 09/15/2025

Drug Name	Tier	Notes
MYLERAN ORAL TABLET 2 MG	5	PA; DX (Diagnosis Validation Required); NDS; SP
oxaliplatin intravenous solution 50 mg/10ml	MB	DX (Diagnosis Validation Required)
thiotepa injection solution reconstituted 15 mg	MB	DX (Diagnosis Validation Required)
ZEPZELCA INTRAVENOUS SOLUTION RECONSTITUTED 4 MG	МВ	PA; DX (Diagnosis Validation Required)
*ANDROGEN BIOSYNTHESIS INHIBITORS***		
abiraterone acetate oral tablet 250 mg	3	QL (120 EA per 30 days); NDS
*ANTIADRENALS***		
LYSODREN ORAL TABLET 500 MG	5	
*ANTIANDROGENS***		·
bicalutamide oral tablet 50 mg	1	DX (Diagnosis Validation Required)
ERLEADA ORAL TABLET 240 MG	5	PA; DX (Diagnosis Validation Required); QL (1 EA per 1 day); SP
ERLEADA ORAL TABLET 60 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days)
flutamide oral capsule 125 mg	1	DX (Diagnosis Validation Required)
NUBEQA ORAL TABLET 300 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS
XTANDI ORAL CAPSULE 40 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS; SP
XTANDI ORAL TABLET 40 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS; SP
XTANDI ORAL TABLET 80 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP
*ANTIESTROGENS***		
tamoxifen citrate oral tablet 10 mg, 20 mg	1	\$0 (\$0 cost share when prescribed with the diagnosis code of Z15.01, Z80.3, Z80.9, Z85.3, Z85.9: Genetic susceptibility or family/personal history of neoplasm of breast.); DX (Diagnosis Validation Required)
toremifene citrate oral tablet 60 mg	5	DX (Diagnosis Validation Required)
*ANTIMETABOLITES***		
ADRUCIL INTRAVENOUS SOLUTION 500 MG/10ML	MB	DX (Diagnosis Validation Required)
capecitabine oral tablet 150 mg, 500 mg	5	DX (Diagnosis Validation Required); NDS
cytarabine (pf) injection solution 100 mg/ml	MB	DX (Diagnosis Validation Required)
DEPOCYT INTRATHECAL SUSPENSION 50 MG/5ML	MB	

MPC032520 73 Effective: 09/15/2025

Drug Name	Tier	Notes
fludarabine phosphate intravenous solution 50 mg/2ml	MB	DX (Diagnosis Validation Required)
FUDR INJECTION SOLUTION RECONSTITUTED 0.5 GM	МВ	DX (Diagnosis Validation Required)
GEMZAR INTRAVENOUS SOLUTION RECONSTITUTED 200 MG	MB	DX (Diagnosis Validation Required)
LEUSTATIN INTRAVENOUS SOLUTION 1 MG/ML	MB	
mercaptopurine oral tablet 50 mg	1	DX (Diagnosis Validation Required)
methotrexate oral tablet 2.5 mg	1	DX (Diagnosis Validation Required)
methotrexate sodium (pf) injection solution 1 gm/40ml, 250 mg/10ml, 50 mg/2ml	1	DX (Diagnosis Validation Required)
methotrexate sodium (pf) injection solution 100 mg/4ml, 25 mg/ml	1	
methotrexate sodium injection solution 25 mg/ml	1	
methotrexate sodium injection solution 250 mg/10ml, 50 mg/2ml	1	DX (Diagnosis Validation Required)
methotrexate sodium injection solution reconstituted 1 gm	1	DX (Diagnosis Validation Required)
methotrexate sodium oral tablet 2.5 mg	1	DX (Diagnosis Validation Required)
nelarabine intravenous solution 5 mg/ml	MB	DX (Diagnosis Validation Required)
TABLOID ORAL TABLET 40 MG	5	PA; DX (Diagnosis Validation Required); NDS; SP
TREXALL ORAL TABLET 10 MG, 15 MG, 5 MG, 7.5 MG	2	DX (Diagnosis Validation Required)
XATMEP ORAL SOLUTION 2.5 MG/ML	5	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - ALK INHIBITORS***		
ALECENSA ORAL CAPSULE 150 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (240 EA per 30 days)
ALUNBRIG ORAL TABLET 180 MG, 90 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP
ALUNBRIG ORAL TABLET 30 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP
ALUNBRIG ORAL TABLET THERAPY PACK 90 & 180 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (30 EA per 30 days)
LORBRENA ORAL TABLET 100 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP
LORBRENA ORAL TABLET 25 MG	5	PA; DX (Diagnosis Validation Required); QL (90 EA per 30 days); NDS; SP
XALKORI ORAL CAPSULE 200 MG, 250 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP

MPC032520 74 Effective: 09/15/2025

Drug Name	Tier	Notes
ZYKADIA ORAL CAPSULE 150 MG	4	PA; DX (Diagnosis Validation Required); QL (150 EA per 30 days); NDS; SP
*ANTINEOPLASTIC - ANTI-BCMA ANTIBODY-DRUG COMPLEX***		
BLENREP INTRAVENOUS SOLUTION RECONSTITUTED 100 MG	МВ	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - ANTI-CD19 ANTIBODIES***		
MONJUVI INTRAVENOUS SOLUTION RECONSTITUTED 200 MG	МВ	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - ANTI-CD20 ANTIBODIES***		
RUXIENCE INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML	MB	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - ANTI-CD22 ANTIBODY-DRUG COMPLEX***		
BESPONSA INTRAVENOUS SOLUTION RECONSTITUTED 0.9 MG	МВ	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - ANTI-CD30 ANTIBODY-DRUG COMPLEX***		
ADCETRIS INTRAVENOUS SOLUTION RECONSTITUTED 50 MG	МВ	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - ANTI-CD33 ANTIBODY-DRUG COMPLEX***		
MYLOTARG INTRAVENOUS SOLUTION RECONSTITUTED 4.5 MG	МВ	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - ANTI-CD38 ANTIBODIES***		
DARZALEX INTRAVENOUS SOLUTION 100 MG/5ML, 400 MG/20ML	MB	PA; DX (Diagnosis Validation Required)
SARCLISA INTRAVENOUS SOLUTION 100 MG/5ML, 500 MG/25ML	MB	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - ANTI-CD79B ANTIBODY-DRUG COMPLEX***		
POLIVY INTRAVENOUS SOLUTION RECONSTITUTED 140 MG	MB	PA; DX (Diagnosis Validation Required)
POLIVY INTRAVENOUS SOLUTION RECONSTITUTED 30 MG	MB	PA; DX (Diagnosis Validation Required); NDS
*ANTINEOPLASTIC - ANTI-HER2 AGENTS***		
OGIVRI INTRAVENOUS SOLUTION RECONSTITUTED 150 MG, 420 MG	MB	DX (Diagnosis Validation Required)

MPC032520 75 Effective: 09/15/2025

Drug Name	Tier	Notes
TUKYSA ORAL TABLET 150 MG, 50 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (120 EA per 30 days)
*ANTINEOPLASTIC - ANTI-NECTIN-4 ANTIBODY-DRUG COMPLEX***		
PADCEV INTRAVENOUS SOLUTION RECONSTITUTED 20 MG, 30 MG	MB	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - ANTI-PD-1 ANTIBODIES***		
LIBTAYO INTRAVENOUS SOLUTION 350 MG/7ML	МВ	PA; DX (Diagnosis Validation Required)
OPDIVO INTRAVENOUS SOLUTION 120 MG/12ML	MB	PA; DX (Diagnosis Validation Required)
TEVIMBRA INTRAVENOUS SOLUTION 100 MG/10ML	MB	РА
*ANTINEOPLASTIC - ANTI-PD-L1 ANTIBODIES***		
TECENTRIQ INTRAVENOUS SOLUTION 1200 MG/20ML, 840 MG/14ML	МВ	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - ANTI-SLAMF7 ANTIBODIES***		
EMPLICITI INTRAVENOUS SOLUTION RECONSTITUTED 300 MG, 400 MG	МВ	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - BCL-2 INHIBITORS***		
VENCLEXTA ORAL TABLET 10 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (60 EA per 30 days)
VENCLEXTA ORAL TABLET 100 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (120 EA per 30 days)
VENCLEXTA ORAL TABLET 50 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (30 EA per 30 days)
VENCLEXTA STARTING PACK ORAL TABLET THERAPY PACK 10 & 50 & 100 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (1 EA per 28 days)
*ANTINEOPLASTIC - BCR-ABL KINASE INHIBITORS***		
BOSULIF ORAL CAPSULE 100 MG	5	PA; QL (3 EA per 1 day); SP
BOSULIF ORAL TABLET 100 MG	5	PA; QL (90 EA per 30 days); NDS; SP
BOSULIF ORAL TABLET 400 MG, 500 MG	5	PA; QL (30 EA per 30 days); NDS; SP
dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg	5	PA; QL (30 EA per 30 days); NDS; SP
ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG	5	PA; LA; QL (30 EA per 30 days); SP
imatinib mesylate oral tablet 100 mg, 400 mg	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP

MPC032520 76 Effective: 09/15/2025

Drug Name	Tier	Notes
nilotinib hcl oral capsule 150 mg, 200 mg, 50 mg	5	PA; QL (120 EA per 30 days); NDS; SP
*ANTINEOPLASTIC - BRAF KINASE INHIBITORS***		•
BRAFTOVI ORAL CAPSULE 50 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (120 EA per 30 days)
BRAFTOVI ORAL CAPSULE 75 MG	5	PA; DX (Diagnosis Validation Required); QL (180 EA per 30 days); NDS; SP
TAFINLAR ORAL CAPSULE 50 MG, 75 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS; SP
ZELBORAF ORAL TABLET 240 MG	5	PA; DX (Diagnosis Validation Required); QL (240 EA per 30 days); NDS; SP
*ANTINEOPLASTIC - BTK INHIBITORS***		
BRUKINSA ORAL CAPSULE 80 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS; SP
CALQUENCE ORAL CAPSULE 100 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP
CALQUENCE ORAL TABLET 100 MG	4	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP
IMBRUVICA ORAL CAPSULE 140 MG	4	PA; LA; DX (Diagnosis Validation Required); QL (1 EA per 1 day); NDS
IMBRUVICA ORAL CAPSULE 70 MG	4	LA; DX (Diagnosis Validation Required); QL (1 EA per 1 day); NDS
IMBRUVICA ORAL SUSPENSION 70 MG/ML	4	PA; LA; DX (Diagnosis Validation Required); QL (6 ML per 1 day); NDS
IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG	4	PA; LA; DX (Diagnosis Validation Required); QL (28 EA per 28 days)
JAYPIRCA ORAL TABLET 100 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); SP
JAYPIRCA ORAL TABLET 50 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); SP
*ANTINEOPLASTIC - EGFR INHIBITORS***		
ERBITUX INTRAVENOUS SOLUTION 100 MG/50ML, 200 MG/100ML	МВ	PA; DX (Diagnosis Validation Required)
erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP

MPC032520 77 Effective: 09/15/2025

Drug Name	Tier	Notes
gefitinib oral tablet 250 mg	5	PA; LA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS
GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (30 EA per 30 days)
TAGRISSO ORAL TABLET 40 MG, 80 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP
VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP
*ANTINEOPLASTIC - FGFR KINASE INHIBITORS***		
BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG	5	PA; DX (Diagnosis Validation Required); SP
PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (14 EA per 21 days)
*ANTINEOPLASTIC - HEDGEHOG PATHWAY INHIBITORS***		
DAURISMO ORAL TABLET 100 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP
DAURISMO ORAL TABLET 25 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP
ERIVEDGE ORAL CAPSULE 150 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP
ODOMZO ORAL CAPSULE 200 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); SP
*ANTINEOPLASTIC - HISTONE DEACETYLASE INHIBITORS***		
FARYDAK ORAL CAPSULE 10 MG, 15 MG, 20 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (6 EA per 21 days)
ZOLINZA ORAL CAPSULE 100 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS; SP
*ANTINEOPLASTIC - IMMUNOMODULATORS***		
POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG	5	PA; DX (Diagnosis Validation Required); QL (21 EA per 28 days); NDS; SP
*ANTINEOPLASTIC - KRAS INHIBITORS***		
KRAZATI ORAL TABLET 200 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (180 EA per 30 days); NDS
MDC032520	78	Effective: 00/15/2024

Drug Name	Tier	Notes	
LUMAKRAS ORAL TABLET 120 MG	5	PA; DX (Diagnosis Validation Required); QL (8 EA per 1 day); NDS; SP	
LUMAKRAS ORAL TABLET 320 MG	5	PA; DX (Diagnosis Validation Required); QL (3 EA per 1 day); SP	
*ANTINEOPLASTIC - MEK INHIBITORS***			
MEKINIST ORAL TABLET 0.5 MG	5	PA; DX (Diagnosis Validation Required); QL (90 EA per 30 days); NDS; SP	
MEKINIST ORAL TABLET 2 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP	
MEKTOVI ORAL TABLET 15 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (180 EA per 30 days)	
*ANTINEOPLASTIC - MET INHIBITORS***			
TABRECTA ORAL TABLET 150 MG, 200 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS; SP	
*ANTINEOPLASTIC - METHYLTRANSFERASE INHIBITORS***			
TAZVERIK ORAL TABLET 200 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (240 EA per 30 days)	
*ANTINEOPLASTIC - MTOR KINASE INHIBITORS***			
everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg	5	PA; DX (Diagnosis Validation Required); NDS; SP	
everolimus oral tablet soluble 2 mg, 3 mg, 5 mg	5	PA; DX (Diagnosis Validation Required); NDS; SP	
TORISEL INTRAVENOUS SOLUTION 25 MG/ML	MB	DX (Diagnosis Validation Required)	
*ANTINEOPLASTIC - MULTIKINASE INHIBITORS***			
CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP	
CAPRELSA ORAL TABLET 100 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (60 EA per 30 days)	
CAPRELSA ORAL TABLET 300 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (30 EA per 30 days)	
COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG	5	PA; LA; DX (Diagnosis Validation Required)	
COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG	5	PA; LA; DX (Diagnosis Validation Required)	
COMETRIQ (60 MG DAILY DOSE) ORAL KIT 20 MG	5	PA; LA; DX (Diagnosis Validation Required)	

MPC032520 79 Effective: 09/15/2025

Drug Name	Tier	Notes
lapatinib ditosylate oral tablet 250 mg	5	PA; DX (Diagnosis Validation Required); QL (180 EA per 30 days); NDS; SP
NERLYNX ORAL TABLET 40 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (180 EA per 30 days); SP
pazopanib hcl oral tablet 200 mg	5	PA; DX (Diagnosis Validation Required); QL (1200 EA per 30 days); NDS; SP
QINLOCK ORAL TABLET 50 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (90 EA per 30 days)
RYDAPT ORAL CAPSULE 25 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days)
sorafenib tosylate oral tablet 200 mg	4	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); SP
STIVARGA ORAL TABLET 40 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS; SP
sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg	5	PA; DX (Diagnosis Validation Required); NDS; SP
UKONIQ ORAL TABLET 200 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (120 EA per 30 days)
XOSPATA ORAL TABLET 40 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (90 EA per 30 days)
*ANTINEOPLASTIC - MULTIPLE RECEPTOR ANTIBODIES***		
RYBREVANT INTRAVENOUS SOLUTION 350 MG/7ML	MB	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - PDGFR-ALPHA INHIBITORS***		
AYVAKIT ORAL TABLET 100 MG, 200 MG, 300 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP
*ANTINEOPLASTIC - PROTEASOME INHIBITORS***		
bortezomib injection solution reconstituted 3.5 mg	5	DX (Diagnosis Validation Required)
bortezomib intravenous solution reconstituted 3.5 mg	MB	DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - RET INHIBITORS***		
RETEVMO ORAL CAPSULE 40 MG	5	PA; DX (Diagnosis Validation Required); QL (180 EA per 30 days); NDS; SP
RETEVMO ORAL CAPSULE 80 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS; SP

MPC032520 80 Effective: 09/15/2025

Drug Name	Tier	Notes
RETEVMO ORAL TABLET 120 MG, 160 MG, 80 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (2 EA per 1 day); NDS
RETEVMO ORAL TABLET 40 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (3 EA per 1 day); NDS
*ANTINEOPLASTIC - TROPOMYOSIN RECEPTOR KINASE INHIBITORS***		
ROZLYTREK ORAL CAPSULE 100 MG, 200 MG	5	PA; DX (Diagnosis Validation Required); NDS; SP
*ANTINEOPLASTIC - TYROSINE KINASE INHIBITORS***		
COMETRIQ (100 MG DAILY DOSE) ORAL KIT 1 X 80 & 1 X 20 MG	4	PA; DX (Diagnosis Validation Required)
COMETRIQ (140 MG DAILY DOSE) ORAL KIT 1 X 80 & 3 X 20 MG	4	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC - XPO1 INHIBITORS***		
XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (4 EA per 28 days)
XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (8 EA per 28 days)
XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG, 40 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (4 EA per 28 days)
XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (4 EA per 28 days)
XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (8 EA per 28 days)
XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG, 60 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (4 EA per 28 days)
XPOVIO (60 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (4 EA per 28 days)
XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 20 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (4 EA per 28 days)
XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG	5	PA; LA; DX (Diagnosis Validation Required)
XPOVIO (80 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (4 EA per 28 days)
*ANTINEOPLASTIC ANTIBIOTICS***		
bleomycin sulfate injection solution reconstituted 15 unit	MB	DX (Diagnosis Validation Required)
CERUBIDINE INTRAVENOUS SOLUTION RECONSTITUTED 20 MG	MB	
COSMEGEN INTRAVENOUS SOLUTION RECONSTITUTED 0.5 MG	MB	DX (Diagnosis Validation Required)
DAUNOXOME INTRAVENOUS INJECTABLE 2 MG/ML	MB	

MPC032520 81 Effective: 09/15/2025

Drug Name	Tier	Notes
ELLENCE INTRAVENOUS SOLUTION 200 MG/100ML	МВ	DX (Diagnosis Validation Required)
IDAMYCIN PFS INTRAVENOUS SOLUTION 5 MG/5ML	MB	DX (Diagnosis Validation Required)
mitomycin intravenous solution reconstituted 5 mg	MB	DX (Diagnosis Validation Required)
mitoxantrone hcl intravenous concentrate 25 mg/12.5ml	МВ	DX (Diagnosis Validation Required)
valrubicin intravesical solution 40 mg/ml	MB	DX (Diagnosis Validation Required)
*ANTINEOPLASTIC ANTIBODY-DRUG COMPLEXES***		
ENHERTU INTRAVENOUS SOLUTION RECONSTITUTED 100 MG	MB	PA; DX (Diagnosis Validation Required)
KADCYLA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 160 MG	MB	PA; DX (Diagnosis Validation Required)
*ANTINEOPLASTIC COMBINATIONS***		
DARZALEX FASPRO SUBCUTANEOUS SOLUTION 1800-30000 MG-UT/15ML	МВ	PA; DX (Diagnosis Validation Required)
INQOVI ORAL TABLET 35-100 MG	5	PA; DX (Diagnosis Validation Required); QL (5 EA per 28 days); NDS; SP
KISQALI FEMARA (200 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG	5	PA; LA; QL (49 EA per 28 days)
KISQALI FEMARA (400 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG	5	PA; LA; QL (70 EA per 28 days)
KISQALI FEMARA (600 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG	5	PA; LA; QL (91 EA per 28 days)
LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG	5	PA; DX (Diagnosis Validation Required); QL (40 EA per 28 days); SP
OPDIVO QVANTIG SUBCUTANEOUS SOLUTION 600-10000 MG-UT/5ML	MB	PA; DX (Diagnosis Validation Required)
TECENTRIQ HYBREZA SUBCUTANEOUS SOLUTION 1875-30000 MG-UT/15ML	МВ	PA; DX (Diagnosis Validation Required)
VYXEOS INTRAVENOUS SUSPENSION RECONSTITUTED 44-100 MG	MB	РА
*ANTINEOPLASTIC ENZYMES***		
ONCASPAR INJECTION SOLUTION 750 UNIT/ML	МВ	PA; DX (Diagnosis Validation Required); NDS
*ANTINEOPLASTICS - PHOTOACTIVATED AGENTS***		
PHOTOFRIN INTRAVENOUS SOLUTION RECONSTITUTED 75 MG	MB	
*ANTINEOPLASTICS MISC.***		
ALFERON N INJECTION SOLUTION 5000000 UNIT/ML	MB	

Drug Name	Tier	Notes
dacarbazine intravenous solution reconstituted 100 mg	МВ	DX (Diagnosis Validation Required)
hydroxyurea oral capsule 500 mg	1	DX (Diagnosis Validation Required)
INTRON A INJECTION SOLUTION 10000000 UNIT/ML, 6000000 UNIT/ML	5	NDS; SP
INTRON A INJECTION SOLUTION RECONSTITUTED 50000000 UNIT	5	NDS; SP
INTRON-A SUBCUTANEOUS KIT 10000000 UNIT/0.2ML	4	
MATULANE ORAL CAPSULE 50 MG	5	PA; DX (Diagnosis Validation Required); SP
NIPENT INTRAVENOUS SOLUTION RECONSTITUTED 10 MG	МВ	DX (Diagnosis Validation Required)
ONTAK INTRAVENOUS SOLUTION 150 MCG/ML	MB	
SYLATRON SUBCUTANEOUS KIT 4 X 200 MCG, 4 X 300 MCG	4	PA; DX (Diagnosis Validation Required)
SYLATRON SUBCUTANEOUS KIT 600 MCG	5	PA; DX (Diagnosis Validation Required); NDS; SP
TRISENOX INTRAVENOUS SOLUTION 12 MG/6ML	MB	DX (Diagnosis Validation Required)
*AROMATASE INHIBITORS***		
anastrozole oral tablet 1 mg	1	\$0 (\$0 cost share when prescribed with the diagnosis code of Z15.01, Z80.3, Z80.9, Z85.3, Z85.9: Genetic susceptibility or family/personal history of neoplasm of breast); DX (Diagnosis code at point of sale accepted)
exemestane oral tablet 25 mg	3	\$0 (\$0 cost share when prescribed with the diagnosis code of Z15.01, Z80.3, Z80.9, Z85.3, Z85.9: Genetic susceptibility or family/personal history of neoplasm of breast); DX (Diagnosis code at point of sale accepted)
letrozole oral tablet 2.5 mg	1	\$0 (\$0 cost share when prescribed with the diagnosis code of Z15.01, Z80.3, Z80.9, Z85.3, Z85.9: Genetic susceptibility or family/personal history of neoplasm of breast); DX (Diagnosis code at point of sale accepted)
*CARDIAC PROTECTIVE AGENTS***		
dexrazoxane intravenous solution reconstituted 250 mg	МВ	
*CYCLIN-DEPENDENT KINASES (CDK) INHIBITORS***		

MPC032520 83 Effective: 09/15/2025

Drug Name	Tier	Notes
IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG	5	PA; DX (Diagnosis Validation Required); QL (21 EA per 28 days); NDS; SP
IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG	5	PA; DX (Diagnosis Validation Required); QL (21 EA per 28 days); NDS; SP
KISQALI (200 MG DOSE) ORAL TABLET THERAPY PACK 200 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (21 EA per 28 days)
KISQALI (400 MG DOSE) ORAL TABLET THERAPY PACK 200 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (42 EA per 28 days)
KISQALI (600 MG DOSE) ORAL TABLET THERAPY PACK 200 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (63 EA per 28 days)
VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); SP
*ESTROGEN RECEPTOR ANTAGONIST***		
fulvestrant intramuscular solution prefilled syringe 250 mg/5ml	5	
*ESTROGENS-ANTINEOPLASTIC***		
EMCYT ORAL CAPSULE 140 MG	5	PA; DX (Diagnosis Validation Required); NDS; SP
*FOLIC ACID ANTAGONISTS RESCUE AGENTS***		
leucovorin calcium injection solution reconstituted 50 mg	MB	
leucovorin calcium oral tablet 10 mg, 15 mg	2	
leucovorin calcium oral tablet 25 mg, 5 mg	1	
*GONADOTROPIN RELEASING HORMONE (GNRH) ANTAGONISTS***		
FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 120 MG	MB	
*IMIDAZOTETRAZINES***		
temozolomide oral capsule 100 mg, 140 mg, 180 mg, 20 mg, 250 mg, 5 mg	3	PA; DX (Diagnosis Validation Required); NDS
*ISOCITRATE DEHYDROGENASE-1 (IDH1) INHIBITORS***		
TIBSOVO ORAL TABLET 250 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (60 EA per 30 days)
*JANUS ASSOCIATED KINASE (JAK) INHIBITORS***		
JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP
*LHRH ANALOGS***		

MPC032520 84 Effective: 09/15/2025

Drug Name	Tier	Notes
leuprolide acetate injection kit 1 mg/0.2ml	MB	DX (Diagnosis Validation Required)
LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 7.5 MG	МВ	DX (Diagnosis Validation Required)
LUPRON DEPOT (3-MONTH) INTRAMUSCULAR KIT 11.25 MG, 22.5 MG	МВ	DX (Diagnosis Validation Required)
LUPRON DEPOT (4-MONTH) INTRAMUSCULAR KIT 30 MG	МВ	DX (Diagnosis Validation Required)
TRELSTAR MIXJECT INTRAMUSCULAR SUSPENSION RECONSTITUTED 11.25 MG, 22.5 MG, 3.75 MG	MB	PA; DX (Diagnosis Validation Required)
VANTAS SUBCUTANEOUS KIT 50 MG	MB	
*MITOTIC INHIBITORS***		
docetaxel intravenous concentrate 160 mg/8ml, 20 mg/ml, 80 mg/4ml	MB	DX (Diagnosis Validation Required)
docetaxel intravenous concentrate 200 mg/10ml	MB	
ETOPOPHOS INTRAVENOUS SOLUTION RECONSTITUTED 100 MG	МВ	DX (Diagnosis Validation Required)
etoposide oral capsule 50 mg	3	DX (Diagnosis Validation Required)
IXEMPRA KIT INTRAVENOUS SOLUTION RECONSTITUTED 15 MG, 45 MG	МВ	DX (Diagnosis Validation Required)
NAVELBINE INTRAVENOUS SOLUTION 10 MG/ML	MB	DX (Diagnosis Validation Required)
ONXOL INTRAVENOUS CONCENTRATE 150 MG/25ML	МВ	DX (Diagnosis Validation Required)
TOPOSAR INTRAVENOUS SOLUTION 100 MG/5ML	MB	DX (Diagnosis Validation Required)
vinblastine sulfate intravenous solution 1 mg/ml	MB	DX (Diagnosis Validation Required)
VINCASAR PFS INTRAVENOUS SOLUTION 1 MG/ML	МВ	DX (Diagnosis Validation Required)
*NITROGEN MUSTARDS AND RELATED ANALOGUES***		
ALKERAN INTRAVENOUS SOLUTION RECONSTITUTED 50 MG	MB	DX (Diagnosis Validation Required)
ALKERAN ORAL TABLET 2 MG	MB	DX (Diagnosis Validation Required)
cyclophosphamide injection solution reconstituted 1 gm	МВ	DX (Diagnosis Validation Required)
cyclophosphamide oral capsule 25 mg, 50 mg	3	DX (Diagnosis Validation Required)
1 GM	MB	DX (Diagnosis Validation Required)
LEUKERAN ORAL TABLET 2 MG	5	PA; DX (Diagnosis Validation Required); NDS; SP
melphalan oral tablet 2 mg	1	DX (Diagnosis Validation Required)
MUSTARGEN INJECTION SOLUTION RECONSTITUTED 10 MG	MB	
*NITROSOUREAS***		

Drug Name	Tier	Notes
carmustine intravenous solution reconstituted 300 mg, 50 mg	MB	
GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG	4	PA; DX (Diagnosis Validation Required)
ZANOSAR INTRAVENOUS SOLUTION RECONSTITUTED 1 GM	МВ	
*PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS***		
COPIKTRA ORAL CAPSULE 15 MG, 25 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (60 EA per 30 days)
ITOVEBI ORAL TABLET 3 MG	5	PA; DX (Diagnosis Validation Required); QL (2 EA per 1 day); NDS; SP
ITOVEBI ORAL TABLET 9 MG	5	PA; DX (Diagnosis Validation Required); QL (1 EA per 1 day); NDS; SP
PIQRAY (200 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP
PIQRAY (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 & 50 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days)
PIQRAY (300 MG DAILY DOSE) ORAL TABLET THERAPY PACK 2 X 150 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP
ZYDELIG ORAL TABLET 100 MG, 150 MG	5	PA; LA; DX (Diagnosis Validation Required); QL (60 EA per 30 days)
*POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS***		
LYNPARZA ORAL TABLET 100 MG, 150 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS; SP
RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS; SP
TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP
ZEJULA ORAL CAPSULE 100 MG	5	PA; DX (Diagnosis Validation Required); QL (90 EA per 30 days); NDS; SP
ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP
*PROGESTINS-ANTINEOPLASTIC***		
DEPO-PROVERA INTRAMUSCULAR SUSPENSION 400 MG/ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)

MPC032520 86 Effective: 09/15/2025

Drug Name	Tier	Notes
megestrol acetate oral suspension 40 mg/ml, 400 mg/10ml	1	
megestrol acetate oral tablet 20 mg, 40 mg	1	
*SELECTIVE ESTROGEN RECEPTOR DEGRADERS***		
ORSERDU ORAL TABLET 345 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); SP
ORSERDU ORAL TABLET 86 MG	5	PA; DX (Diagnosis Validation Required); QL (90 EA per 30 days); SP
*SELECTIVE RETINOID X RECEPTOR AGONISTS***		
bexarotene oral capsule 75 mg	5	PA; DX (Diagnosis Validation Required); NDS; SP
*TOPOISOMERASE I INHIBITORS***		
CAMPTOSAR INTRAVENOUS SOLUTION 40 MG/2ML	МВ	DX (Diagnosis Validation Required)
HYCAMTIN ORAL CAPSULE 0.25 MG, 1 MG	5	PA; DX (Diagnosis Validation Required); NDS; SP
*URINARY TRACT PROTECTIVE AGENTS***		
MESNEX INTRAVENOUS SOLUTION 100 MG/ML	МВ	
MESNEX ORAL TABLET 400 MG	5	
*VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS***		
INLYTA ORAL TABLET 1 MG, 5 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS; SP
LENVIMA (10 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); SP
LENVIMA (12 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 3 X 4 MG	5	PA; DX (Diagnosis Validation Required); QL (90 EA per 30 days); SP
LENVIMA (14 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 & 4 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); SP
LENVIMA (18 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG & 2 X 4 MG	5	PA; DX (Diagnosis Validation Required); QL (90 EA per 30 days); SP
LENVIMA (20 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); SP

MPC032520 87 Effective: 09/15/2025

Drug Name	Tier	Notes
LENVIMA (24 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG & 4 MG	5	PA; DX (Diagnosis Validation Required); QL (90 EA per 30 days); SP
LENVIMA (4 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 4 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); SP
LENVIMA (8 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 4 MG	5	PA; DX (Diagnosis Validation Required); QL (60 EA per 30 days); SP
ANTIPARKINSON AND RELATED THERAPY AGENTS		
*ANTIPARKINSON ANTICHOLINERGICS***		
benztropine mesylate oral tablet 0.5 mg, 1 mg, 2 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost
		share is subject to applicable benefit plans.)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
COGENTIN INJECTION SOLUTION 1 MG/ML	МВ	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
trihexyphenidyl hcl oral elixir 0.4 mg/ml	1	
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
trihexyphenidyl hcl oral tablet 2 mg, 5 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*ANTIPARKINSON DOPAMINERGICS***		
amantadine hcl oral capsule 100 mg	1	
amantadine hcl oral syrup 50 mg/5ml	1	
amantadine hcl oral tablet 100 mg	1	

MPC032520 88 Effective: 09/15/2025

Drug Name	Tier	Notes
bromocriptine mesylate oral capsule 5 mg	1	
bromocriptine mesylate oral tablet 2.5 mg	1	
*ANTIPARKINSON MONOAMINE OXIDASE INHIBITORS***		•
rasagiline mesylate oral tablet 0.5 mg, 1 mg	3	ST
selegiline hcl oral capsule 5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
selegiline hcl oral tablet 5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*CENTRAL/PERIPHERAL COMT INHIBITORS***		
tolcapone oral tablet 100 mg	3	
*LEVODOPA COMBINATIONS***	L	
carbidopa-levodopa er oral tablet extended release 25-100 mg, 50-200 mg	1	
carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg	1	
carbidopa-levodopa oral tablet dispersible 10-100 mg, 25-100 mg, 25-250 mg	1	
carbidopa-levodopa-entacapone oral tablet 12.5-50- 200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25- 125-200 mg, 37.5-150-200 mg, 50-200-200 mg	3	
*NONERGOLINE DOPAMINE RECEPTOR AGONISTS***		
APOKYN SUBCUTANEOUS SOLUTION 10 MG/ML	4	PA; LA
KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG	5	PA; LA; QL (150 EA per 30 days)
KYNMOBI TITRATION KIT SUBLINGUAL KIT 10&15&20&25&30 MG	5	PA; LA; QL (1 EA per 180 days)

MPC032520 89 Effective: 09/15/2025

Drug Name	Tier	Notes
pramipexole dihydrochloride oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
ropinirole hcl oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg	1	
*PERIPHERAL COMT INHIBITORS***		
entacapone oral tablet 200 mg	1	
ONGENTYS ORAL CAPSULE 50 MG	5	PA; QL (30 EA per 30 days); NDS; SP
ANTIPSYCHOTICS/ANTIMANIC AGENTS		
*ANTIMANIC AGENTS***		
lithium carbonate er oral tablet extended release 300 mg, 450 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
lithium carbonate oral capsule 150 mg, 300 mg, 600 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
lithium carbonate oral tablet 300 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 90 Effective: 09/15/2025

Drug Name	Tier	Notes
lithium oral solution 8 meq/5ml	2	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*ANTIPSYCHOTICS - MISC.***		pians.)
CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG	4	PA; QL (30 EA per 30 days); AL (Min 18 Years)
lurasidone hcl oral tablet 120 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 13 Years)
lurasidone hcl oral tablet 20 mg, 40 mg, 60 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 10 Years)
lurasidone hcl oral tablet 80 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 10 Years)

MPC032520 91 Effective: 09/15/2025

Drug Name	Tier	Notes
VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG	4	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1 EA per 1 day); AL (Min 18 Years)
VRAYLAR ORAL CAPSULE THERAPY PACK 1.5 & 3 MG	4	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (7 EA per 365 days); AL (Min 18 Years)
ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 6 Years)
*BENZISOXAZOLES***		
FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG	5	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 18 Years)

MPC032520 92 Effective: 09/15/2025

Drug Name	Tier	Notes
FANAPT TITRATION PACK A ORAL TABLET 1 & 2 & 4 & 6 MG	5	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1 EA per 365 days); AL (Min 18 Years)
FANAPT TITRATION PACK ORAL TABLET 1 & 2 & 4 & 6 MG	5	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1 EA per 365 days); AL (Min 18 Years)
INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117 MG/0.75ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.75 ML per 28 days); AL (Min 18 Years); NDS
INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 156 MG/ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1 ML per 28 days); AL (Min 18 Years); NDS

MPC032520 93 Effective: 09/15/2025

Drug Name	Tier	Notes
INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 234 MG/1.5ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.5 ML per 28 days); AL (Min 18 Years); NDS
INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 39 MG/0.25ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.25 ML per 28 days); AL (Min 18 Years); NDS
INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 78 MG/0.5ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.5 ML per 28 days); AL (Min 18 Years); NDS
INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.875ML	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.88 ML per 84 days); AL (Min 18 Years); NDS

MPC032520 94 Effective: 09/15/2025

Drug Name	Tier	Notes
INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (0.88 ML per 84 days); AL (Min 18 Years); NDS
INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 410 MG/1.315ML	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.32 ML per 84 days); AL (Min 18 Years); NDS
INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 410 MG/1.32ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.32 ML per 84 days); AL (Min 18 Years); NDS
INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 546 MG/1.75ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.75 ML per 84 days); AL (Min 18 Years); NDS

Drug Name	Tier	Notes
INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 819 MG/2.625ML	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2.63 ML per 84 days); AL (Min 18 Years); NDS
INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 819 MG/2.63ML	4	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2.63 ML per 84 days); AL (Min 18 Years); NDS
paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg, 6 mg, 9 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 12 Years)
risperidone microspheres er intramuscular suspension reconstituted er 12.5 mg, 25 mg, 37.5 mg, 50 mg	5	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2 EA per 28 days); AL (Min 18 Years); NDS

Drug Name	Tier	Notes
risperidone oral solution 1 mg/ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (480 ML per 30 days); AL
		(Min 5 Years) BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
risperidone oral tablet 0.25 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 5 Years)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
risperidone oral tablet 0.5 mg, 1 mg, 2 mg, 3 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 5 Years)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
risperidone oral tablet 4 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days); AL (Min 5 Years)

Drug Name	Tier	Notes
risperidone oral tablet dispersible 0.25 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 5 Years)
risperidone oral tablet dispersible 0.5 mg, 1 mg, 2 mg, 3 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 5 Years)
risperidone oral tablet dispersible 4 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days); AL (Min 5 Years)
*BUTYROPHENONES***		
haloperidol decanoate intramuscular solution 100 mg/ml, 50 mg/ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Min 18 Years)

MPC032520 98 Effective: 09/15/2025

Drug Name	Tier	Notes
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
haloperidol lactate injection solution 5 mg/ml	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Min 18 Years)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
haloperidol lactate oral concentrate 2 mg/ml	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Min 3 Years)
halanaridal aral tablat 0.5 mg, 1 mg, 10 mg, 2 mg, 20		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Min 3 Years)
*DIBENZODIAZEPINES***		
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
clozapine oral tablet 100 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (270 EA per 30 days); AL (Min 6 Years)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
clozapine oral tablet 200 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (135 EA per 30 days); AL (Min 6 Years)

MPC032520 99 Effective: 09/15/2025

Drug Name	Tier	Notes
clozapine oral tablet 25 mg, 50 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 6 Years)
*DIBENZO-OXEPINO PYRROLES***		
asenapine maleate sublingual tablet sublingual 10 mg, 2.5 mg, 5 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 10 Years)
SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24HR, 5.7 MG/24HR, 7.6 MG/24HR	5	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero cost share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*DIBENZOTHIAZEPINES***		
quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg, 300 mg, 50 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)

MPC032520 100 Effective: 09/15/2025

Drug Name	Tier	Notes
quetiapine fumarate er oral tablet extended release 24 hour 400 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to
		deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
quetiapine fumarate oral tablet 100 mg, 200 mg, 25 mg, 400 mg, 50 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (90 EA per 30 days); AL (Min 6 Years)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
quetiapine fumarate oral tablet 150 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
quetiapine fumarate oral tablet 300 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days); AL (Min 6 Years)
*DIBENZOXAZEPINES***		
loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 101 Effective: 09/15/2025

Drug Name	Tier	Notes	
*MUSCARINIC AGENT - COMBINATIONS***			
COBENFY ORAL CAPSULE 100-20 MG, 125-30 MG, 50-20 MG	5	PA; QL (2 EA per 1 day); AL (Min 18 Years)	
COBENFY STARTER PACK ORAL CAPSULE THERAPY PACK 50-20 & 100-20 MG	5	PA; QL (56 EA per 365 days); AL (Min 18 Years)	
*PHENOTHIAZINES***			
chlorpromazine hcl injection solution 25 mg/ml, 50 mg/2ml		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.	
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)	
chlorpromazine hcl oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)	
COMPRO RECTAL SUPPOSITORY 25 MG	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)	
fluphenazine decanoate injection solution 25 mg/ml	МВ	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)	

MPC032520 102 Effective: 09/15/2025

Drug Name	Tier	Notes
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
fluphenazine hcl oral concentrate 5 mg/ml	2	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
fluphenazine hcl oral elixir 2.5 mg/5ml	2	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
fluphenazine hcl oral tablet 5 mg	1	
perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost
		share is subject to applicable benefit plans.)
prochlorperazine edisylate injection solution 10 mg/2ml		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
	MB	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 103 Effective: 09/15/2025

Drug Name	Tier	Notes
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
prochlorperazine edisylate injection solution 5 mg/ml	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
prochlorperazine maleate oral tablet 10 mg, 5 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
prochlorperazine rectal suppository 25 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
this vide zine hel eval tablet 10 mg, 100 mg, 25 mg, 50		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
thioridazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
trifluoperazine hcl oral tablet 1 mg, 10 mg, 2 mg, 5 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*QUINOLINONE DERIVATIVES***		

MPC032520 104 Effective: 09/15/2025

Drug Name	Tier	Notes
ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE 300 MG, 400 MG	5	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (3 EA per 84 days); AL (Min 18 Years)
ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 300 MG, 400 MG	5	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (3 EA per 84 days); AL (Min 18 Years)
aripiprazole oral solution 1 mg/ml	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (750 ML per 30 days); AL (Min 6 Years)
aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years)

MPC032520 105 Effective: 09/15/2025

Drug Name	Tier	Notes
aripiprazole oral tablet dispersible 10 mg, 15 mg	4	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years)
ARISTADA INITIO INTRAMUSCULAR PREFILLED SYRINGE 675 MG/2.4ML	5	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2.4 ML per 30 days); AL (Min 18 Years)
ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 1064 MG/3.9ML	5	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (3.9 ML per 56 days); AL (Min 18 Years); NDS
ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 441 MG/1.6ML	5	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1.6 ML per 28 days); AL (Min 18 Years); NDS

MPC032520 106 Effective: 09/15/2025

Drug Name	Tier	Notes
ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 662 MG/2.4ML	5	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2.4 ML per 28 days); AL (Min 18 Years); NDS
ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 882 MG/3.2ML	5	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (3.2 ML per 28 days); AL (Min 18 Years); NDS
REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG	5	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 13 Years)
*THIENBENZODIAZEPINES***		
olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years)

MPC032520 107 Effective: 09/15/2025

Drug Name	Tier	Notes
olanzapine oral tablet dispersible 10 mg, 15 mg, 20 mg, 5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); AL (Min 6 Years)
*THIOXANTHENES***		
thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
ANTISEPTICS & DISINFECTANTS		
*CHLORINE ANTISEPTICS***		
chlorhexidine gluconate solution 20 %	1	
ANTIVIRALS		
*ANTIRETROVIRAL COMBINATIONS***		
abacavir sulfate-lamivudine oral tablet 600-300 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)

MPC032520 108 Effective: 09/15/2025

Drug Name	Tier	Notes
abacavir-lamivudine-zidovudine oral tablet 300-150- 300 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
BIKTARVY ORAL TABLET 30-120-15 MG, 50-200- 25 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
CABENUVA INTRAMUSCULAR SUSPENSION EXTENDED RELEASE 400 & 600 MG/2ML, 600 & 900 MG/3ML	MB	PA
CIMDUO ORAL TABLET 300-300 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)

Drug Name	Tier	Notes
DELSTRIGO ORAL TABLET 100-300-300 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
DESCOVY ORAL TABLET 120-15 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
DESCOVY ORAL TABLET 200-25 MG	\$0	\$0 (Zero Dollar Copay); DX (Covered at a zero-dollar copay for the diagnosis of Pre-exposure prophylaxis (PrEP) per ACA); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)

MPC032520 110 Effective: 09/15/2025

Drug Name	Tier	Notes
efavirenz-lamivudine-tenofovir oral tablet 400-300-300 mg, 600-300-300 mg	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
emtricitabine-tenofovir df oral tablet 100-150 mg, 133- 200 mg	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
emtricitabine-tenofovir df oral tablet 167-250 mg	5	\$0 (Zero Dollar Copay); DX (Covered at a zero-dollar copay for the diagnosis of Pre-exposure prophylaxis (PrEP) per ACA); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)

MPC032520 111 Effective: 09/15/2025

Drug Name	Tier	Notes
emtricitabine-tenofovir df oral tablet 200-300 mg	\$0	\$0 (Zero Dollar Copay); DX (Covered at a zero-dollar copay for the diagnosis of Pre-exposure prophylaxis (PrEP) per ACA); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
emtricitab-rilpivir-tenofov df oral tablet 200-25-300 mg	\$0	plans.); QL (30 EA per 30 days) STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
EVOTAZ ORAL TABLET 300-150 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
GENVOYA ORAL TABLET 150-150-200-10 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)

MPC032520 112 Effective: 09/15/2025

Drug Name	Tier	Notes
JULUCA ORAL TABLET 50-25 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
		plans.); QL (30 EA per 30 days) \$0 (Zero Dollar Copay); STI
lamivudine-zidovudine oral tablet 150-300 mg	\$0	(Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
lopinavir-ritonavir oral solution 400-100 mg/5ml	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (300 ML per 30 days)
lopinavir-ritonavir oral tablet 100-25 mg, 200-50 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)

MPC032520 113 Effective: 09/15/2025

Drug Name	Tier	Notes
ODEFSEY ORAL TABLET 200-25-25 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
PREZCOBIX ORAL TABLET 800-150 MG	5	plans.); QL (30 EA per 30 days) \$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
STRIBILD ORAL TABLET 150-150-200-300 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
SYMTUZA ORAL TABLET 800-150-200-10 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)

MPC032520 114 Effective: 09/15/2025

Drug Name	Tier	Notes
TRIUMEQ ORAL TABLET 600-50-300 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
triumeq pd oral tablet soluble 60-5-30 mg *ANTIRETROVIRALS - CCR5	5	plans.); QL (30 EA per 30 days) \$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days)
ANTAGONISTS (ENTRY INHIBITOR)***		
maraviroc oral tablet 150 mg, 300 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)

MPC032520 115 Effective: 09/15/2025

Drug Name	Tier	Notes
SELZENTRY ORAL SOLUTION 20 MG/ML	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (900 ML per 30 days)
SELZENTRY ORAL TABLET 25 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)
SELZENTRY ORAL TABLET 75 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
*ANTIRETROVIRALS - CD4-DIRECTED POST-ATTACHMENT INHIBITOR***		
TROGARZO INTRAVENOUS SOLUTION 200 MG/1.33ML	MB	
*ANTIRETROVIRALS - FUSION INHIBITORS***		

MPC032520 116 Effective: 09/15/2025

Drug Name	Tier	Notes
FUZEON SUBCUTANEOUS KIT 90 MG	\$0	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED 90 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*ANTIRETROVIRALS - GP120-DIRECTED ATTACHMENT INHIBITOR***		
RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HOUR 600 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
*ANTIRETROVIRALS - INTEGRASE INHIBITORS***		
APRETUDE INTRAMUSCULAR SUSPENSION EXTENDED RELEASE 600 MG/3ML	MB	

MPC032520 117 Effective: 09/15/2025

Drug Name	Tier	Notes
ISENTRESS HD ORAL TABLET 600 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
		plans.); QL (60 EA per 30 days) \$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be
ISENTRESS ORAL PACKET 100 MG	\$0	covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
ISENTRESS ORAL TABLET 400 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
ISENTRESS ORAL TABLET CHEWABLE 100 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)

MPC032520 118 Effective: 09/15/2025

Drug Name	Tier	Notes
ISENTRESS ORAL TABLET CHEWABLE 25 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to
		deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)
TIVICAY ORAL TABLET 10 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
TIVICAY ORAL TABLET 25 MG, 50 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
TIVICAY PD ORAL TABLET SOLUBLE 5 MG	5	PA; \$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days); AL (Max 12 Years)

MPC032520 119 Effective: 09/15/2025

Drug Name	Tier	Notes
VITEKTA ORAL TABLET 150 MG, 85 MG	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
*ANTIRETROVIRALS - PROTEASE INHIBITORS***		
APTIVUS ORAL CAPSULE 250 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)
APTIVUS ORAL SOLUTION 100 MG/ML	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
atazanavir sulfate oral capsule 150 mg, 200 mg, 300 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)

MPC032520 120 Effective: 09/15/2025

Drug Name	Tier	Notes
CRIXIVAN ORAL CAPSULE 200 MG	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days)
CRIXIVAN ORAL CAPSULE 400 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
darunavir oral tablet 600 mg	\$0	plans.); QL (180 EA per 30 days) \$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
darunavir oral tablet 800 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)

MPC032520 121 Effective: 09/15/2025

Drug Name	Tier	Notes
fosamprenavir calcium oral tablet 700 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)
INVIRASE ORAL CAPSULE 200 MG	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)
INVIRASE ORAL TABLET 500 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)
LEXIVA ORAL SUSPENSION 50 MG/ML	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 122 Effective: 09/15/2025

Drug Name	Tier	Notes
NORVIR ORAL CAPSULE 100 MG	\$0	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (360 EA per 30 days)
NORVIR ORAL SOLUTION 80 MG/ML	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost
		share is subject to applicable benefit plans.); QL (450 ML per 30 days)
PREZISTA ORAL TABLET 150 MG, 75 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
REYATAZ ORAL PACKET 50 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (150 EA per 30 days); AL (Max 8 Years)

MPC032520 123 Effective: 09/15/2025

Drug Name	Tier	Notes
ritonavir oral tablet 100 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (360 EA per 30 days)
VIRACEPT ORAL TABLET 250 MG, 625 MG	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (120 EA per 30 days)
*ANTIRETROVIRALS - RTI-NON- NUCLEOSIDE ANALOGUES***		
EDURANT ORAL TABLET 25 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 124 Effective: 09/15/2025

Drug Name	Tier	Notes
efavirenz oral capsule 200 mg, 50 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
efavirenz oral tablet 600 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
etravirine oral tablet 100 mg, 200 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
INTELENCE ORAL TABLET 25 MG	5	
nevirapine er oral tablet extended release 24 hour 400 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to
		deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)

MPC032520 125 Effective: 09/15/2025

Drug Name	Tier	Notes
nevirapine oral suspension 50 mg/5ml	\$0	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1200 ML per 30 days)
nevirapine oral tablet 200 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
PIFELTRO ORAL TABLET 100 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
RESCRIPTOR ORAL TABLET 100 MG	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days)

Drug Name	Tier	Notes
RESCRIPTOR ORAL TABLET 200 MG	\$0	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days)
*ANTIRETROVIRALS - RTI-NUCLEOSIDE ANALOGUES-PURINES***		
abacavir sulfate oral solution 20 mg/ml	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (900 ML per 30 days)
abacavir sulfate oral tablet 300 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
didanosine oral capsule delayed release 125 mg, 200 mg, 250 mg, 400 mg	\$0	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)

MPC032520 127 Effective: 09/15/2025

Drug Name	Tier	Notes
VIDEX ORAL SOLUTION RECONSTITUTED 2 GM, 4 GM	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1200 ML per 30 days)
*ANTIRETROVIRALS - RTI-NUCLEOSIDE ANALOGUES-PYRIMIDINES***		
emtricitabine oral capsule 200 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
EMTRIVA ORAL SOLUTION 10 MG/ML	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
lamivudine oral solution 10 mg/ml	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (900 ML per 30 days)

MPC032520 128 Effective: 09/15/2025

Drug Name	Tier	Notes
lamivudine oral tablet 150 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
lamivudine oral tablet 300 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
*ANTIRETROVIRALS - RTI-NUCLEOSIDE		plans.); QL (30 EA per 30 days)
ANALOGUES-THYMIDINES***		
RETROVIR INTRAVENOUS SOLUTION 10 MG/ML	\$0	
stavudine oral capsule 15 mg, 20 mg, 30 mg, 40 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)

MPC032520 129 Effective: 09/15/2025

Drug Name	Tier	Notes
stavudine oral solution reconstituted 1 mg/ml	\$0	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (2400 EA per 30 days)
zidovudine oral capsule 100 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
zidovudine oral syrup 50 mg/5ml	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1800 ML per 30 days)
zidovudine oral tablet 300 mg	\$0	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
*ANTIRETROVIRALS - RTI-NUCLEOTIDE ANALOGUES***		

MPC032520 130 Effective: 09/15/2025

Drug Name	Tier	Notes
tenofovir disoproxil fumarate oral tablet 300 mg	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
VIREAD ORAL POWDER 40 MG/GM	5	plans.); QL (30 EA per 30 days) \$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (225 GM per 30 days)
VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG	5	\$0 (Zero Dollar Copay); STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
*ANTIRETROVIRALS ADJUVANTS***		
TYBOST ORAL TABLET 150 MG	\$0	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
		plans.); QL (30 EA per 30 days)

Drug Name	Tier	Notes
PAXLOVID (150/100) ORAL TABLET THERAPY PACK 10 X 150 MG & 10 X 100MG	3	QL (40 EA per 365 days)
PAXLOVID (300/100) ORAL TABLET THERAPY PACK 20 X 150 MG & 10 X 100MG	3	QL (60 EA per 365 days)
PAXLOVID ORAL TABLET THERAPY PACK 10 X 150 MG & 10 X 100MG	3	QL (40 EA per 365 days)
PAXLOVID ORAL TABLET THERAPY PACK 20 X 150 MG & 10 X 100MG	3	QL (60 EA per 365 days)
*CMV AGENTS***		
CYTOVENE INTRAVENOUS SOLUTION RECONSTITUTED 500 MG	MB	
foscarnet sodium intravenous solution 24 mg/ml	MB	
valganciclovir hcl oral solution reconstituted 50 mg/ml	5	PA; QL (900 ML per 30 days)
valganciclovir hcl oral tablet 450 mg	3	PA; QL (60 EA per 30 days)
VISTIDE INTRAVENOUS SOLUTION 75 MG/ML	MB	
*HEPATITIS B AGENTS***	•	·
entecavir oral tablet 0.5 mg, 1 mg	5	PA; QL (30 EA per 30 days); NDS; SP
EPIVIR HBV ORAL SOLUTION 5 MG/ML	2	QL (900 ML per 30 days)
lamivudine oral tablet 100 mg	1	QL (30 EA per 30 days)
VEMLIDY ORAL TABLET 25 MG	5	QL (30 EA per 30 days); NDS; SP
*HEPATITIS C AGENT - COMBINATIONS***		
MAVYRET ORAL PACKET 50-20 MG	4	PA; QL (150 EA per 30 days); NDS; SP
MAVYRET ORAL TABLET 100-40 MG	4	PA; QL (3 EA per 1 day); NDS; SP
sofosbuvir-velpatasvir oral tablet 400-100 mg	4	PA; QL (84 EA per 365 days); NDS; SP
TECHNIVIE ORAL TABLET 12.5-75-50 MG	4	PA; NDS; SP
VIEKIRA PAK ORAL TABLET THERAPY PACK 12.5-75-50 &250 MG	5	PA; QL (112 EA per 28 days); AL (Min 18 Years); NDS; SP
VIEKIRA XR ORAL TABLET EXTENDED RELEASE 24 HOUR 200-8.33-50- 33.33 MG	4	PA; QL (90 EA per 30 days); NDS; SP
*HEPATITIS C AGENTS***	-	•
PEGASYS PROCLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 180 MCG/0.5ML	4	PA; QL (2 ML per 28 days); SP
	4	PA
PEGASYS SUBCUTANEOUS KIT 180 MCG/0.5ML	4	
PEGASYS SUBCUTANEOUS KIT 180 MCG/0.5ML PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML	5	PA; NDS; SP
PEGASYS SUBCUTANEOUS SOLUTION 180		
PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML PEGASYS SUBCUTANEOUS SOLUTION	5	PA; NDS; SP

MPC032520 132 Effective: 09/15/2025

Drug Name	Tier	Notes	
*HERPES AGENTS - PURINE ANALOGUES***			
acyclovir oral capsule 200 mg	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)	
acyclovir oral suspension 200 mg/5ml	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)	
acyclovir oral tablet 400 mg, 800 mg	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)	
acyclovir sodium intravenous solution 50 mg/ml	MB		
valacyclovir hcl oral tablet 1 gm, 500 mg	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)	

MPC032520 133 Effective: 09/15/2025

Drug Name	Tier	Notes	
*HERPES AGENTS - THYMIDINE ANALOGUES***			
famciclovir oral tablet 125 mg, 250 mg, 500 mg	3	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)	
*INFLUENZA AGENTS***			
rimantadine hcl oral tablet 100 mg	2		
*MISC. ANTIVIRALS***			
LAGEVRIO ORAL CAPSULE 200 MG	3	QL (80 EA per 365 days)	
VEKLURY INTRAVENOUS SOLUTION 100 MG/20ML	MB		
VEKLURY INTRAVENOUS SOLUTION RECONSTITUTED 100 MG	MB		
*NEURAMINIDASE INHIBITORS***			
oseltamivir phosphate oral capsule 30 mg	3	QL (20 EA per 180 days)	
oseltamivir phosphate oral capsule 45 mg, 75 mg	3	QL (10 EA per 180 days)	
oseltamivir phosphate oral suspension reconstituted 6 mg/ml	3	QL (180 ML per 180 days)	
RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5 MG/BLISTER	3	QL (20 EA per 126 days)	
BETA BLOCKERS			
*ALPHA-BETA BLOCKERS***			
carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg	1		
labetalol hcl intravenous solution 5 mg/ml	1		
labetalol hcl oral tablet 100 mg, 200 mg, 300 mg	1		
*BETA BLOCKERS CARDIO- SELECTIVE***			
acebutolol hcl oral capsule 200 mg, 400 mg	1		
atenolol oral tablet 100 mg, 25 mg, 50 mg	1		
betaxolol hcl oral tablet 10 mg, 20 mg	1		
bisoprolol fumarate oral tablet 10 mg, 5 mg	1		
metoprolol succinate er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 50 mg	1		

MPC032520 134 Effective: 09/15/2025

Drug Name	Tier	Notes
metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg	1	
nebivolol hcl oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg	3	
*BETA BLOCKERS NON-SELECTIVE***		
LEVATOL ORAL TABLET 20 MG	3	
nadolol oral tablet 20 mg, 40 mg, 80 mg	1	
pindolol oral tablet 10 mg, 5 mg	1	
propranolol hcl er oral capsule extended release 24 hour 120 mg, 160 mg, 60 mg, 80 mg	1	
propranolol hcl oral solution 20 mg/5ml, 40 mg/5ml	2	
propranolol hcl oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg	1	
sotalol hcl (af) oral tablet 120 mg, 160 mg, 80 mg	1	
sotalol hcl oral tablet 120 mg, 160 mg, 240 mg, 80 mg	1	
timolol maleate oral tablet 10 mg, 20 mg, 5 mg	2	
CALCIUM CHANNEL BLOCKERS		
*CALCIUM CHANNEL BLOCKERS***		
amlodipine besylate oral tablet 10 mg, 2.5 mg, 5 mg	1	
CARDENE SR ORAL CAPSULE EXTENDED RELEASE 12 HOUR 30 MG, 60 MG	3	
CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG, 300 MG	1	
dilt-cd oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg	1	
diltiazem hcl er beads oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg	1	
diltiazem hcl er coated beads oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg, 300 mg	1	
diltiazem hcl er oral capsule extended release 12 hour 120 mg, 60 mg, 90 mg	1	
diltiazem hcl er oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg	1	
diltiazem hcl intravenous solution 50 mg/10ml	MB	
diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg	1	
felodipine er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg	1	
isradipine oral capsule 2.5 mg, 5 mg	1	
KATERZIA ORAL SUSPENSION 1 MG/ML	3	AL (Max 12 Years)
nicardipine hcl in nacl intravenous solution 20-0.9 mg/200ml-%, 40-0.9 mg/200ml-%	МВ	

MPC032520 135 Effective: 09/15/2025

Drug Name	Tier	Notes
nicardipine hcl oral capsule 20 mg, 30 mg	1	
NIFEDIAC CC ORAL TABLET EXTENDED RELEASE 24 HOUR 90 MG	1	
NIFEDICAL XL ORAL TABLET EXTENDED RELEASE 24 HOUR 30 MG, 60 MG	1	
nifedipine er oral tablet extended release 24 hour 30 mg, 60 mg, 90 mg	1	
nifedipine er osmotic release oral tablet extended release 24 hour 30 mg, 60 mg, 90 mg	1	
nifedipine oral capsule 10 mg, 20 mg	1	
nimodipine oral capsule 30 mg	3	PA
nisoldipine er oral tablet extended release 24 hour 17 mg, 20 mg, 25.5 mg, 30 mg, 34 mg, 40 mg, 8.5 mg	3	ST; QL (30 EA per 30 days)
TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 360 MG	1	
TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG, 300 MG, 360 MG, 420 MG	1	
verapamil hcl er oral capsule extended release 24 hour 100 mg, 200 mg, 300 mg, 360 mg	2	
verapamil hcl er oral capsule extended release 24 hour 120 mg, 240 mg	1	
verapamil hcl er oral capsule extended release 24 hour 180 mg	1	QL (60 EA per 30 days)
verapamil hcl er oral tablet extended release 180 mg, 240 mg	1	
verapamil hcl oral tablet 120 mg, 40 mg, 80 mg	1	
CARDIOTONICS		
*CARDIAC GLYCOSIDES***		
digoxin oral tablet 125 mcg, 250 mcg	1	
LANOXIN INJECTION SOLUTION 0.25 MG/ML	MB	
*INOTROPES***		
dobutamine hcl intravenous solution 250 mg/20ml	MB	
dopamine hcl intravenous solution 40 mg/ml	MB	
milrinone lactate intravenous solution 20 mg/20ml	MB	
CARDIOVASCULAR AGENTS - MISC.		
*CALCIUM CHANNEL BLOCKER & HMG COA REDUCTASE INHIBIT COMB***		
amlodipine-atorvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg	3	QL (30 EA per 30 days)

MPC032520 136 Effective: 09/15/2025

Drug Name	Tier	Notes	
*NEPRILYSIN INHIB (ARNI)-ANGIOTENSIN II RECEPT ANTAG COMB***			
ENTRESTO ORAL CAPSULE SPRINKLE 15-16 MG, 6-6 MG	3	PA; QL (60 EA per 30 days)	
sacubitril-valsartan oral tablet 24-26 mg, 49-51 mg, 97-103 mg	3	PA; QL (60 EA per 30 days)	
*PERIPHERAL VASODILATORS***			
papaverine hcl injection solution 30 mg/ml	3	PA	
*PULMONARY HYPERTENSION - ENDOTHELIN RECEPTOR ANTAGONISTS***			
ambrisentan oral tablet 10 mg, 5 mg	5	PA; QL (30 EA per 30 days); NDS; SP	
*PULMONARY HYPERTENSION - PHOSPHODIESTERASE INHIBITORS***			
sildenafil citrate oral tablet 20 mg	3	PA; QL (90 EA per 30 days)	
*VASOACTIVE NATRIURETIC PEPTIDES***			
NATRECOR INTRAVENOUS SOLUTION RECONSTITUTED 1.5 MG	MB		
CEPHALOSPORINS	•		
*CEPHALOSPORIN COMBINATIONS***			
AVYCAZ INTRAVENOUS SOLUTION RECONSTITUTED 2.5 (2-0.5) GM	МВ		
*CEPHALOSPORINS - 1ST GENERATION***			
cefadroxil oral capsule 500 mg	1		
cefadroxil oral suspension reconstituted 250 mg/5ml, 500 mg/5ml	1		
cefadroxil oral tablet 1 gm	1		
cefazolin sodium-dextrose intravenous solution 1-4 gm/50ml-%	МВ		
cephalexin oral capsule 250 mg, 500 mg	1		
cephalexin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml	1		
*CEPHALOSPORINS - 2ND GENERATION***			
cefaclor oral capsule 250 mg, 500 mg	1		
cefoxitin sodium intravenous solution reconstituted 1 gm	MB		
cefprozil oral suspension reconstituted 125 mg/5ml, 250 mg/5ml	1		
cefprozil oral tablet 250 mg, 500 mg	1		
MPC032520	137	Effective: 00/15/2025	

cefuroxime axetil oral tablet 250 mg, 500 mg 2INACEF INTRAVENOUS SOLUTION RECONSTITUTED 750 MG *CEPHALOSPORINS - 3RD GENERATION*** ceftinir oral capsule 300 mg ceftinir oral capsule 300 mg ceftinir oral capsule 300 mg ceftinir oral suspension reconstituted 125 mg/5ml, 200 mg/5ml ceftinire oral suspension reconstituted 100 mg/5ml, 200 mg/5ml cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 200 mg/5ml 1 cefpodoxime proxetil oral tablet 100 mg, 200 mg 1 STI (Formulary prescription drugs used for the prevention or trealment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. *High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) ### To provide the provide in	Drug Name	Tier	Notes
ZINACEF INTRAVENOUS SOLUTION RECONSTITUTED 750 MG **CEPHALOSPORINS - 3RD GENERATION*** cefdinir oral capsule 300 mg	cefuroxime axetil oral suspension reconstituted 125 mg/5ml	1	
RECONSTITUTED 750 MG "CEPHALOSPORINS - 3RD GENERATION*** celfainir oral capsule 300 mg celfinir oral suspension reconstituted 125 mg/5ml, 250 mg/5ml celfpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 1 celfpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 200 mg/5ml celfpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml celfpodoxime proxetil oral tablet 100 mg, 200 mg STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for no-sexually transmitted infections. "High Deductible Health Plan copaya/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) celfriaxone sodium injection solution reconstituted 100 gm. 2 gm. 250 mg. 500 mg FORTAZ INJECTION SOLUTION RECONSTITUTED 500 MG SUPRAX ORAL TABLET 400 MG "CEPHALOSPORINS - 4TH GENERATION*** MB RECONSTITUTED 250 MG SUPRAX ORAL TABLET 400 MG "CEPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 desogestre-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1	cefuroxime axetil oral tablet 250 mg, 500 mg	1	
GENERATION*** ceffdinir oral capsule 300 mg 1 ceffixine oral suspension reconstituted 125 mg/5ml, 250 mg/5ml cefixime oral suspension reconstituted 100 mg/5ml, 200 mg/5ml cefixime oral suspension reconstituted 100 mg/5ml, 200 mg/5ml cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml cefpodoxime proxetil oral tablet 100 mg, 200 mg 1 STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. 'High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) ceftriaxone sodium injection solution reconstituted 100 gm, 2 gm, 250 mg, 500 mg FORTAZ INJECTION SOLUTION RECONSTITUTED MB ROCEPHIN INJECTION SOLUTION RECONSTITUTED MB ROCEPHIN INJECTION SOLUTION RECONSTITUTED MB SUPRAX ORAL TABLET 400 MG *CEPHALOSPORINS - 4TH GENERATION** MAXIPIME INJECTION SOLUTION MB *CONSTITUTED 1 GM *CONTRACEPTIVES* *BIPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 desogestre-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1 desogestre-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1	ZINACEF INTRAVENOUS SOLUTION RECONSTITUTED 750 MG	MB	
ceftinir oral suspension reconstituted 125 mg/5ml, 250 mg/5ml 1 cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 200 mg/5ml 1 cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml 1 cefpodoxime proxetil oral tablet 100 mg, 200 mg 1 STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. *High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) ceftriaxone sodium injection solution reconstituted 100 gm, 2 gm, 250 mg, 500 mg FORTAZ INJECTION SOLUTION RECONSTITUTED 500 MB ROCEPHIN INJECTION SOLUTION RECONSTITUTED 500 MB ROCEPHIN INJECTION SOLUTION RECONSTITUTED 500 MB ROCEPHIN INJECTION SOLUTION RECONSTITUTED 400 MB SUPRAX ORAL TABLET 400 MG 2 *CEPHALOSPORINS - 4TH GENERATION*** MAXIPIME INJECTION SOLUTION RECONSTITUTED 1 GM *CONTRACEPTIVES** MAXIPIME INJECTION SOLUTION RECONSTITUTED 1 GM *CONTRACEPTIVES** BIPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 Mg (21/5) 1			
250 mg/5ml cefixime oral suspension reconstituted 100 mg/5ml, 200 mg/5ml cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml cefpodoxime proxetil oral tablet 100 mg, 200 mg 1 STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share a cost sharing applies for non-sexually transmitted infections. "High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) ceftriaxone sodium injection solution reconstituted 100 gm, 2 gm, 250 mg, 500 mg ROCEPHAIN INJECTION SOLUTION RECONSTITUTED MB ROCEPHIN INJECTION SOLUTION MB SUPRAX ORAL TABLET 400 MG *CEPHAL OSPORINS - 4TH GENERATION*** MAXIPIME INJECTION SOLUTION MB *CONTRACEPTIVES* **BIPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 desogestret-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1	cefdinir oral capsule 300 mg	1	
200 mg/5ml cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml cefpodoxime proxetil oral tablet 100 mg, 200 mg 1 STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. ' High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) ceftriaxone sodium injection solution reconstituted 100 gm, 2 gm, 250 mg, 500 mg FORTAZ INJECTION SOLUTION RECONSTITUTED MB ROCEPHIN INJECTION SOLUTION RECONSTITUTED MB SUPRAX ORAL TABLET 400 MG *CEPHALOSPORINS - 4TH GENERATION*** MAXIPIME INJECTION SOLUTION RECONSTITUTED 1 gM *CONTRACEPTIVES* *BIPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1 desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1 mg (21/5)		1	
ceftriaxone sodium injection solution reconstituted 1 gm ceftriaxone sodium injection solution reconstituted 100 gm 2 gm 250 mg 550 mg FORTAZ INJECTION SOLUTION RECONSTITUTED 500 MG ROCEPHIN INJECTION SOLUTION RECONSTITUTED 500 MG ROCEPHIN INJECTION SOLUTION RECONSTITUTED 250 MG SUPRAX ORAL TABLET 400 MG *CEPHALOSPORINS - 4TH GENERATION*** MAXIPIME INJECTION SOLUTION RECONSTITUTED 1 gM *CONTRACEPTIVES* *BIPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1 desogestrel-ethi		1	
STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) * Ceftriaxone sodium injection solution reconstituted 100 gm, 2 gm, 250 mg, 500 mg * FORTAZ INJECTION SOLUTION RECONSTITUTED 500 MG **ROCEPHIN INJECTION SOLUTION RECONSTITUTED 500 MG **SUPRAX ORAL TABLET 400 MG **CEPHALOSPORINS - 4TH **GENERATION**** MAXIPIME INJECTION SOLUTION RECONSTITUTED 1 GM **CONTRACEPTIVES* **BIPHASIC CONTRACEPTIVES - ORAL*** **AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 **BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 **Georgestrei-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1 **Georgestrei-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1		1	
used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.) **Ceftriaxone sodium injection solution reconstituted 100 gm, 2 gm, 250 mg, 500 mg **FORTAZ INJECTION SOLUTION RECONSTITUTED 500 MG **ROCEPHIN INJECTION SOLUTION RECONSTITUTED 500 MG **SUPRAX ORAL TABLET 400 MG **CEPHALOSPORINS - 4TH **GENERATION**** **MAXIPIME INJECTION SOLUTION MB **CONTRACEPTIVES** **BIPHASIC CONTRACEPTIVES - ORAL*** **AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 **BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 **desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1	cefpodoxime proxetil oral tablet 100 mg, 200 mg	1	
gm, 2 gm, 250 mg, 500 mg FORTAZ INJECTION SOLUTION RECONSTITUTED 500 MG ROCEPHIN INJECTION SOLUTION MB RECONSTITUTED 250 MG SUPRAX ORAL TABLET 400 MG *CEPHALOSPORINS - 4TH GENERATION*** MAXIPIME INJECTION SOLUTION RECONSTITUTED 1 GM *CONTRACEPTIVES* *BIPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1 mg (21/5)	ceftriaxone sodium injection solution reconstituted 1 gm	1	used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
ROCEPHIN INJECTION SOLUTION RECONSTITUTED 250 MG SUPRAX ORAL TABLET 400 MG *CEPHALOSPORINS - 4TH GENERATION*** MAXIPIME INJECTION SOLUTION RECONSTITUTED 1 GM *CONTRACEPTIVES* *BIPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) MB MB 1 2	ceftriaxone sodium injection solution reconstituted 100 gm, 2 gm, 250 mg, 500 mg	1	
RECONSTITUTED 250 MG SUPRAX ORAL TABLET 400 MG *CEPHALOSPORINS - 4TH GENERATION*** MAXIPIME INJECTION SOLUTION RECONSTITUTED 1 GM *CONTRACEPTIVES* *BIPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5)	FORTAZ INJECTION SOLUTION RECONSTITUTED 500 MG	МВ	
*CEPHALOSPORINS - 4TH GENERATION*** MAXIPIME INJECTION SOLUTION RECONSTITUTED 1 GM *CONTRACEPTIVES* *BIPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1	ROCEPHIN INJECTION SOLUTION RECONSTITUTED 250 MG	МВ	
MAXIPIME INJECTION SOLUTION RECONSTITUTED 1 GM *CONTRACEPTIVES* *BIPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1	SUPRAX ORAL TABLET 400 MG	2	
CONTRACEPTIVES *BIPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1	*CEPHALOSPORINS - 4TH GENERATION***		
*BIPHASIC CONTRACEPTIVES - ORAL*** AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1	MAXIPIME INJECTION SOLUTION RECONSTITUTED 1 GM	МВ	
AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1 desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1	*CONTRACEPTIVES*		
BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5) desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5) 1	*BIPHASIC CONTRACEPTIVES - ORAL***		
desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5)	AZURETTE ORAL TABLET 0.15-0.02/0.01 MG (21/5)	1	
mg (21/5)	BEKYREE ORAL TABLET 0.15-0.02/0.01 MG (21/5)	1	
KARIVA ORAL TABLET 0.15-0.02/0.01 MG (21/5) 1	desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5)	1	
	KARIVA ORAL TABLET 0.15-0.02/0.01 MG (21/5)	1	

Drug Name	Tier	Notes
KIMIDESS ORAL TABLET 0.15-0.02/0.01 MG (21/5)	1	
LO LOESTRIN FE ORAL TABLET 1 MG-10 MCG / 10 MCG	3	PA
NECON 10/11 (28) ORAL TABLET 35 MCG	2	
PIMTREA ORAL TABLET 0.15-0.02/0.01 MG (21/5)	1	
SIMLIYA ORAL TABLET 0.15-0.02/0.01 MG (21/5)	1	
viorele oral tablet 0.15-0.02/0.01 mg (21/5)	1	
VOLNEA ORAL TABLET 0.15-0.02/0.01 MG (21/5)	1	
*COMBINATION CONTRACEPTIVES - ORAL***		
AFIRMELLE ORAL TABLET 0.1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ALTAVERA ORAL TABLET 0.15-30 MG-MCG	1	
alyacen 1/35 oral tablet 1-35 mg-mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
APRI ORAL TABLET 0.15-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
AUBRA ORAL TABLET 0.1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
AUROVELA 1.5/30 ORAL TABLET 1.5-30 MG-MCG	1	
AUROVELA 1/20 ORAL TABLET 1-20 MG-MCG	1	
AUROVELA 24 FE ORAL TABLET 1-20 MG- MCG(24)	1	
AUROVELA FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
AUROVELA FE 1/20 ORAL TABLET 1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
AVIANE ORAL TABLET 0.1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
AYUNA ORAL TABLET 0.15-30 MG-MCG	1	
BALZIVA ORAL TABLET 0.4-35 MG-MCG	1	
BLISOVI 24 FE ORAL TABLET 1-20 MG-MCG(24)	1	
BLISOVI FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
BLISOVI FE 1/20 ORAL TABLET 1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
briellyn oral tablet 0.4-35 mg-mcg	1	
CHATEAL ORAL TABLET 0.15-30 MG-MCG	1	
CRYSELLE-28 ORAL TABLET 0.3-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
CYCLAFEM 1/35 ORAL TABLET 1-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
CYRED ORAL TABLET 0.15-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
DASETTA 1/35 (28) ORAL TABLET 1-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
DELYLA ORAL TABLET 0.1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
desogestrel-ethinyl estradiol oral tablet 0.15-30 mg- mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
drospiren-eth estrad-levomefol oral tablet 3-0.02-0.451 mg	3	

MPC032520 139 Effective: 09/15/2025

Drug Name	Tier	Notes
drospirenone-ethinyl estradiol oral tablet 3-0.02 mg, 3-0.03 mg	1	
ELINEST ORAL TABLET 0.3-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
EMOQUETTE ORAL TABLET 0.15-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ENSKYCE ORAL TABLET 0.15-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ESTARYLLA ORAL TABLET 0.25-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ethynodiol diac-eth estradiol oral tablet 1-50 mg-mcg	1	
FALMINA ORAL TABLET 0.1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
FEMYNOR ORAL TABLET 0.25-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
GIANVI ORAL TABLET 3-0.02 MG	1	
GILDAGIA ORAL TABLET 0.4-35 MG-MCG	1	\$0 (\$0 Copay per PPACA guidelines.)
GILDESS 1.5/30 ORAL TABLET 1.5-30 MG-MCG	1	\$0 (\$0 copay for the following NDCs: 00603-7606-15, 00603-7606-48. Preventative services.)
GILDESS 1/20 ORAL TABLET 1-20 MG-MCG	1	\$0 (\$0 copay for the following NDCs: 00603-7607-15, 00603-7607-48. Preventative care.)
GILDESS 24 FE ORAL TABLET 1-20 MG-MCG(24)	1	
GILDESS FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
GILDESS FE 1/20 ORAL TABLET 1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
HAILEY 1.5/30 ORAL TABLET 1.5-30 MG-MCG	1	
HAILEY 24 FE ORAL TABLET 1-20 MG-MCG(24)	1	
HAILEY FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
HAILEY FE 1/20 ORAL TABLET 1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ISIBLOOM ORAL TABLET 0.15-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
JASMIEL ORAL TABLET 3-0.02 MG	1	
JULEBER ORAL TABLET 0.15-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
JUNEL 1.5/30 ORAL TABLET 1.5-30 MG-MCG	1	
JUNEL 1/20 ORAL TABLET 1-20 MG-MCG	1	
JUNEL FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
JUNEL FE 1/20 ORAL TABLET 1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
JUNEL FE 24 ORAL TABLET 1-20 MG-MCG(24)	1	
KAITLIB FE ORAL TABLET CHEWABLE 0.8-25 MG-MCG	1	
KALLIGA ORAL TABLET 0.15-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
KELNOR 1/35 ORAL TABLET 1-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
KELNOR 1/50 ORAL TABLET 1-50 MG-MCG	1	
KURVELO ORAL TABLET 0.15-30 MG-MCG	1	
LARIN 1.5/30 ORAL TABLET 1.5-30 MG-MCG	1	

Drug Name	Tier	Notes
LARIN 1/20 ORAL TABLET 1-20 MG-MCG	1	
LARIN 24 FE ORAL TABLET 1-20 MG-MCG(24)	1	
LARIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
LARIN FE 1/20 ORAL TABLET 1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
LARISSIA ORAL TABLET 0.1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
LAYOLIS FE ORAL TABLET CHEWABLE 0.8-25 MG-MCG	1	
LESSINA ORAL TABLET 0.1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg- mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
levonorgestrel-ethinyl estrad oral tablet 0.15-30 mg- mcg	1	
LEVORA 0.15/30 (28) ORAL TABLET 0.15-30 MG- MCG	1	
LOESTRIN 1.5/30 (21) ORAL TABLET 1.5-30 MG-MCG	1	
LOESTRIN 1/20 (21) ORAL TABLET 1-20 MG-MCG	1	
LOESTRIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
LOMEDIA 24 FE ORAL TABLET 1-20 MG-MCG(24)	1	
LORYNA ORAL TABLET 3-0.02 MG	1	
LOW-OGESTREL ORAL TABLET 0.3-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
LO-ZUMANDIMINE ORAL TABLET 3-0.02 MG	1	
LUTERA ORAL TABLET 0.1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
marlissa oral tablet 0.15-30 mg-mcg	1	
MICROGESTIN 1.5/30 ORAL TABLET 1.5-30 MG-MCG	1	
MICROGESTIN 1/20 ORAL TABLET 1-20 MG-MCG	1	
MICROGESTIN 24 FE ORAL TABLET 1-20 MG-MCG	1	
MICROGESTIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
MICROGESTIN FE 1/20 ORAL TABLET 1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
MILI ORAL TABLET 0.25-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
MONO-LINYAH ORAL TABLET 0.25-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
MONONESSA ORAL TABLET 0.25-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
NECON 0.5/35 (28) ORAL TABLET 0.5-35 MG-MCG	1	
NECON 1/35 (28) ORAL TABLET 1-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
NECON 1/50 (28) ORAL TABLET 1-50 MG-MCG	2	
NIKKI ORAL TABLET 3-0.02 MG	1	
norethin ace-eth estrad-fe oral tablet 1-20 mg-mcg(24)	1	

Drug Name	Tier	Notes
norethin ace-eth estrad-fe oral tablet 1-20 mg-mcg, 1.5-30 mg-mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
norethindrone acet-ethinyl est oral tablet 1-20 mg- mcg, 1.5-30 mg-mcg	1	
norethin-eth estradiol-fe oral tablet chewable 0.4-35 mg-mcg, 0.8-25 mg-mcg	1	
norgestimate-eth estradiol oral tablet 0.25-35 mg-mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
NORTREL 0.5/35 (28) ORAL TABLET 0.5-35 MG-MCG	1	
NORTREL 1/35 (21) ORAL TABLET 1-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
NORTREL 1/35 (28) ORAL TABLET 1-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
NYMYO ORAL TABLET 0.25-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
OCELLA ORAL TABLET 3-0.03 MG	1	
OGESTREL ORAL TABLET 0.5-50 MG-MCG	2	
ORSYTHIA ORAL TABLET 0.1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
PHILITH ORAL TABLET 0.4-35 MG-MCG	1	
PIRMELLA 1/35 ORAL TABLET 1-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
PORTIA-28 ORAL TABLET 0.15-30 MG-MCG	1	
PREVIFEM ORAL TABLET 0.25-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
RAJANI ORAL TABLET 3-0.02-0.451 MG	3	
RECLIPSEN ORAL TABLET 0.15-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
SOLIA ORAL TABLET 0.15-30 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
SPRINTEC 28 ORAL TABLET 0.25-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
SRONYX ORAL TABLET 0.1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
SYEDA ORAL TABLET 3-0.03 MG	1	
TARINA 24 FE ORAL TABLET 1-20 MG-MCG(24)	\$0	
TARINA FE 1/20 ORAL TABLET 1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
VESTURA ORAL TABLET 3-0.02 MG	1	
VIENVA ORAL TABLET 0.1-20 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
VYFEMLA ORAL TABLET 0.4-35 MG-MCG	1	
VYLIBRA ORAL TABLET 0.25-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
WERA ORAL TABLET 0.5-35 MG-MCG	1	
WYMZYA FE ORAL TABLET CHEWABLE 0.4-35 MG-MCG	1	
ZARAH ORAL TABLET 3-0.03 MG	1	
ZENCHENT FE ORAL TABLET CHEWABLE 0.4-35 MG-MCG	1	
ZENCHENT ORAL TABLET 0.4-35 MG-MCG	1	
ZOVIA 1/35E (28) ORAL TABLET 1-35 MG-MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ZUMANDIMINE ORAL TABLET 3-0.03 MG	1	

Drug Name	Tier	Notes
*COMBINATION CONTRACEPTIVES - TRANSDERMAL***		
XULANE TRANSDERMAL PATCH WEEKLY 150-35 MCG/24HR	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (3 EA per 28 days); AL (Max 55 Years)
ZAFEMY TRANSDERMAL PATCH WEEKLY 150-35 MCG/24HR	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
*COMBINATION CONTRACEPTIVES - VAGINAL***		
ELURYNG VAGINAL RING 0.12-0.015 MG/24HR	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (1 EA per 28 days); AL (Max 55 Years)
etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24hr	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (1 EA per 28 days); AL (Max 55 Years)
*CONTINUOUS CONTRACEPTIVES - ORAL***		
AMETHYST ORAL TABLET 90-20 MCG	1	
levonorgestrel-ethinyl estrad oral tablet 90-20 mcg	1	
*COPPER CONTRACEPTIVES - IUD***		
PARAGARD INTRAUTERINE COPPER INTRAUTERINE INTRAUTERINE DEVICE	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (1 EA per 10 Yearss); AL (Max 55 Years)
*EMERGENCY CONTRACEPTIVES***		
AFTERA ORAL TABLET 1.5 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ECONTRA EZ ORAL TABLET 1.5 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ELLA ORAL TABLET 30 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
FALLBACK SOLO ORAL TABLET 1.5 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
levonorgestrel oral tablet 0.75 mg, 1.5 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
MY WAY ORAL TABLET 1.5 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
NEXT CHOICE ONE DOSE ORAL TABLET 1.5 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (3 EA per 365 days)
NEXT CHOICE ORAL TABLET 0.75 MG	1	\$0 (\$0 Copay per PPACA guidelines.)
OPCICON ONE-STEP ORAL TABLET 1.5 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
TAKE ACTION ORAL TABLET 1.5 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
*EXTENDED-CYCLE CONTRACEPTIVES - ORAL***		
AMETHIA LO ORAL TABLET 0.1-0.02 & 0.01 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
AMETHIA ORAL TABLET 0.15-0.03 &0.01 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ASHLYNA ORAL TABLET 0.15-0.03 &0.01 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
CAMRESE LO ORAL TABLET 0.1-0.02 & 0.01 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
CAMRESE ORAL TABLET 0.15-0.03 &0.01 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)

MPC032520 143 Effective: 09/15/2025

Drug Name	Tier	Notes
DAYSEE ORAL TABLET 0.15-0.03 &0.01 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ICLEVIA ORAL TABLET 0.15-0.03 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
INTROVALE ORAL TABLET 0.15-0.03 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
JAIMIESS ORAL TABLET 0.15-0.03 &0.01 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
JOLESSA ORAL TABLET 0.15-0.03 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
levonorgest-eth estrad 91-day oral tablet 0.1-0.02 & 0.01 mg, 0.15-0.03 &0.01 mg, 0.15-0.03 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
LOJAIMIESS ORAL TABLET 0.1-0.02 & 0.01 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
QUASENSE ORAL TABLET 0.15-0.03 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
SETLAKIN ORAL TABLET 0.15-0.03 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
SIMPESSE ORAL TABLET 0.15-0.03 &0.01 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
*PROGESTIN CONTRACEPTIVES - IMPLANTS***		
NEXPLANON SUBCUTANEOUS IMPLANT 68 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (1 EA per 3 Yearss); AL (Max 55 Years)
*PROGESTIN CONTRACEPTIVES - INJECTABLE***		
DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 104 MG/0.65ML	\$0	\$0 (\$0 Copay per PPACA guidelines.)
medroxyprogesterone acetate intramuscular suspension 150 mg/ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
medroxyprogesterone acetate intramuscular suspension prefilled syringe 150 mg/ml	\$0	\$0 (\$0 Copay per PPACA guidelines.)
*PROGESTIN CONTRACEPTIVES - IUD***		
KYLEENA INTRAUTERINE INTRAUTERINE DEVICE 19.5 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
MIRENA (52 MG) INTRAUTERINE INTRAUTERINE DEVICE 20 MCG/24HR, 20 MCG/DAY	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
*PROGESTIN CONTRACEPTIVES - ORAL***		
CAMILA ORAL TABLET 0.35 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
DEBLITANE ORAL TABLET 0.35 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ERRIN ORAL TABLET 0.35 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
HEATHER ORAL TABLET 0.35 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
JENCYCLA ORAL TABLET 0.35 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
JOLIVETTE ORAL TABLET 0.35 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
LYLEQ ORAL TABLET 0.35 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
LYZA ORAL TABLET 0.35 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
NORA-BE ORAL TABLET 0.35 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
norethindrone oral tablet 0.35 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
NORLYDA ORAL TABLET 0.35 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)

MPC032520 144 Effective: 09/15/2025

Drug Name	Tier	Notes
NORLYROC ORAL TABLET 0.35 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
OPILL ORAL TABLET 0.075 MG	\$0	\$0 (Zero Dollar Copay)
SHAROBEL ORAL TABLET 0.35 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
*TRIPHASIC CONTRACEPTIVES - ORAL***		
alyacen 7/7/7 oral tablet 0.5/0.75/1-35 mg-mcg	1	
ARANELLE ORAL TABLET 0.5/1/0.5-35 MG-MCG	1	
CAZIANT ORAL TABLET 0.1/0.125/0.15 -0.025 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
CESIA ORAL TABLET 0.1/0.125/0.15 -0.025 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
CYCLAFEM 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG	1	
DASETTA 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG	1	
ENPRESSE-28 ORAL TABLET 50-30/75-40/ 125-30 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
LEENA ORAL TABLET 0.5/1/0.5-35 MG-MCG	1	
LEVONEST ORAL TABLET 50-30/75-40/ 125-30 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
levonorg-eth estrad triphasic oral tablet , 50-30/75-40/125-30 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
MYZILRA ORAL TABLET 50-30/75-40/ 125-30 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
NECON 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG	1	
norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25 mg-25 mcg	1	
norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25 mg-35 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
NORTREL 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG	1	
PIRMELLA 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG	1	
TILIA FE ORAL TABLET 1-20/1-30/1-35 MG-MCG	1	
TRI FEMYNOR ORAL TABLET 0.18/0.215/0.25 MG- 35 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
TRI-ESTARYLLA ORAL TABLET 0.18/0.215/0.25 MG-35 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
TRI-LEGEST FE ORAL TABLET 1-20/1-30/1-35 MG-MCG	1	
TRI-LINYAH ORAL TABLET 0.18/0.215/0.25 MG-35 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
TRI-LO-ESTARYLLA ORAL TABLET 0.18/0.215/0.25 MG-25 MCG	1	
TRI-LO-MARZIA ORAL TABLET 0.18/0.215/0.25 MG-25 MCG	1	

MPC032520 145 Effective: 09/15/2025

Drug Name	Tier	Notes
TRI-LO-MILI ORAL TABLET 0.18/0.215/0.25 MG-25 MCG	1	
TRI-LO-SPRINTEC ORAL TABLET 0.18/0.215/0.25 MG-25 MCG	1	
TRI-MILI ORAL TABLET 0.18/0.215/0.25 MG-35 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
TRINESSA (28) ORAL TABLET 0.18/0.215/0.25 MG- 35 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
TRINESSA LO ORAL TABLET 0.18/0.215/0.25 MG- 25 MCG	1	\$0 (\$0 Copay per PPACA guidelines.)
TRI-NYMYO ORAL TABLET 0.18/0.215/0.25 MG-35 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
TRI-PREVIFEM ORAL TABLET 0.18/0.215/0.25 MG- 35 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
TRI-SPRINTEC ORAL TABLET 0.18/0.215/0.25 MG- 35 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
TRIVORA (28) ORAL TABLET 50-30/75-40/ 125-30 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
TRI-VYLIBRA LO ORAL TABLET 0.18/0.215/0.25 MG-25 MCG	1	
TRI-VYLIBRA ORAL TABLET 0.18/0.215/0.25 MG- 35 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
VELIVET ORAL TABLET 0.1/0.125/0.15 -0.025 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
CORTICOSTEROIDS		
*GLUCOCORTICOSTEROIDS***		
A-HYDROCORT INJECTION SOLUTION RECONSTITUTED 100 MG	3	
ARISTOSPAN INTRA-ARTICULAR INJECTION SUSPENSION 20 MG/ML	МВ	
budesonide er oral capsule extended release 24 hour 3 mg	3	
budesonide oral capsule delayed release particles 3 mg	3	QL (448 EA per 365 days)
cortisone acetate oral tablet 25 mg	2	
DEPO-MEDROL INJECTION SUSPENSION 20 MG/ML, 40 MG/ML, 80 MG/ML	МВ	
DEXAMETHASONE INTENSOL ORAL CONCENTRATE 1 MG/ML	2	
dexamethasone oral elixir 0.5 mg/5ml	1	
dexamethasone oral solution 0.5 mg/5ml	1	
dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg	1	
dexamethasone sodium phosphate injection solution 4 mg/ml	MB	

MPC032520 146 Effective: 09/15/2025

Drug Name	Tier	Notes
dexamethasone sodium phosphate injection solution prefilled syringe 4 mg/ml	MB	
hydrocortisone oral tablet 10 mg, 20 mg, 5 mg	1	
KENALOG INJECTION SUSPENSION 40 MG/ML	MB	
KENALOG-40 INJECTION SUSPENSION 40 MG/ML	MB	
methylprednisolone (pak) oral tablet 4 mg	1	
methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg	1	
methylprednisolone sodium succ injection solution reconstituted 1000 mg, 125 mg, 40 mg	МВ	
prednisolone oral solution 15 mg/5ml	1	
prednisolone sodium phosphate oral solution 15 mg/5ml, 5 mg/5ml	1	
prednisone oral solution 5 mg/5ml	1	
prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg	1	
SOLU-CORTEF INJECTION SOLUTION RECONSTITUTED 100 MG	МВ	
SOLU-MEDROL (PF) INJECTION SOLUTION RECONSTITUTED 1000 MG, 125 MG, 40 MG, 500 MG	МВ	
SOLU-MEDROL INJECTION SOLUTION RECONSTITUTED 1000 MG, 125 MG, 2 GM, 40 MG, 500 MG	MB	
*MINERALOCORTICOIDS***		
fludrocortisone acetate oral tablet 0.1 mg	1	
*STEROID COMBINATIONS***		
betamethasone sod phos & acet injection suspension 6 (3-3) mg/ml	МВ	
CELESTONE SOLUSPAN INJECTION SUSPENSION 6 (3-3) MG/ML	MB	
COUGH/COLD/ALLERGY		
*ANTITUSSIVE - NONNARCOTIC***		
benzonatate oral capsule 100 mg, 200 mg	1	
*ANTITUSSIVE-EXPECTORANT***		
cheratussin ac oral syrup 100-10 mg/5ml	1	PA; AL (Min 12 Years)
dex-tuss oral liquid 300-10 mg/5ml	1	PA; AL (Min 12 Years)
FLOWTUSS ORAL SOLUTION 2.5-200 MG/5ML	3	QL (473 ML per 30 days)
guaiatussin ac oral syrup 100-10 mg/5ml	1	PA; AL (Min 12 Years)
guaifenesin ac oral syrup 100-10 mg/5ml	1	PA; AL (Min 12 Years)
guaifenesin-codeine oral solution 100-10 mg/5ml	1	PA; AL (Min 12 Years)
guaifenesin-codeine oral syrup 100-10 mg/5ml	1	PA; AL (Min 12 Years)

MPC032520 147 Effective: 09/15/2025

Drug Name	Tier	Notes
*MISC. RESPIRATORY INHALANTS***		•
sodium chloride inhalation nebulization solution 0.9 %, 7 %	1	
*MUCOLYTICS***		•
acetylcysteine inhalation solution 10 %, 20 %	1	
*OPIOID ANTITUSSIVE-ANTIHISTAMINE***		•
promethazine-codeine oral syrup 6.25-10 mg/5ml	1	PA; AL (Min 12 Years)
DERMATOLOGICALS		•
*ACNE ANTIBIOTICS***		
AKNE-MYCIN EXTERNAL OINTMENT 2 %	2	QL (25 GM per 30 days)
clindamycin phos (once-daily) external gel 1 %	1	QL (60 ML per 30 days)
clindamycin phos (twice-daily) external gel 1 %	1	QL (60 GM per 30 days)
clindamycin phosphate external gel 1 %	1	QL (60 GM per 30 days)
clindamycin phosphate external lotion 1 %	1	QL (60 ML per 30 days)
clindamycin phosphate external solution 1 %	1	
clindamycin phosphate external swab 1 %	1	
dapsone external gel 5 %, 7.5 %	3	
erythromycin external gel 2 %	1	
erythromycin external solution 2 %	1	
sulfacetamide sodium (acne) external lotion 10 %	3	
*ACNE COMBINATIONS***		
BENZAMYCINPAK EXTERNAL PACKET 5-3 %	2	
benzoyl peroxide-erythromycin external gel 5-3 %	1	
clindamycin phos-benzoyl perox external gel 1-5 %, 1.2-5 %	3	
ROSULA EXTERNAL PAD 10-5 %	3	QL (30 EA per 30 days)
sulfacetamide sodium-sulfur external cream 10-5 %	1	
sulfacetamide sodium-sulfur external emulsion 10-5 %	1	
sulfacetamide sodium-sulfur external lotion 10-5 %	1	
sulfacetamide sodium-sulfur external suspension 10-5 %	1	
*ACNE PRODUCTS***		
adapalene external cream 0.1 %	1	AL (Max 40 Years)
adapalene external gel 0.1 %	1	AL (Max 40 Years)
AMNESTEEM ORAL CAPSULE 10 MG	3	
AMNESTEEM ORAL CAPSULE 20 MG, 40 MG	3	AL (Max 40 Years)
AZELEX EXTERNAL CREAM 20 %	3	
benzoyl peroxide wash external liquid 10 %	1	

MPC032520 148 Effective: 09/15/2025

Drug Name	Tier	Notes
CLARAVIS ORAL CAPSULE 10 MG, 20 MG, 30 MG, 40 MG	3	QL (60 EA per 30 days)
isotretinoin oral capsule 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg	3	QL (60 EA per 30 days); AL (Min 12 Years)
MYORISAN ORAL CAPSULE 10 MG	3	QL (60 EA per 30 days)
MYORISAN ORAL CAPSULE 20 MG, 30 MG, 40 MG	3	QL (60 EA per 30 days); AL (Max 40 Years)
tretinoin external cream 0.025 %, 0.05 %, 0.1 %	1	AL (Max 40 Years)
tretinoin external gel 0.01 %, 0.025 %	1	AL (Max 40 Years)
ZENATANE ORAL CAPSULE 10 MG	3	QL (60 EA per 30 days)
ZENATANE ORAL CAPSULE 20 MG, 30 MG, 40 MG	3	QL (60 EA per 30 days); AL (Max 40 Years)
*AGENTS FOR EXTERNAL GENITAL AND PERIANAL WARTS***		
VEREGEN EXTERNAL OINTMENT 15 %	3	PA; QL (15 GM per 30 days)
*ANTIBIOTIC STEROID COMBINATIONS - TOPICAL***		
CORTISPORIN EXTERNAL CREAM 3.5-10000-0.5	3	
*ANTIBIOTICS - TOPICAL***		
ALTABAX EXTERNAL OINTMENT 1 %	3	ST
gentamicin sulfate external cream 0.1 %	1	
gentamicin sulfate external ointment 0.1 %	2	
mupirocin external ointment 2 %	1	
*ANTIFUNGALS - TOPICAL COMBINATIONS***		
clotrimazole-betamethasone external cream 1-0.05 %	1	
clotrimazole-betamethasone external lotion 1-0.05 %	1	
nystatin-triamcinolone external cream 100000-0.1 unit/gm-%	1	
nystatin-triamcinolone external ointment 100000-0.1 unit/gm-%	1	
*ANTIFUNGALS - TOPICAL***		
ciclopirox external gel 0.77 %	1	
ciclopirox external shampoo 1 %	1	
ciclopirox external solution 8 %	1	QL (19.8 ML per 365 days)
ciclopirox olamine external cream 0.77 %	1	
ciclopirox olamine external suspension 0.77 %	1	
nystatin external cream 100000 unit/gm	1	
nystatin external ointment 100000 unit/gm	1	
nystatin external powder 100000 unit/gm	1	
MDC033530	140	Effective: 00/15/2025

MPC032520 149 Effective: 09/15/2025

Drug Name	Tier	Notes
NYSTOP EXTERNAL POWDER 100000 UNIT/GM	1	
pedi-dri external powder 100000 unit/gm	1	
*ANTINEOPLASTIC ANTIMETABOLITES - TOPICAL***		
fluorouracil external cream 5 %	1	
fluorouracil external solution 2 %	2	
*ANTIPSORIATICS - SYSTEMIC***		
acitretin oral capsule 10 mg, 17.5 mg, 25 mg	5	PA; QL (60 EA per 30 days); NDS; SP
IMULDOSA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML	4	PA; DX (Diagnosis Validation Required); QL (0.5 ML per 84 days); SP
IMULDOSA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 90 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (1 ML per 56 days); SP
SKYRIZI (150 MG DOSE) SUBCUTANEOUS PREFILLED SYRINGE KIT 75 MG/0.83ML	4	PA; DX (Diagnosis Validation Required); QL (1 kit per 84 days); NDS; SP
SKYRIZI PEN SUBCUTANEOUS SOLUTION AUTO- INJECTOR 150 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (1 kit per 84 days); NDS; SP
SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (1 kit per 84 days); NDS; SP
STEQEYMA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML	4	PA; DX (Diagnosis Validation Required); QL (0.5 ML per 84 days); SP
STEQEYMA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 90 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (1 ML per 56 days); SP
TALTZ SUBCUTANEOUS SOLUTION AUTO- INJECTOR 80 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (1 ML per 28 days); NDS; SP
TALTZ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/0.25ML	4	PA; DX (Diagnosis Validation Required); QL (0.25 ML per 28 days); NDS; SP
TALTZ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/0.5ML	4	PA; DX (Diagnosis Validation Required); QL (0.5 ML per 28 days); NDS; SP
TALTZ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 80 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (1 ML per 28 days); NDS; SP
YESINTEK SUBCUTANEOUS SOLUTION 45 MG/0.5ML	4	PA; DX (Diagnosis Validation Required); QL (0.5 ML per 84 days); SP
YESINTEK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML	4	PA; DX (Diagnosis Validation Required); QL (0.5 ML per 84 days); SP

MPC032520 150 Effective: 09/15/2025

Drug Name	Tier	Notes
YESINTEK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 90 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (1 ML per 56 days); SP
*ANTIPSORIATICS***	-	*
calcipotriene external cream 0.005 %	3	
calcipotriene external ointment 0.005 %	3	
calcipotriene external solution 0.005 %	3	
CALCITRENE EXTERNAL OINTMENT 0.005 %	3	
calcitriol external ointment 3 mcg/gm	3	ST
tazarotene external cream 0.05 %, 0.1 %	3	ST; QL (60 GM per 30 days)
tazarotene external gel 0.05 %, 0.1 %	3	ST; QL (100 GM per 30 days)
TAZORAC EXTERNAL CREAM 0.05 %	3	ST; QL (60 GM per 30 days)
*ANTISEBORRHEIC PRODUCTS***		•
selenium sulfide external lotion 2.5 %	1	
*ANTIVIRALS - TOPICAL***		<u> </u>
penciclovir external cream 1 %	2	QL (5 GM per 30 days)
*ATOPIC DERMATITIS - MONOCLONAL ANTIBODIES***		,
DUPIXENT SUBCUTANEOUS SOLUTION AUTO- INJECTOR 200 MG/1.14ML	5	PA; DX (Diagnosis Validation Required); QL (2.28 ML per 28 days); NDS; SP
DUPIXENT SUBCUTANEOUS SOLUTION AUTO- INJECTOR 300 MG/2ML	5	PA; DX (Diagnosis Validation Required); QL (4 ML per 28 days); NDS; SP
DUPIXENT SUBCUTANEOUS SOLUTION PEN- INJECTOR 200 MG/1.14ML	5	PA; QL (2.28 ML per 28 days); NDS; SP
DUPIXENT SUBCUTANEOUS SOLUTION PEN- INJECTOR 300 MG/2ML	5	PA; QL (4 ML per 28 days); NDS; SP
DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.67ML	5	PA; DX (Diagnosis Validation Required); QL (1.34 ML per 28 days); NDS; SP
DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML	5	PA; DX (Diagnosis Validation Required); QL (2.28 ML per 28 days); NDS; SP
DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300 MG/2ML	5	PA; DX (Diagnosis Validation Required); QL (4 ML per 28 days); NDS; SP
*BURN PRODUCTS***		
mafenide acetate external packet 5 %	3	PA
silver sulfadiazine external cream 1 %	1	
*CORTICOSTEROIDS - TOPICAL***		
alclometasone dipropionate external cream 0.05 %	1	
alclometasone dipropionate external ointment 0.05 %	1	
, , , , , , , , , , , , , , , , , , , ,		

MPC032520 151 Effective: 09/15/2025

Drug Name	Tier	Notes
amcinonide external ointment 0.1 %	3	
betamethasone dipropionate aug external cream 0.05 %	1	
betamethasone dipropionate aug external gel 0.05 %	1	
betamethasone dipropionate aug external lotion 0.05 %	1	
betamethasone dipropionate aug external ointment 0.05 %	1	
betamethasone dipropionate external cream 0.05 %	1	
betamethasone dipropionate external lotion 0.05 %	1	
betamethasone dipropionate external ointment 0.05 %	1	
betamethasone valerate external cream 0.1 %	1	
betamethasone valerate external lotion 0.1 %	1	
betamethasone valerate external ointment 0.1 %	1	
clobetasol propionate emollient cream 0.05 % external	1	
clobetasol propionate external cream 0.05 %	1	QL (60 GM per 30 days)
clobetasol propionate external gel 0.05 %	1	
clobetasol propionate external ointment 0.05 %	1	
clobetasol propionate external solution 0.05 %	1	
clocortolone pivalate external cream 0.1 %	3	ST; QL (45 GM per 30 days)
CORMAX SCALP APPLICATION EXTERNAL SOLUTION 0.05 %	3	
desoximetasone external cream 0.25 %	1	
diflorasone diacetate external ointment 0.05 %	3	
fluocinolone acetonide body external oil 0.01 %	1	
fluocinolone acetonide external cream 0.01 %, 0.025 %	1	
fluocinolone acetonide external ointment 0.025 %	1	
fluocinolone acetonide external solution 0.01 %	1	
fluocinolone acetonide scalp external oil 0.01 %	1	
fluocinonide external cream 0.05 %	1	
fluocinonide external gel 0.05 %	1	
fluocinonide external ointment 0.05 %	1	
fluocinonide external solution 0.05 %	1	
fluticasone propionate external cream 0.05 %	1	
fluticasone propionate external ointment 0.005 %	1	
halcinonide external cream 0.1 %	3	ST; QL (60 GM per 30 days)
halobetasol propionate external cream 0.05 %	1	

Drug Name	Tier	Notes
hydrocortisone butyrate external cream 0.1 %	1	
hydrocortisone butyrate external ointment 0.1 %	1	
hydrocortisone butyrate external solution 0.1 %	1	
hydrocortisone external cream 2.5 %	1	
hydrocortisone external lotion 2.5 %	1	
hydrocortisone external ointment 2.5 %	1	
hydrocortisone valerate external cream 0.2 %	1	
LANACORT 10 EXTERNAL CREAM 1 %	1	
mometasone furoate external cream 0.1 %	1	
mometasone furoate external ointment 0.1 %	1	
mometasone furoate external solution 0.1 %	1	
prednicarbate external ointment 0.1 %	3	
triamcinolone acetonide external cream 0.025 %, 0.1 %, 0.5 %	1	
triamcinolone acetonide external lotion 0.025 %, 0.1 %	1	
triamcinolone acetonide external ointment 0.025 %, 0.1 %, 0.5 %	1	
*IMIDAZOLE-RELATED ANTIFUNGALS - TOPICAL***		
clotrimazole external cream 1 %	1	
econazole nitrate external cream 1 %	1	
EXELDERM EXTERNAL CREAM 1 %	3	PA
EXELDERM EXTERNAL SOLUTION 1 %	3	PA
ketoconazole external cream 2 %	1	
ketoconazole external shampoo 2 %	1	
*IMMUNOMODULATORS IMIDAZOQUINOLINAMINES - TOPICAL***		
imiquimod external cream 5 %	3	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (12 EA per 30 days)
*KERATOLYTIC/ANTIMITOTIC/VESICANT AGENTS***		

MPC032520 153 Effective: 09/15/2025

Drug Name	Tier	Notes
podofilox external solution 0.5 %	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*LOCAL ANESTHETICS - TOPICAL***		[
lidocaine external ointment 5 %	3	QL (500 GM per 30 days)
lidocaine external patch 5 %	3	QL (30 EA per 30 days)
lidocaine hcl external cream 3 %	1	
lidocaine hcl external gel 2 %	1	
lidocaine hcl external solution 4 %	1	
*MACROLIDE IMMUNOSUPPRESSANTS - TOPICAL***		
pimecrolimus external cream 1 %	3	QL (120 GM per 365 days); AL (Min 2 Years)
tacrolimus external ointment 0.03 %, 0.1 %	3	ST; AL (Min 2 Years)
*PHOSPHODIESTERASE 4 (PDE4) INHIBITORS - TOPICAL***		
EUCRISA EXTERNAL OINTMENT 2 %	5	PA; QL (60 GM per 30 days)
*PHOTODYNAMIC THERAPY AGENTS - TOPICAL***		
AMELUZ EXTERNAL GEL 10 %	MB	
LEVULAN KERASTICK EXTERNAL SOLUTION RECONSTITUTED 20 %	МВ	
*PIGMENTING AGENTS***		
OXSORALEN EXTERNAL LOTION 1 %	3	PA; QL (29.57 ML per 30 days)
*ROSACEA AGENTS***		
azelaic acid external gel 15 %	3	
FINACEA EXTERNAL FOAM 15 %	2	
metronidazole external cream 0.75 %	1	
metronidazole external gel 0.75 %	1	
metronidazole external lotion 0.75 %	1	
ROSADAN EXTERNAL GEL 0.75 %	1	
*SCABICIDES & PEDICULICIDES***		
EURAX EXTERNAL CREAM 10 %	2	
<u> </u>		

Drug Name	Tier	Notes
EURAX EXTERNAL LOTION 10 %	2	
ivermectin external lotion 0.5 %	3	ST
lindane external shampoo 1 %	2	
malathion external lotion 0.5 %	3	ST; QL (60 ML per 90 days)
permethrin external cream 5 %	1	
ULESFIA EXTERNAL LOTION 5 %	3	PA; QL (227 GM per 30 days)
*TOPICAL ANESTHETIC COMBINATIONS***		
ANECREAM EXTERNAL KIT 4 %	3	
lidocaine-prilocaine external cream 2.5-2.5 %	3	
lidocaine-transparent dressing external kit 4 %	3	
LIDOCREAM EXTERNAL KIT 4 %	3	
*TOPICAL STEROID COMBINATIONS***		
calcipotriene-betameth diprop external ointment 0.005-0.064 %	3	
*WOUND CARE - GROWTH FACTOR AGENTS***		
REGRANEX EXTERNAL GEL 0.01 %	3	
DIAGNOSTIC PRODUCTS		
*DIAGNOSTIC DRUGS***		
ACTHREL INTRAVENOUS SOLUTION RECONSTITUTED 100 MCG	MB	
CORTROSYN INJECTION SOLUTION RECONSTITUTED 0.25 MG	MB	
dipyridamole intravenous solution 5 mg/ml	MB	
KINEVAC INJECTION SOLUTION RECONSTITUTED 5 MCG	MB	
PROVOCHOLINE INHALATION SOLUTION RECONSTITUTED 100 MG	MB	
THYROGEN INTRAMUSCULAR SOLUTION RECONSTITUTED 0.9 MG, 1.1 MG	MB	QL (1 Course per 1 Lifetime); SP
*DIAGNOSTIC TESTS***		
ACCU-CHEK AVIVA PLUS IN VITRO STRIP	1	Blood Glucose Test strip and lancet limits for members: 100 every 90 days for those not using insulin, 300 every 90 days for those using insulin, and 200 every 365 days for those using a continuous glucose monitor (CGM).

MPC032520 155 Effective: 09/15/2025

Drug Name	Tier	Notes
ACCU-CHEK GUIDE IN VITRO STRIP	1	Blood Glucose Test strip and lancet limits for members: 100 every 90 days for those not using insulin, 300 every 90 days for those using insulin, and 200 every 365 days for those using a continuous glucose monitor (CGM).
ACCU-CHEK GUIDE TEST IN VITRO STRIP	1	Blood Glucose Test strip and lancet limits for members: 100 every 90 days for those not using insulin, 300 every 90 days for those using insulin, and 200 every 365 days for those using a continuous glucose monitor (CGM).
ACCU-CHEK SMARTVIEW IN VITRO STRIP	1	Blood Glucose Test strip and lancet limits for members: 100 every 90 days for those not using insulin, 300 every 90 days for those using insulin, and 200 every 365 days for those using a continuous glucose monitor (CGM).
KETOSTIX IN VITRO STRIP	2	
DIGESTIVE AIDS		
*DIGESTIVE ENZYMES***		
CREON ORAL CAPSULE DELAYED RELEASE PARTICLES 12000-38000 UNIT, 24000-76000 UNIT, 3000-9500 UNIT, 36000-114000 UNIT, 6000-19000 UNIT	2	
PANCREAZE ORAL CAPSULE DELAYED RELEASE PARTICLES 10500-35500 UNIT, 16800- 56800 UNIT, 21000-54700 UNIT, 2600-8800 UNIT, 37000-97300 UNIT, 4200-14200 UNIT	2	
DIURETICS		
*CARBONIC ANHYDRASE INHIBITORS***		
acetazolamide er oral capsule extended release 12 hour 500 mg	1	
acetazolamide oral tablet 125 mg, 250 mg	1	
acetazolamide sodium injection solution reconstituted 500 mg	MB	
methazolamide oral tablet 25 mg, 50 mg	1	
*DIURETIC COMBINATIONS***		
ALDACTAZIDE ORAL TABLET 50-50 MG	2	
amiloride-hydrochlorothiazide oral tablet 5-50 mg	1	
spironolactone-hctz oral tablet 25-25 mg	1	
triamterene-hctz oral capsule 37.5-25 mg	1	
triamterene-hctz oral tablet 37.5-25 mg, 75-50 mg	1	
*LOOP DIURETICS***		

MPC032520 156 Effective: 09/15/2025

Drug Name	Tier	Notes
bumetanide oral tablet 0.5 mg, 1 mg, 2 mg	1	
ethacrynic acid oral tablet 25 mg	5	PA; QL (480 EA per 30 days)
furosemide injection solution 10 mg/ml	MB	
furosemide oral solution 10 mg/ml	1	
furosemide oral solution 8 mg/ml	2	
furosemide oral tablet 20 mg, 40 mg, 80 mg	1	
torsemide oral tablet 10 mg, 100 mg, 20 mg, 5 mg	1	
*OSMOTIC DIURETICS***		
mannitol intravenous solution 25 %	MB	
*POTASSIUM SPARING DIURETICS***		
amiloride hcl oral tablet 5 mg	1	
spironolactone oral tablet 100 mg, 25 mg, 50 mg	1	
triamterene oral capsule 100 mg, 50 mg	3	
*THIAZIDES AND THIAZIDE-LIKE DIURETICS***		
chlorothiazide sodium intravenous solution reconstituted 500 mg	MB	
chlorthalidone oral tablet 25 mg, 50 mg	1	
hydrochlorothiazide oral capsule 12.5 mg	1	
hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg	1	
indapamide oral tablet 1.25 mg, 2.5 mg	1	
methyclothiazide oral tablet 5 mg	2	
metolazone oral tablet 10 mg, 2.5 mg, 5 mg	1	
ENDOCRINE AND METABOLIC AGENTS - MISC.		
*ABORTIFACIENT - PROGESTERONE RECEPTOR ANTAGONISTS***		
mifepristone oral tablet 200 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.)
*BISPHOSPHONATES***		
alendronate sodium oral tablet 10 mg, 35 mg, 5 mg, 70 mg	1	
alendronate sodium oral tablet 40 mg	2	
etidronate disodium oral tablet 200 mg, 400 mg	2	
FOSAMAX PLUS D ORAL TABLET 70-2800 MG- UNIT, 70-5600 MG-UNIT	3	
ibandronate sodium oral tablet 150 mg	3	ST; QL (1 EA per 28 days)
risedronate sodium oral tablet 150 mg	3	QL (1 EA per 28 days)
risedronate sodium oral tablet 30 mg, 5 mg	3	QL (30 EA per 30 days)

MPC032520 157 Effective: 09/15/2025

Drug Name	Tier	Notes
risedronate sodium oral tablet 35 mg	3	QL (4 EA per 28 days)
risedronate sodium oral tablet delayed release 35 mg	3	QL (30 EA per 30 days)
zoledronic acid intravenous solution 4 mg/100ml	MB	
*CALCIMIMETIC AGENTS***		
cinacalcet hcl oral tablet 30 mg	1	
cinacalcet hcl oral tablet 60 mg, 90 mg	1	PA
*CALCITONINS***		
calcitonin (salmon) injection solution 200 unit/ml	5	
calcitonin (salmon) nasal solution 200 unit/act	1	
*CALCIUM REGULATORS - MISC.***		
GANITE INTRAVENOUS SOLUTION 25 MG/ML	MB	
*CARNITINE REPLENISHER - AGENTS***		
levocarnitine intravenous solution 200 mg/ml	MB	
*DOPAMINE RECEPTOR AGONISTS***		
cabergoline oral tablet 0.5 mg	1	QL (56 EA per 28 days)
*GNRH/LHRH ANTAGONISTS***		
ORILISSA ORAL TABLET 150 MG	5	PA; QL (30 EA per 30 days); NDS; SP
ORILISSA ORAL TABLET 200 MG	5	PA; QL (60 EA per 30 days); NDS; SP
*GROWTH HORMONES***		
OMNITROPE SUBCUTANEOUS SOLUTION 10 MG/1.5ML, 5 MG/1.5ML	4	PA; NDS; SP
OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE 10 MG/1.5ML, 5 MG/1.5ML	4	PA; NDS; SP
*HYPERPARATHYROID TREATMENT - VITAMIN D ANALOGS***		
calcitriol oral capsule 0.25 mcg, 0.5 mcg	1	
doxercalciferol intravenous solution 4 mcg/2ml	MB	
doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg	3	
ZEMPLAR INTRAVENOUS SOLUTION 5 MCG/ML	MB	
*HYPOPHOSPHATASIA (HPP) AGENTS***		
STRENSIQ SUBCUTANEOUS SOLUTION 18 MG/0.45ML, 28 MG/0.7ML, 40 MG/ML, 80 MG/0.8ML	5	PA; LA
*INSULIN-LIKE GROWTH FACTORS (SOMATOMEDINS)***		
INCRELEX SUBCUTANEOUS SOLUTION 40 MG/4ML	5	PA; NDS; SP
*LHRH/GNRH AGONIST ANALOG PITUITARY SUPPRESSANTS***		

MPC032520 158 Effective: 09/15/2025

Drug Name	Tier	Notes	
LUPRON DEPOT-PED (3-MONTH) INTRAMUSCULAR KIT 30 MG	MB		
SUPPRELIN LA SUBCUTANEOUS KIT 50 MG	MB		
*NEUROKININ 3 (NK3) RECEPTOR ANTAGONISTS***			
VEOZAH ORAL TABLET 45 MG	3	PA; QL (2 EA per 1 day); AL (Min 18 Years); NDS	
*PARATHYROID HORMONE AND DERIVATIVES***			
teriparatide subcutaneous solution pen-injector 560 mcg/2.24ml, 600 mcg/2.4ml	5	PA; NDS; SP	
TYMLOS SUBCUTANEOUS SOLUTION PEN- INJECTOR 3120 MCG/1.56ML	5	PA; NDS; SP	
*PHENYLKETONURIA TREATMENT - AGENTS***			
PALYNZIQ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 10 MG/0.5ML	5	PA; LA; QL (7 ML per 28 days)	
PALYNZIQ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 2.5 MG/0.5ML	5	PA; LA; QL (3 ML per 35 days)	
PALYNZIQ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML	5	PA; LA; QL (28 ML per 28 days)	
sapropterin dihydrochloride oral packet 100 mg, 500 mg	5	PA; LA	
sapropterin dihydrochloride oral tablet 100 mg	5	PA	
*RANK LIGAND (RANKL) INHIBITORS***			
JUBBONTI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 60 MG/ML	MB	SP	
WYOST SUBCUTANEOUS SOLUTION 120 MG/1.7ML	MB	SP	
*SCLEROSTIN INHIBITORS***			
EVENITY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 105 MG/1.17ML	MB	PA; SP	
*SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)***			
raloxifene hcl oral tablet 60 mg	\$0	DX (Covered at a zero-dollar copay for the prevention of breast cancer per ACA)	
*SOMATOSTATIC AGENTS***			
octreotide acetate injection solution 1000 mcg/ml	МВ	PA	
octreotide acetate intramuscular kit 20 mg, 30 mg	MB		
SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 50 MCG/ML, 500 MCG/ML	МВ		
SANDOSTATIN INJECTION SOLUTION 1000 MCG/ML	MB	PA	

Drug Name	Tier	Notes
*VASOPRESSIN***		•
desmopressin ace rhinal tube nasal solution 0.01 %	1	
desmopressin ace spray refrig nasal solution 0.01 %	1	
desmopressin acetate oral tablet 0.1 mg, 0.2 mg	1	
desmopressin acetate spray nasal solution 0.01 %	1	
*X-LINKED HYPOPHOSPHATEMIA (XLH) TREATMENT - AGENTS***		
CRYSVITA SUBCUTANEOUS SOLUTION 10 MG/ML, 20 MG/ML, 30 MG/ML	МВ	PA
ESTROGENS		
*ESTROGEN & ANDROGEN***		
methyltest-est estrogens oral tablet 2.5-1.25 mg	1	
*ESTROGEN & PROGESTIN***		
COMBIPATCH TRANSDERMAL PATCH TWICE WEEKLY 0.05-0.14 MG/DAY, 0.05-0.25 MG/DAY	3	ST; QL (8 EA per 28 days)
estradiol-norethindrone acet oral tablet 0.5-0.1 mg, 1-0.5 mg	1	
JINTELI ORAL TABLET 1-5 MG-MCG	1	
norethindrone-eth estradiol oral tablet 1-5 mg-mcg	1	
PREFEST ORAL TABLET 1/1-0.09 MG (15/15)	2	
PREMPHASE ORAL TABLET 0.625-5 MG	2	
PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG	2	
*ESTROGEN-PROGESTIN-GNRH ANTAGONIST***		
ORIAHNN ORAL CAPSULE THERAPY PACK 300-1-0.5 & 300 MG	5	PA; QL (60 EA per 30 days)
*ESTROGENS***		
ALORA TRANSDERMAL PATCH TWICE WEEKLY 0.025 MG/24HR, 0.05 MG/24HR, 0.075 MG/24HR, 0.1 MG/24HR	3	QL (8 EA per 28 days)
CENESTIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG	3	
DELESTROGEN INTRAMUSCULAR OIL 10 MG/ML, 20 MG/ML, 40 MG/ML	MB	
DEPO-ESTRADIOL INTRAMUSCULAR OIL 5 MG/ML	MB	
DOTTI TRANSDERMAL PATCH TWICE WEEKLY 0.025 MG/24HR, 0.0375 MG/24HR, 0.05 MG/24HR, 0.075 MG/24HR, 0.1 MG/24HR	1	QL (8 EA per 28 days)
estradiol oral tablet 0.5 mg, 1 mg, 2 mg	1	

MPC032520 160 Effective: 09/15/2025

Drug Name	Tier	Notes
estradiol transdermal gel 0.25 mg/0.25gm, 0.5 mg/0.5gm, 0.75 mg/0.75gm, 1 mg/gm, 1.25 mg/1.25gm	1	
estradiol transdermal patch twice weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr	1	QL (8 EA per 28 days)
estradiol transdermal patch weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.06 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr	1	QL (4 EA per 28 days)
ESTRASORB TRANSDERMAL EMULSION 4.35 MG/1.74GM	3	
ESTROGEL TRANSDERMAL GEL 0.75 MG/1.25 GM (0.06%)	3	
estropipate oral tablet 0.75 mg, 1.5 mg, 3 mg	1	
EVAMIST TRANSDERMAL SOLUTION 1.53 MG/SPRAY	3	
LYLLANA TRANSDERMAL PATCH TWICE WEEKLY 0.025 MG/24HR, 0.1 MG/24HR	1	QL (8 EA per 30 days)
LYLLANA TRANSDERMAL PATCH TWICE WEEKLY 0.0375 MG/24HR, 0.05 MG/24HR, 0.075 MG/24HR	1	
PREMARIN INJECTION SOLUTION RECONSTITUTED 25 MG	MB	
PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG	2	
FLUOROQUINOLONES		
*FLUOROQUINOLONES***		
AVELOX INTRAVENOUS SOLUTION 400 MG/250ML	MB	
AVELOX ORAL TABLET 400 MG	3	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 161 Effective: 09/15/2025

Drug Name	Tier	Notes
CIPRO ORAL SUSPENSION RECONSTITUTED 500 MG/5ML (10%)	2	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
ciprofloxacin hcl oral tablet 100 mg	2	plans.) STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to
		deductible first. Coverage at no cost share is subject to applicable benefit plans.) STI (Formulary prescription drugs
ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg	1	used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
ciprofloxacin in d5w intravenous solution 400 mg/200ml	MB	
ciprofloxacin oral suspension reconstituted 250 mg/5ml (5%)	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
FACTIVE ORAL TABLET 320 MG	3	
levofloxacin in d5w intravenous solution 250 mg/50ml	MB	

MPC032520 162 Effective: 09/15/2025

Drug Name	Tier	Notes
levofloxacin oral solution 25 mg/ml	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
levofloxacin oral tablet 250 mg, 500 mg, 750 mg	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
moxifloxacin hcl oral tablet 400 mg	3	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
NOROXIN ORAL TABLET 400 MG	3	,
GASTROINTESTINAL AGENTS - MISC.		1
*GALLSTONE SOLUBILIZING AGENTS***		
ursodiol oral capsule 300 mg	1	
ursodiol oral tablet 250 mg, 500 mg	1	
*GASTROINTESTINAL CHLORIDE CHANNEL ACTIVATORS***		
lubiprostone oral capsule 24 mcg, 8 mcg	2	QL (60 EA per 30 days)
*GASTROINTESTINAL STIMULANTS***		
metoclopramide hcl injection solution 5 mg/ml	MB	
metoclopramide hcl oral solution 5 mg/5ml	1	
metoclopramide hcl oral tablet 10 mg, 5 mg	1	

Drug Name	Tier	Notes
*IBS AGENT - SELECTIVE 5-HT3 RECEPTOR ANTAGONISTS***		
alosetron hcl oral tablet 0.5 mg, 1 mg	5	
*INFLAMMATORY BOWEL AGENTS***		
balsalazide disodium oral capsule 750 mg	1	
mesalamine er oral capsule extended release 24 hour 0.375 gm	3	QL (120 EA per 30 days)
mesalamine oral capsule delayed release 400 mg	3	
mesalamine oral tablet delayed release 1.2 gm	3	QL (120 EA per 30 days)
mesalamine rectal enema 4 gm	1	QL (1682 ML per 28 days)
mesalamine rectal suppository 1000 mg	5	QL (30 EA per 30 days)
sulfasalazine oral tablet 500 mg	1	
sulfasalazine oral tablet delayed release 500 mg	1	
*INTERLEUKIN ANTAGONISTS***		
IMULDOSA INTRAVENOUS SOLUTION 130 MG/26ML	MB	PA; DX (Diagnosis Validation Required)
SKYRIZI INTRAVENOUS SOLUTION 600 MG/10ML	MB	PA; DX (Diagnosis Validation Required); QL (30 ML per 365 days)
SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 180 MG/1.2ML	4	PA; DX (Diagnosis Validation Required); QL (1.2 ML per 56 days); NDS; SP
SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 360 MG/2.4ML	4	PA; DX (Diagnosis Validation Required); QL (2.4 ML per 56 days); NDS; SP
STEQEYMA INTRAVENOUS SOLUTION 130 MG/26ML	MB	PA; DX (Diagnosis Validation Required)
YESINTEK INTRAVENOUS SOLUTION 130 MG/26ML	МВ	PA; DX (Diagnosis Validation Required)
*INTESTINAL ACIDIFIERS***		
generlac oral solution 10 gm/15ml	1	
lactulose encephalopathy oral solution 10 gm/15ml	1	
*PHOSPHATE BINDER AGENTS***		
calcium acetate (phos binder) oral capsule 667 mg	1	
calcium acetate (phos binder) oral tablet 667 mg	1	
calcium acetate oral capsule 667 mg	1	
ferric citrate oral tablet 1 gm 210 mg(fe)	5	PA; QL (12 EA per 1 day)
lanthanum carbonate oral tablet chewable 1000 mg, 500 mg	5	PA; QL (3 EA per 1 day)
lanthanum carbonate oral tablet chewable 750 mg	5	PA; QL (6 EA per 1 day)
PHOSLYRA ORAL SOLUTION 667 MG/5ML	2	
sevelamer carbonate oral tablet 800 mg	5	
		· · · · · · · · · · · · · · · · · · ·

MPC032520 164 Effective: 09/15/2025

Drug Name	Tier	Notes
sevelamer hcl oral tablet 400 mg	2	
*TRYPTOPHAN HYDROXYLASE INHIBITORS***		
XERMELO ORAL TABLET 250 MG	5	PA; LA; QL (90 EA per 30 days)
*TUMOR NECROSIS FACTOR ALPHA BLOCKERS***		
AVSOLA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG	МВ	PA; DX (Diagnosis Validation Required)
CIMZIA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 200 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (1 EA per 28 days); NDS; SP
CIMZIA PREFILLED SUBCUTANEOUS PREFILLED SYRINGE KIT 2 X 200 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (1 kit per 28 days); NDS; SP
CIMZIA STARTER KIT SUBCUTANEOUS PREFILLED SYRINGE KIT 6 X 200 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (3 kits per 28 days); NDS; SP
CIMZIA SUBCUTANEOUS KIT 2 X 200 MG	4	PA; DX (Diagnosis Validation Required); QL (1 EA per 28 days); NDS; SP
CIMZIA SUBCUTANEOUS PREFILLED SYRINGE KIT 2 X 200 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (1 kit per 28 days); NDS; SP
CIMZIA-STARTER SUBCUTANEOUS PREFILLED SYRINGE KIT 200 MG/ML	4	PA; DX (Diagnosis Validation Required); QL (3 EA per 28 days); NDS; SP
infliximab solution reconstituted 100 mg intravenous	MB	PA; SP
GENITOURINARY AGENTS - MISCELLANEOUS		
*5-ALPHA REDUCTASE INHIBITORS***		
dutasteride oral capsule 0.5 mg	3	
finasteride oral tablet 5 mg	1	
*ALPHA 1-ADRENOCEPTOR ANTAGONISTS***		
alfuzosin hcl er oral tablet extended release 24 hour 10 mg	1	QL (30 EA per 30 days)
silodosin oral capsule 4 mg, 8 mg	3	ST; QL (30 EA per 30 days)
tamsulosin hcl oral capsule 0.4 mg	1	
*ANTI-INFECTIVE GENITOURINARY IRRIGANTS***		
neomycin-polymyxin b gu irrigation solution 40-200000	1	
*CITRATES***		
citric acid-sodium citrate oral solution 334-500 mg/5ml	1	

MPC032520 165 Effective: 09/15/2025

Drug Name	Tier	Notes
potassium citrate er oral tablet extended release 10 meq (1080 mg), 15 meq (1620 mg), 5 meq (540 mg)	1	
sod citrate-citric acid oral solution 500-334 mg/5ml	1	
*INTERSTITIAL CYSTITIS AGENTS***		•
ELMIRON ORAL CAPSULE 100 MG	3	PA; QL (90 EA per 30 days)
*URINARY ANALGESICS***	-	•
phenazopyridine hcl oral tablet 100 mg, 200 mg	1	
*URINARY STONE AGENTS***		
tiopronin oral tablet 100 mg	3	PA; LA; QL (300 EA per 30 days)
GOUT AGENTS		•
*GOUT AGENT COMBINATIONS***		
colchicine-probenecid oral tablet 0.5-500 mg	1	
*GOUT AGENTS***	L	
allopurinol oral tablet 100 mg, 300 mg	1	
colchicine oral tablet 0.6 mg	1	
febuxostat oral tablet 40 mg, 80 mg	3	QL (30 EA per 30 days)
*URICOSURICS***		
probenecid oral tablet 500 mg	1	
HEMATOLOGICAL AGENTS - MISC.	L	
*ANTIHEMOPHILIC PRODUCTS***		
ADVATE INTRAVENOUS SOLUTION RECONSTITUTED 2000 UNIT, 250 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT	МВ	
AFSTYLA INTRAVENOUS KIT 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 2500 UNIT, 3000 UNIT, 500 UNIT	MB	
ALPHANATE INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 500 UNIT	MB	
ALPHANATE/VWF COMPLEX/HUMAN INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 500 UNIT	MB	
ALPHANINE SD INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 500 UNIT	MB	
ALPROLIX INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT	MB	
BENEFIX INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT	MB	
CORIFACT INTRAVENOUS KIT 1000-1600 UNIT	MB	
FEIBA INTRAVENOUS SOLUTION RECONSTITUTED	MB	
MPC032520	166	Effective: 00/15/202

Drug Name	Tier	Notes
FIBRYGA INTRAVENOUS SOLUTION RECONSTITUTED	МВ	
HELIXATE FS INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT	МВ	
HEMOFIL M INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1700 UNIT, 250 UNIT, 500 UNIT	МВ	
HUMATE-P INTRAVENOUS SOLUTION RECONSTITUTED 1000-2400 UNIT, 250-600 UNIT, 500-1200 UNIT	MB	
KCENTRA INTRAVENOUS KIT 1000 UNIT, 500 UNIT	МВ	
KOATE-DVI INTRAVENOUS SOLUTION RECONSTITUTED 250 UNIT, 500 UNIT	МВ	
KOGENATE FS INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT	МВ	
KOVALTRY INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT	MB	
MONOCLATE-P INTRAVENOUS KIT 1000 UNIT	MB	
MONONINE INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT	МВ	
NOVOEIGHT INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT, 500 UNIT	MB	
NOVOSEVEN RT INTRAVENOUS SOLUTION RECONSTITUTED 1 MG, 2 MG, 5 MG, 8 MG	МВ	
NUWIQ INTRAVENOUS KIT 1000 UNIT, 1500 UNIT, 2000 UNIT, 250 UNIT, 2500 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT	МВ	
NUWIQ INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 2000 UNIT, 250 UNIT, 2500 UNIT, 3000 UNIT, 4000 UNIT, 500 UNIT	MB	
obizur intravenous solution reconstituted 500 unit	MB	
PROFILNINE INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 500 UNIT	МВ	
PROFILNINE SD INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 1500 UNIT, 500 UNIT	МВ	
RECOMBINATE INTRAVENOUS SOLUTION RECONSTITUTED 1241-1800 UNIT, 1801-2400 UNIT, 220-400 UNIT, 401-800 UNIT, 801-1240 UNIT	МВ	
RIASTAP INTRAVENOUS SOLUTION RECONSTITUTED	МВ	
rixubis intravenous solution reconstituted 1000 unit, 2000 unit, 250 unit, 3000 unit, 500 unit	МВ	
TRETTEN INTRAVENOUS SOLUTION RECONSTITUTED 2000-3125 UNIT	MB	

Drug Name	Tier	Notes	
TRETTEN INTRAVENOUS SOLUTION RECONSTITUTED 2500 UNIT	5		
WILATE INTRAVENOUS KIT 1000-1000 UNIT, 500- 500 UNIT	МВ		
XYNTHA INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 500 UNIT	МВ		
XYNTHA SOLOFUSE INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 3000 UNIT	МВ		
*BRADYKININ B2 RECEPTOR ANTAGONISTS***			
icatibant acetate subcutaneous solution prefilled syringe 30 mg/3ml	5	PA; QL (18 ML per 28 days); NDS; SP	
SAJAZIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 30 MG/3ML	5	PA; QL (18 ML per 28 days); NDS; SP	
*C1 ESTERASE INHIBITORS***			
HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT, 3000 UNIT	МВ	PA; NDS; SP	
*COMPLEMENT C5 INHIBITORS***	_		
SOLIRIS INTRAVENOUS SOLUTION 300 MG/30ML	МВ	PA; DX (Diagnosis Validation Required)	
ULTOMIRIS INTRAVENOUS SOLUTION 1100 MG/11ML, 300 MG/3ML	МВ	PA; DX (Diagnosis Validation Required)	
ULTOMIRIS INTRAVENOUS SOLUTION 300 MG/30ML	МВ	PA; DX (Diagnosis Validation Required); NDS; SP	
*DIRECT-ACTING P2Y12 INHIBITORS***			
ticagrelor oral tablet 60 mg, 90 mg	2	QL (60 EA per 30 days)	
*GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITORS***			
AGGRASTAT INTRAVENOUS CONCENTRATE 3.75 MG/15ML	МВ		
AGGRASTAT INTRAVENOUS SOLUTION 5-0.9 MG/100ML-%	МВ		
REOPRO INTRAVENOUS SOLUTION 2 MG/ML	MB		
*HEMATORHEOLOGIC AGENTS***	•		
pentoxifylline er oral tablet extended release 400 mg	3		
*HUMAN PROTEIN C***			
CEPROTIN INTRAVENOUS SOLUTION RECONSTITUTED 1000 UNIT, 500 UNIT	MB		
*PHOSPHODIESTERASE III INHIBITORS***			
cilostazol oral tablet 100 mg, 50 mg	1		
*PLASMA EXPANDERS***			
LMD IN D5W INTRAVENOUS SOLUTION 10-5 %	MB		

MPC032520 168 Effective: 09/15/2025

Drug Name	Tier	Notes
LMD IN NACL INTRAVENOUS SOLUTION 10-0.9 %	MB	
*PLASMA KALLIKREIN INHIBITORS - MONOCLONAL ANTIBODIES***		
TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2ML	5	PA; QL (2 ML per 28 days); NDS; SP
TAKHZYRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML	5	PA; QL (2 ML per 28 days); NDS; SP
TAKHZYRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 300 MG/2ML	5	PA; QL (4 ML per 28 days); NDS; SP
*PLATELET AGGREGATION INHIBITOR COMBINATIONS***		
aspirin-dipyridamole er oral capsule extended release 12 hour 25-200 mg	3	
*PLATELET AGGREGATION INHIBITORS***		
dipyridamole oral tablet 25 mg, 50 mg, 75 mg	1	
*PROTAMINE***		
protamine sulfate intravenous solution 10 mg/ml	MB	
*QUINAZOLINE AGENTS***		
anagrelide hcl oral capsule 0.5 mg, 1 mg	1	
*THIENOPYRIDINE DERIVATIVES***		
clopidogrel bisulfate oral tablet 75 mg	1	
prasugrel hcl oral tablet 10 mg	3	
prasugrel hcl oral tablet 5 mg	3	PA
ticlopidine hcl oral tablet 250 mg	3	PA; QL (60 EA per 30 days)
*TISSUE PLASMINOGEN ACTIVATORS***		
ACTIVASE INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 50 MG	МВ	
CATHFLO ACTIVASE INJECTION SOLUTION RECONSTITUTED 2 MG	МВ	
HEMATOPOIETIC AGENTS		
*COBALAMINS***		
cyanocobalamin injection solution 1000 mcg/ml	1	
*ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)***		
ARANESP (ALBUMIN FREE) INJECTION SOLUTION 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML	МВ	PA; NDS

MPC032520 169 Effective: 09/15/2025

Drug Name	Tier	Notes
ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE 10 MCG/0.4ML, 100 MCG/0.5ML, 150 MCG/0.3ML, 200 MCG/0.4ML, 25 MCG/0.42ML, 300 MCG/0.6ML, 40 MCG/0.4ML, 500 MCG/ML, 60 MCG/0.3ML	МВ	PA; NDS
RETACRIT INJECTION SOLUTION 10000 UNIT/ML	МВ	PA; QL (12 ML per 28 days); NDS; SP
RETACRIT INJECTION SOLUTION 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML	МВ	PA; QL (12 ML per 28 days)
RETACRIT INJECTION SOLUTION 40000 UNIT/ML	MB	PA; QL (4 ML per 28 days)
*FOLIC ACID/FOLATES***		
cvs folic acid oral tablet 800 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
eql folic acid oral tablet 400 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
FA-8 ORAL TABLET 800 MCG	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
folic acid oral tablet 1 mg	1	
folic acid oral tablet 400 mcg, 800 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
gnp folic acid oral tablet 400 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
hm folic acid oral tablet 400 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
kp folic acid oral tablet 800 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
px folic acid oral tablet 400 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
ra folic acid oral tablet 400 mcg, 800 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
sm folic acid oral tablet 400 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
th folic acid oral tablet 400 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
yl folic acid oral tablet 400 mcg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
*GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSF)***		
FULPHILA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML	МВ	PA; NDS; SP
NEULASTA ONPRO SUBCUTANEOUS PREFILLED SYRINGE KIT 6 MG/0.6ML	МВ	PA; NDS; SP
UDENYCA ONBODY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML	МВ	PA; NDS; SP
UDENYCA SUBCUTANEOUS SOLUTION AUTO- INJECTOR 6 MG/0.6ML	МВ	PA; NDS; SP

MPC032520 170 Effective: 09/15/2025

Drug Name	Tier	Notes
ZARXIO INJECTION SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML, 480 MCG/0.8ML	MB	PA; NDS; SP
ZIEXTENZO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML	MB	PA; NDS; SP
*INTERLEUKINS***		
NEUMEGA SUBCUTANEOUS SOLUTION RECONSTITUTED 5 MG	МВ	PA
*IRON***		·
ferretts ips oral solution 40 mg/15ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 12 Years)
FERRIMIN 150 ORAL TABLET 150 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 12 Years)
ferronate oral tablet 325 mg	1	\$0 (\$0 Copay per PPACA guidelines.)
FERRO-SEQUELS ORAL TABLET EXTENDED RELEASE 50 MG	2	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 12 Years)
ferumoxytol intravenous solution 510 mg/17ml	MB	
INJECTAFER INTRAVENOUS SOLUTION 100 MG/2ML	МВ	
iron oral tablet 246 (28 fe) mg, 90 (18 fe) mg	2	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 12 Years)
NOVAFERRUM PEDIATRIC DROPS ORAL LIQUID 15 MG/ML	1	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 12 Years)
slow release iron oral tablet extended release 140 (45 fe) mg	2	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 12 Years)
*THROMBOPOIETIN (TPO) RECEPTOR AGONISTS***		
MULPLETA ORAL TABLET 3 MG	5	PA; QL (7 EA per 7 days); NDS; SP
HEMOSTATICS		
*HEMOSTATICS - SYSTEMIC***		
aminocaproic acid oral solution 0.25 gm/ml	5	PA; AL (Max 12 Years)
aminocaproic acid oral tablet 1000 mg, 500 mg	5	
CYKLOKAPRON INTRAVENOUS SOLUTION 1000 MG/10ML	MB	
tranexamic acid intravenous solution 1000 mg/10ml	MB	
tranexamic acid oral tablet 650 mg	1	QL (30 EA per 30 days)
HYPNOTICS/SEDATIVES/SLEEP DISORDER AGENTS		•
*BARBITURATE HYPNOTICS***		
AMYTAL SODIUM INJECTION SOLUTION RECONSTITUTED 500 MG	MB	
LUMINAL INJECTION SOLUTION 130 MG/ML	MB	
pentobarbital sodium injection solution 50 mg/ml	MB	

MPC032520 171 Effective: 09/15/2025

Drug Name	Tier	Notes
phenobarbital oral elixir 20 mg/5ml, 30 mg/7.5ml, 60 mg/15ml	1	
phenobarbital oral tablet 100 mg, 15 mg, 60 mg	2	
phenobarbital oral tablet 16.2 mg, 30 mg, 32.4 mg, 64.8 mg, 97.2 mg	1	
*BENZODIAZEPINE HYPNOTICS***	-	
flurazepam hcl oral capsule 15 mg, 30 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
midazolam hcl (pf) injection solution 10 mg/2ml, 2 mg/2ml, 5 mg/ml	1	ST; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
midazolam hcl injection solution 10 mg/10ml, 10 mg/2ml, 2 mg/2ml, 25 mg/5ml, 5 mg/5ml, 5 mg/ml, 50 mg/10ml	1	ST; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
midazolam hcl oral syrup 2 mg/ml	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 172 Effective: 09/15/2025

Drug Name	Tier	Notes
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
temazepam oral capsule 15 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
temazepam oral capsule 30 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
triazolam oral tablet 0.125 mg, 0.25 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)
*NON-BENZODIAZEPINE - GABA- RECEPTOR MODULATORS***		
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
eszopiclone oral tablet 1 mg, 2 mg, 3 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
		BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
zaleplon oral capsule 10 mg, 5 mg	1	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (60 EA per 30 days)

MPC032520 173 Effective: 09/15/2025

Drug Name	Tier	Notes
zolpidem tartrate er oral tablet extended release 12.5 mg, 6.25 mg	3	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
zolpidem tartrate oral tablet 10 mg, 5 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
*OREXIN RECEPTOR ANTAGONISTS***		
BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG	3	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
DAYVIGO ORAL TABLET 10 MG, 5 MG	5	PA; QL (30 EA per 30 days)
*SELECTIVE MELATONIN RECEPTOR AGONISTS***		•
ramelteon oral tablet 8 mg	3	PA; QL (30 EA per 30 days)
LAXATIVES		
*BOWEL EVACUANT COMBINATIONS***		
GAVILYTE-C ORAL SOLUTION RECONSTITUTED 240 GM	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (8000 ML per 365 days); AL (Min 50 Years)
GAVILYTE-G ORAL SOLUTION RECONSTITUTED 236 GM	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (8000 ML per 365 days); AL (Min 50 Years)
HALFLYTELY WITH FLAVOR PACKS ORAL KIT 5- 210 MG-GM	3	
peg 3350/electrolytes oral solution reconstituted 240 gm	1	QL (8000 ML per 30 days)
peg 3350-kcl-na bicarb-nacl oral solution reconstituted 420 gm	\$0	\$0 (\$0 Copay per PPACA guidelines.)

MPC032520 174 Effective: 09/15/2025

Drug Name	Tier	Notes
peg-3350/electrolytes oral solution reconstituted 236 gm	1	QL (8000 ML per 30 days)
PEG-PREP ORAL KIT 5-210 MG-GM	3	
PREPOPIK ORAL PACKET 10-3.5-12 MG-GM-GM	3	PA
*LAXATIVES - MISCELLANEOUS***		•
lactulose oral solution 10 gm/15ml	1	
peg 3350 oral powder 17 gm/scoop	1	
polyethylene glycol 3350 oral powder 17 gm/scoop	1	
*SALINE LAXATIVES***		
magnesium citrate oral solution 1.745 gm/30ml	1	
LOCAL ANESTHETICS-PARENTERAL		-
*LOCAL ANESTHETICS - AMIDES***		
EXPAREL INJECTION SUSPENSION 1.3 %	MB	
NAROPIN INJECTION SOLUTION 2 MG/ML	MB	
ropivacaine hcl injection solution 10 mg/ml, 2 mg/ml, 5 mg/ml, 7.5 mg/ml	MB	
ropivacaine hcl-nacl injection solution 0.2-0.9 %	MB	
*LOCAL ANESTHETICS - ESTERS***		•
chloroprocaine hcl (pf) injection solution 2 %	MB	
MACROLIDES		
*AZITHROMYCIN***		
azithromycin oral suspension reconstituted 100 mg/5ml, 200 mg/5ml	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 175 Effective: 09/15/2025

Drug Name	Tier	Notes
azithromycin oral tablet 250 mg, 500 mg, 600 mg	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
ZITHROMAX INTRAVENOUS SOLUTION RECONSTITUTED 500 MG	МВ	
*CLARITHROMYCIN***		-
clarithromycin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml	1	
clarithromycin oral tablet 250 mg, 500 mg	1	
*ERYTHROMYCINS***		1
E.E.S. GRANULES ORAL SUSPENSION RECONSTITUTED 200 MG/5ML	3	PA; STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Max 12 Years)
ERYPED 200 ORAL SUSPENSION RECONSTITUTED 200 MG/5ML	3	PA; STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Max 12 Years)

MPC032520 176 Effective: 09/15/2025

Drug Name	Tier	Notes
ERYPED 400 ORAL SUSPENSION RECONSTITUTED 400 MG/5ML	3	PA; STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit
ERY-TAB ORAL TABLET DELAYED RELEASE 250 MG, 333 MG, 500 MG	3	plans.); AL (Max 12 Years) STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost
ERYTHROCIN LACTOBIONATE INTRAVENOUS SOLUTION RECONSTITUTED 500 MG	MB	share is subject to applicable benefit plans.)
erythromycin base oral tablet 250 mg, 500 mg	3	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
erythromycin base oral tablet delayed release 250 mg	3	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 177 Effective: 09/15/2025

Drug Name	Tier	Notes
erythromycin base oral tablet delayed release 333 mg, 500 mg	4	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to
		deductible first. Coverage at no cost share is subject to applicable benefit plans.)
erythromycin ethylsuccinate oral suspension	3	PA; STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
reconstituted 200 mg/5ml	C	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); AL (Max 12 Years)
rythromycin ethylsuccinate oral tablet 400 mg	3	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
erythromycin oral tablet delayed release 250 mg, 333	3	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections.
mg, 500 mg		* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 178 Effective: 09/15/2025

Drug Name	Tier	Notes
erythromycin stearate oral tablet 250 mg	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*FIDAXOMICIN***		
DIFICID ORAL SUSPENSION RECONSTITUTED 40 MG/ML	5	PA; QL (10 ML per 1 day)
MEDICAL DEVICES AND SUPPLIES		
*CERVICAL CAPS***	,	
FEMCAP VAGINAL DEVICE 22 MM, 26 MM, 30 MM	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
PRENTIF CAVITY-RIM CERV CAP VAGINAL DEVICE 22 MM	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
PRENTIF CAVITY-RIM CERV CAP VAGINAL DEVICE 25 MM, 28 MM, 31 MM	1	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
PRENTIF FITTING SET VAGINAL	1	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
*CONDOMS - FEMALE***		
FC FEMALE CONDOM	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
FC2 FEMALE CONDOM	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
*CONDOMS - MALE***		
condoms	\$0	\$0 (\$0 Copay per PPACA guidelines.)
*DIAPHRAGMS***		
CAYA VAGINAL DIAPHRAGM	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
OMNIFLEX DIAPHRAGM VAGINAL DIAPHRAGM	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
ORTHO DIAPHRAGM COIL VAGINAL KIT 100 MM, 105 MM, 50 MM	1	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
ORTHO DIAPHRAGM FLAT VAGINAL KIT 55 MM, 60 MM, 65 MM, 70 MM, 75 MM, 80 MM, 85 MM, 90 MM, 95 MM	1	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
WIDE-SEAL DIAPHRAGM 60 VAGINAL DIAPHRAGM 2 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
WIDE-SEAL DIAPHRAGM 65 VAGINAL DIAPHRAGM 2 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)

MPC032520 179 Effective: 09/15/2025

Drug Name	Tier	Notes
WIDE-SEAL DIAPHRAGM 70 VAGINAL DIAPHRAGM 2 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
WIDE-SEAL DIAPHRAGM 75 VAGINAL DIAPHRAGM 2 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
WIDE-SEAL DIAPHRAGM 80 VAGINAL DIAPHRAGM 2 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
WIDE-SEAL DIAPHRAGM 85 VAGINAL DIAPHRAGM 2 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
WIDE-SEAL DIAPHRAGM 90 VAGINAL DIAPHRAGM 2 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
WIDE-SEAL DIAPHRAGM 95 VAGINAL DIAPHRAGM 2 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
*GLUCOSE MONITORING TEST SUPPLIES***		
ACCU-CHEK FASTCLIX LANCET KIT	1	QL (1 EA per 180 days)
ACCU-CHEK FASTCLIX LANCETS	1	Blood Glucose Test strip and lancet limits for members: 100 every 90 days for those not using insulin, 300 every 90 days for those using insulin, and 200 every 365 days for those using a continuous glucose monitor (CGM).
ACCU-CHEK MULTICLIX LANCETS	1	Blood Glucose Test strip and lancet limits for members: 100 every 90 days for those not using insulin, 300 every 90 days for those using insulin, and 200 every 365 days for those using a continuous glucose monitor (CGM).
ACCU-CHEK SOFTCLIX LANCET DEV KIT	1	QL (1 EA per 180 days)
ACCU-CHEK SOFTCLIX LANCETS	1	Blood Glucose Test strip and lancet limits for members: 100 every 90 days for those not using insulin, 300 every 90 days for those using insulin, and 200 every 365 days for those using a continuous glucose monitor (CGM).
DEXCOM G6 RECEIVER DEVICE	2	PA; QL (1 EA per 365 days)
DEXCOM G6 SENSOR	2	PA; QL (3 EA per 30 days)
DEXCOM G6 TRANSMITTER	2	PA; QL (1 EA per 90 days)
DEXCOM G7 RECEIVER DEVICE	2	PA; QL (1 EA per 365 days)
DEXCOM G7 SENSOR	2	PA; QL (3 EA per 30 days)
FREESTYLE LIBRE 14 DAY READER DEVICE	2	ST; QL (1 EA per 365 days)
FREESTYLE LIBRE 14 DAY SENSOR	2	ST; QL (2 EA per 28 days)
FREESTYLE LIBRE 2 PLUS SENSOR	2	ST; QL (2 EA per 28 days)
FREESTYLE LIBRE 2 READER DEVICE	2	ST; QL (1 EA per 365 days)
FREESTYLE LIBRE 2 SENSOR	2	ST; QL (2 EA per 28 days)
FREESTYLE LIBRE 3 PLUS SENSOR	2	ST; QL (2 EA per 28 days)
FREESTYLE LIBRE 3 READER DEVICE	2	ST; QL (1 EA per 365 days)

MPC032520 180 Effective: 09/15/2025

Drug Name	Tier	Notes
FREESTYLE LIBRE 3 SENSOR	2	ST; QL (2 EA per 28 days)
FREESTYLE LIBRE READER DEVICE	2	ST; QL (1 EA per 365 days)
GUARDIAN 4 GLUCOSE SENSOR	2	PA; QL (5 EA per 30 days)
GUARDIAN 4 TRANSMITTER	2	PA; QL (1 EA per 365 days)
GUARDIAN LINK 3 TRANSMITTER	2	PA; QL (1 EA per 365 days)
GUARDIAN SENSOR (3)	2	PA; QL (5 EA per 30 days)
guardian sensor 3	2	PA; QL (5 EA per 30 days)
*INSULIN ADMINISTRATION SUPPLIES***		
MINIMED GUARDIAN LINK 3	2	PA; QL (1 EA per 365 days)
OMNIPOD 5 LIBRE2 G6 INTRO G5 KIT	3	PA; QL (1 EA per 365 days); NDS
OMNIPOD 5 LIBRE2 PLUS G6 PODS	3	PA; QL (10 Pods per 30 days); NDS
OMNIPOD DASH INTRO (GEN 4) KIT	3	PA; QL (1 EA per 365 days)
OMNIPOD DASH PODS (GEN 4)	3	PA; QL (10 EA per 30 days); NDS
*NEEDLES & SYRINGES***		
BD INSULIN SYRINGE ULTRAFINE 31G X 5/16" 1	1	
BD PEN NEEDLE MINI U/F 31G X 5 MM	1	QL (100 EA per 30 days)
BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM	1	QL (100 EA per 30 days)
BD PEN NEEDLE NANO U/F 32G X 4 MM	1	QL (100 EA per 30 days)
BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM	1	QL (100 EA per 30 days)
BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM	1	QL (100 EA per 30 days)
BD PEN NEEDLE ORIGINAL U/F 29G X 12.7MM	1	QL (100 EA per 30 days)
BD PEN NEEDLE SHORT U/F 31G X 8 MM	1	QL (100 EA per 30 days)
BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM	1	QL (100 EA per 30 days)
NOVOFINE PEN NEEDLE 32G X 6 MM	1	
NOVOTWIST PEN NEEDLE 32G X 5 MM	1	
pen needles 3/16" 31g x 5 mm	1	QL (100 EA per 30 days)
pen needles 5/16" 30g x 8 mm	1	QL (100 EA per 30 days)
*PEAK FLOW METERS***		
ASSESS PEAK FLOW METER DEVICE	2	
*SPACER/AEROSOL-HOLDING CHAMBERS & SUPPLIES***		
AEROCHAMBER PLUS FLO-VU	3	QL (2 EA per 180 days)
AEROCHAMBER PLUS FLOW VU	3	QL (2 EA per 180 days)
AEROCHAMBER Z-STAT PLUS	1	QL (2 EA per 180 days)
EASIVENT	3	QL (2 EA per 180 days)
E-Z SPACER DEVICE	3	QL (2 EA per 180 days)
LITEAIRE DEVICE	1	QL (2 EA per 180 days)
MICROCHAMBER	1	QL (2 EA per 180 days)
MICROSPACER	1	QL (2 EA per 180 days)

MPC032520 181 Effective: 09/15/2025

Drug Name	Tier	Notes
OPTICHAMBER DIAMOND	1	QL (2 EA per 180 days)
OPTICHAMBER DIAMOND-LG MASK DEVICE	1	QL (2 EA per 180 days)
OPTICHAMBER DIAMOND-MD MASK	1	QL (2 EA per 180 days)
OPTICHAMBER DIAMOND-SM MASK	1	QL (2 EA per 180 days)
OPTIHALER	1	QL (2 EA per 180 days)
POCKET CHAMBER DEVICE	1	QL (2 EA per 180 days)
MIGRAINE PRODUCTS		
*CGRP RECEPTOR ANTAGONISTS - MONOCOLONAL ANTIBODIES***		
AIMOVIG SUBCUTANEOUS SOLUTION AUTO- INJECTOR 140 MG/ML, 70 MG/ML	2	PA; QL (1 ML per 28 days); NDS
*ERGOT COMBINATIONS***		
CAFERGOT ORAL TABLET 1-100 MG	3	QL (40 EA per 30 days)
*MIGRAINE PRODUCTS***		
dihydroergotamine mesylate injection solution 1 mg/ml	3	QL (8 ML per 30 days)
dihydroergotamine mesylate nasal solution 4 mg/ml	5	ST; QL (8 ML per 30 days)
ERGOMAR SUBLINGUAL TABLET SUBLINGUAL 2 MG	3	ST; QL (12 EA per 30 days)
*SELECTIVE SEROTONIN AGONISTS 5- HT(1)***		
almotriptan malate oral tablet 12.5 mg, 6.25 mg	3	ST; QL (18 EA per 30 days)
eletriptan hydrobromide oral tablet 20 mg, 40 mg	3	ST; QL (18 EA per 30 days)
frovatriptan succinate oral tablet 2.5 mg	3	ST; QL (18 EA per 30 days)
IMITREX STATDOSE SYSTEM SUBCUTANEOUS SOLUTION AUTO-INJECTOR 4 MG/0.5ML	МВ	
IMITREX SUBCUTANEOUS SOLUTION 6 MG/0.5ML	MB	
naratriptan hcl oral tablet 1 mg	3	QL (18 EA per 30 days)
naratriptan hcl oral tablet 2.5 mg	1	QL (18 EA per 30 days)
rizatriptan benzoate oral tablet 10 mg, 5 mg	1	QL (18 EA per 30 days)
rizatriptan benzoate oral tablet dispersible 10 mg, 5 mg	1	QL (18 EA per 30 days)
sumatriptan nasal solution 20 mg/act, 5 mg/act	1	QL (6 EA per 30 days)
sumatriptan succinate oral tablet 100 mg, 25 mg, 50 mg	1	QL (18 EA per 30 days)
sumatriptan succinate refill subcutaneous solution cartridge 6 mg/0.5ml	1	QL (2 ML per 30 days)
sumatriptan succinate subcutaneous solution auto- injector 4 mg/0.5ml, 6 mg/0.5ml	1	QL (2 ML per 30 days)
sumatriptan succinate subcutaneous solution prefilled syringe 6 mg/0.5ml	1	QL (2 ML per 30 days)
zolmitriptan oral tablet 2.5 mg, 5 mg	1	ST; QL (18 EA per 30 days)
zolmitriptan oral tablet dispersible 2.5 mg, 5 mg	3	ST; QL (18 EA per 30 days)

MPC032520 182 Effective: 09/15/2025

Drug Name	Tier	Notes
ZOMIG NASAL SOLUTION 2.5 MG, 5 MG	3	QL (6 EA per 30 days)
MINERALS & ELECTROLYTES		
*BICARBONATES***		
sodium acetate intravenous solution 2 meq/ml	1	
*CALCIUM***		,
CALPHOSAN INJECTION SOLUTION 50-50 MG/10ML	MB	
*ELECTROLYTES & DEXTROSE***		
dextrose in lactated ringers intravenous solution 5 %	MB	
dextrose-nacl intravenous solution 5-0.9 %	MB	
dextrose-sodium chloride intravenous solution 5-0.9 %	MB	
*ELECTROLYTES PARENTERAL***		·
lactated ringers intravenous solution	MB	
*FLUORIDE***		
FLURA-DROPS ORAL SOLUTION 0.275 (0.125 F) MG/DROP	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 6 Years)
FLURA-DROPS ORAL SOLUTION 0.55 (0.25 F) MG/DROP	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 1 Years and Max 6 Years)
sodium fluoride oral solution 1.1 (0.5 f) mg/ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 6 Years)
sodium fluoride oral tablet chewable 0.55 (0.25 f) mg, 1.1 (0.5 f) mg, 2.2 (1 f) mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 6 Years)
*MAGNESIUM***		•
magnesium sulfate in d5w intravenous solution 1-5 gm/100ml-%	MB	
magnesium sulfate injection solution 50 %	MB	
magnesium sulfate intravenous solution 2 gm/50ml, 20 gm/500ml, 4 gm/100ml, 4 gm/50ml, 40 gm/1000ml	MB	
*POTASSIUM***		
KLOR-CON 10 TABLET EXTENDED RELEASE 10 MEQ ORAL	1	
KLOR-CON M10 ORAL TABLET EXTENDED RELEASE 10 MEQ	1	
KLOR-CON M15 ORAL TABLET EXTENDED RELEASE 15 MEQ	1	
KLOR-CON M20 ORAL TABLET EXTENDED RELEASE 20 MEQ	1	
KLOR-CON ORAL PACKET 20 MEQ	1	
KLOR-CON ORAL TABLET EXTENDED RELEASE 8 MEQ	1	

MPC032520 183 Effective: 09/15/2025

Drug Name	Tier	Notes
KLOR-CON/EF ORAL TABLET EFFERVESCENT 25 MEQ	1	
potassium chloride crys er oral tablet extended release 10 meq, 15 meq, 20 meq	1	
potassium chloride er oral capsule extended release 10 meq, 8 meq	1	
potassium chloride er oral tablet extended release 10 meq, 8 meq	1	
potassium chloride intravenous solution 2 meq/ml	MB	
potassium chloride oral packet 20 meq	1	
potassium chloride oral solution 20 meq/15ml (10%)	1	
*ZINC***		
zinc sulfate intravenous solution 3 mg/ml	MB	
MISCELLANEOUS THERAPEUTIC CLASSES		
*ANTILEPROTICS***		
THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG	5	PA; DX (Diagnosis Validation Required); NDS; SP
*B-LYMPHOCYTE STIMULATOR (BLYS)- SPECIFIC INHIBITORS***		
BENLYSTA SUBCUTANEOUS SOLUTION AUTO- INJECTOR 200 MG/ML	5	PA; DX (Diagnosis Validation Required); QL (4 ML per 28 days); NDS; SP
BENLYSTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/ML	5	PA; DX (Diagnosis Validation Required); QL (4 ML per 28 days); NDS; SP
*CHELATING AGENTS***		
penicillamine oral capsule 250 mg	5	PA; QL (240 EA per 30 days)
penicillamine oral tablet 250 mg	5	PA; QL (240 EA per 30 days)
*CYCLOSPORINE ANALOGS***		
cyclosporine intravenous solution 50 mg/ml	MB	
cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg	1	
cyclosporine modified oral solution 100 mg/ml	1	
cyclosporine oral capsule 100 mg, 25 mg	1	
GENGRAF ORAL SOLUTION 100 MG/ML	2	
SANDIMMUNE INTRAVENOUS SOLUTION 50 MG/ML	MB	
SANDIMMUNE ORAL SOLUTION 100 MG/ML	2	
*ENZYMES***		
HYLENEX INJECTION SOLUTION 150 UNIT/ML	MB	PA

MPC032520 184 Effective: 09/15/2025

Drug Name	Tier	Notes
*IMMUNE GLOBULIN IMMUNOSUPPRESSANTS***		
ATGAM INTRAVENOUS INJECTABLE 50 MG/ML	MB	
ATGAM INTRAVENOUS SOLUTION 50 MG/ML	MB	
THYMOGLOBULIN INTRAVENOUS SOLUTION RECONSTITUTED 25 MG	MB	
*IMMUNOMODULATORS FOR MYELODYSPLASTIC SYNDROMES***		
lenalidomide oral capsule 10 mg, 15 mg, 25 mg, 5 mg	5	PA; LA; DX (Diagnosis Validation Required); NDS
lenalidomide oral capsule 2.5 mg, 20 mg	5	PA; DX (Diagnosis Validation Required); NDS; SP
REVLIMID ORAL CAPSULE 2.5 MG	5	PA; DX (Diagnosis Validation Required); NDS; SP
*INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS***		
mycophenolate mofetil oral capsule 250 mg	1	
mycophenolate mofetil oral suspension reconstituted 200 mg/ml	5	PA; AL (Max 12 Years)
mycophenolate mofetil oral tablet 500 mg	1	
*MACROLIDE		
IMMUNOSUPPRESSANTS***	l .	
ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG	3	PA; QL (30 EA per 30 days)
ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 1 MG	5	PA; QL (120 EA per 30 days)
ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 5 MG	5	PA; QL (90 EA per 30 days)
everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg	5	PA; NDS; SP
everolimus oral tablet 1 mg	5	PA
HECORIA ORAL CAPSULE 0.5 MG, 1 MG, 5 MG	1	
PROGRAF INTRAVENOUS SOLUTION 5 MG/ML	MB	
sirolimus oral solution 1 mg/ml	5	QL (60 ML per 30 days)
sirolimus oral tablet 0.5 mg, 1 mg, 2 mg	3	
tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg	1	
*MONOCLONAL ANTIBODIES***		
GAMIFANT INTRAVENOUS SOLUTION 10 MG/2ML, 50 MG/10ML	MB	РА
SIMULECT INTRAVENOUS SOLUTION RECONSTITUTED 20 MG	MB	
ZENAPAX INTRAVENOUS CONCENTRATE 25 MG/5ML	MB	

MPC032520 185 Effective: 09/15/2025

Drug Name	Tier	Notes
*POTASSIUM REMOVING AGENTS***		•
KIONEX COMBINATION SUSPENSION 15 GM/60ML	1	
KIONEX ORAL POWDER	1	
KIONEX ORAL SUSPENSION 15 GM/60ML	1	
LOKELMA ORAL PACKET 10 GM	4	PA; QL (30 EA per 30 days)
LOKELMA ORAL PACKET 5 GM	4	PA; QL (90 EA per 30 days)
sodium polystyrene sulfonate oral powder	1	
VELTASSA ORAL PACKET 1 GM, 16.8 GM, 25.2 GM, 8.4 GM	5	PA; QL (30 EA per 30 days)
*PURINE ANALOGS***		
azathioprine oral tablet 50 mg	1	
azathioprine sodium injection solution reconstituted 100 mg	MB	
*SCLEROSING AGENTS***	-	
ETHAMOLIN INTRAVENOUS SOLUTION 5 %	MB	
MOUTH/THROAT/DENTAL AGENTS		
*ANESTHETICS TOPICAL ORAL***		
lidocaine viscous mouth/throat solution 2 %	1	
*ANTI-INFECTIVES - THROAT***		
clotrimazole mouth/throat troche 10 mg	1	
nystatin mouth/throat suspension 100000 unit/ml	1	
*ANTISEPTICS - MOUTH/THROAT***		·
chlorhexidine gluconate mouth/throat solution 0.12 %	1	
PAROEX MOUTH/THROAT SOLUTION 0.12 %	1	
PERIOGARD MOUTH/THROAT SOLUTION 0.12 %	1	
*SALIVA STIMULANTS***		
cevimeline hcl oral capsule 30 mg	3	ST; QL (90 EA per 30 days)
pilocarpine hcl oral tablet 5 mg, 7.5 mg	1	QL (90 EA per 30 days)
*STEROIDS - MOUTH/THROAT/DENTAL***		
ORALONE MOUTH/THROAT PASTE 0.1 %	1	QL (5 GM per 30 days)
triamcinolone acetonide mouth/throat paste 0.1 %	1	QL (5 GM per 30 days)
MULTIVITAMINS		
*PED VITAMINS ACD W/ FLUORIDE***		
triple-vitamin/fluoride oral solution 0.25 mg/ml	1	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 6 Years)
tri-vit/fluoride oral solution 0.25 mg/ml, 0.5 mg/ml	1	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 6 Years)

MPC032520 186 Effective: 09/15/2025

Drug Name	Tier	Notes
tri-vitamin/fluoride oral solution 0.25 mg/ml, 0.5 mg/ml	1	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 6 Years)
vitamins acd-fluoride oral solution 0.25 mg/ml	1	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 6 Years)
*PRENATAL MV & MIN W/FE-FA***		7
completenate oral tablet chewable 29-1 mg	2	
CO-NATAL FA ORAL TABLET	2	
INATAL ADVANCE ORAL TABLET 90-1 MG	2	
INATAL GT ORAL TABLET	2	
INATAL ULTRA ORAL TABLET , 90-1 MG	2	
multi prenatal oral tablet 27-0.8 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
M-VIT ORAL TABLET	2	
MYNATAL ADVANCE ORAL TABLET	2	
MYNATAL ORAL TABLET 90-1 MG	2	
natal-v rx oral tablet 29-1 mg	2	
NIVA-PLUS ORAL TABLET 27-1 MG	2	
OBSTETRIX EC (WITH DOCUSATE) ORAL TABLET 29-1 MG	2	
OBSTETRIX EC ORAL TABLET 29-1 MG	2	
OBTREX ORAL TABLET	2	
O-CAL FA ORAL TABLET 27-1 MG	2	
pnv folic acid + iron oral tablet 27-1 mg	2	
pnv prenatal plus multivitamin oral tablet 27-1 mg	2	
pnv tabs 29-1 oral tablet 29-1 mg	2	
pnv-vp-u oral capsule 106.5-1 mg	2	
prenaplus oral tablet 27-1 mg	2	
prenatabs fa oral tablet	2	
PRENATABS RX ORAL TABLET 29-1 MG	2	
prenatal 19 oral tablet chewable , 29-1 mg	2	
PRENATAL AD ORAL TABLET	2	
prenatal formula oral tablet 27-1 mg	2	
prenatal low iron oral tablet 27-0.8 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
prenatal low iron oral tablet 27-1 mg	2	
PRENATAL MULTIVITAMIN-ULTRA ORAL TABLET	2	
prenatal one daily oral tablet 27-0.8 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)

MPC032520 187 Effective: 09/15/2025

Drug Name	Tier	Notes
prenatal oral tablet 27-0.8 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
prenatal oral tablet 27-1 mg	2	
prenatal plus iron oral tablet 29-1 mg	2	
prenatal plus oral tablet 27-1 mg	2	
prenatal plus/iron oral tablet 27-1 mg	2	
prenatal vitamin oral tablet 27-0.8 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
prenatal vitamins plus oral tablet 27-1 mg	2	
PRENATAL/FOLIC ACID ORAL TABLET	2	
PRENATAL-U ORAL CAPSULE 106.5-1 MG	2	
preplus oral tablet 27-1 mg	2	
pretab oral tablet 29-1 mg	2	
right step prenatal oral tablet 27-0.8 mg	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
se-natal 19 oral tablet chewable 29-1 mg	2	
THERANATAL CORE NUTRITION ORAL TABLET 27-1 MG	2	
triadvance oral tablet 90-1 mg	2	
TRICARE ORAL TABLET	2	
trinatal gt oral tablet 90-1 mg	2	
trinatal ultra oral tablet 90-1 mg	2	
TRIVEEN-U ORAL CAPSULE 106.5-1 MG	2	
ULTRA NATALCARE ORAL TABLET 90-1 MG	2	
ultra tabs oral tablet	2	
venatal-fa oral tablet 29-1 mg	2	
VINATE GT ORAL TABLET 90-1 MG	2	
vinate ultra oral tablet	2	
virt-advance oral tablet 90-1 mg	2	
virt-vite gt oral tablet 90-1 mg	2	
vol-plus oral tablet 27-1 mg	2	
vol-tab rx oral tablet 29-1 mg	2	
MUSCULOSKELETAL THERAPY AGENTS		
*CENTRAL MUSCLE RELAXANTS***		
baclofen intrathecal solution 10 mg/20ml	МВ	
baclofen oral tablet 10 mg, 20 mg	1	

Drug Name	Tier	Notes
chlorzoxazone oral tablet 500 mg	1	
cyclobenzaprine hcl oral tablet 10 mg, 5 mg	1	
LIORESAL INTRATHECAL SOLUTION 0.05 MG/ML	MB	
metaxalone oral tablet 800 mg	3	ST; QL (120 EA per 30 days)
methocarbamol injection solution 1000 mg/10ml	MB	
methocarbamol oral tablet 500 mg, 750 mg	1	
orphenadrine citrate er oral tablet extended release 12 hour 100 mg	1	
orphenadrine citrate injection solution 30 mg/ml	MB	
tizanidine hcl oral tablet 2 mg, 4 mg	1	
*DIRECT MUSCLE RELAXANTS***		•
dantrolene sodium oral capsule 100 mg, 25 mg, 50 mg	1	
*MUSCLE RELAXANT COMBINATIONS***		
norgesic forte oral tablet 50-770-60 mg	3	PA; QL (4 EA per 1 day)
*VISCOSUPPLEMENTS***		
DUROLANE INTRA-ARTICULAR PREFILLED SYRINGE 60 MG/3ML	MB	PA; NDS
NASAL AGENTS - SYSTEMIC AND TOPICAL		
*NASAL ANTIBIOTICS***		
BACTROBAN NASAL NASAL OINTMENT 2 %	2	
*NASAL ANTICHOLINERGICS***		
ipratropium bromide nasal solution 0.03 %, 0.06 %	1	
*NASAL ANTIHISTAMINES***		
azelastine hcl nasal solution 0.1 %, 137 mcg/spray	1	
olopatadine hcl nasal solution 0.6 %	3	PA; QL (30.5 GM per 30 days)
*NASAL STEROIDS***		•
BECONASE AQ NASAL SUSPENSION 42 MCG/SPRAY	3	ST
budesonide nasal suspension 32 mcg/act	3	ST
flunisolide nasal solution 25 mcg/act (0.025%)	2	
flunisolide nasal solution 29 mcg/act (0.025%)	1	
fluticasone propionate nasal suspension 50 mcg/act	1	
mometasone furoate nasal suspension 50 mcg/act	3	ST
NASACORT AQ NASAL AEROSOL, SOLUTION 55 MCG/ACT	1	
*TOPICAL DECONGESTANTS***		
ADRENALIN NASAL SOLUTION 0.1 %	MB	

Drug Name	Tier	Notes
NEUROMUSCULAR AGENTS		
*BENZATHIAZOLES***		
riluzole oral tablet 50 mg	5	
*DEPOLARIZING MUSCLE RELAXANTS***		-
ANECTINE INJECTION SOLUTION 20 MG/ML	MB	
QUELICIN INJECTION SOLUTION 20 MG/ML	MB	
*NEUROMUSCULAR BLOCKING AGENT - NEUROTOXINS***		
BOTOX INJECTION SOLUTION RECONSTITUTED 200 UNIT	MB	РА
MYOBLOC INTRAMUSCULAR SOLUTION 10000 UNIT/2ML, 2500 UNIT/0.5ML, 5000 UNIT/ML	МВ	РА
*NONDEPOLARIZING MUSCLE RELAXANTS***		
atracurium besylate intravenous solution 100 mg/10ml	1	
NUTRIENTS		
*AMINO ACIDS-SINGLE***		_
n-acetyl-l-cysteine oral capsule 600 mg	1	
*CARBOHYDRATES***		
dextrose intravenous solution 5 %	MB	
OPHTHALMIC AGENTS		
*BETA-BLOCKERS - OPHTHALMIC COMBINATIONS***		
brimonidine tartrate-timolol ophthalmic solution 0.2-0.5 %	3	
dorzolamide hcl-timolol mal ophthalmic solution 2-0.5 %	1	
*BETA-BLOCKERS - OPHTHALMIC***		
betaxolol hcl ophthalmic solution 0.5 %	1	
BETOPTIC-S OPHTHALMIC SUSPENSION 0.25 %	2	
carteolol hcl ophthalmic solution 1 %	1	
levobunolol hcl ophthalmic solution 0.25 %, 0.5 %	1	
metipranolol ophthalmic solution 0.3 %	2	
timolol maleate (once-daily) ophthalmic solution 0.5 %	3	
timolol maleate ophthalmic solution 0.25 %, 0.5 %	1	
*CYCLOPLEGIC MYDRIATICS***		
atropine sulfate ophthalmic ointment 1 %	1	
atropine sulfate ophthalmic solution 1 %	2	

MPC032520 190 Effective: 09/15/2025

cyclopentolate hcl ophthalmic solution 1 %, 2 % HOMATROPAIRE OPHTHALMIC SOLUTION 5 % SOPTO HOMATROPINE OPHTHALMIC SOLUTION 2 % SSOPTO HOMATROPINE OPHTHALMIC SOLUTION 0.25 % BIOPTO HYOSCINE OPHTHALMIC SOLUTION 0.25 % phenylephrine hcl ophthalmic solution 10 %, 2.5 % tropicamide ophthalmic solution 0.5 %, 1 % **MIOTICS - CHOLINESTERASE INHIBITORS*** PHOSPHOLINE IODIDE OPHTHALMIC SOLUTION RECONSTITUTED 0.125 % **SIOPTO CARBACHOL OPHTHALMIC SOLUTION 1.5 %, 3 % price of the phthalmic solution 1 %, 2 %, 4 % **OPHTHALMIC ANTIALLERGIC*** ALOCRIL OPHTHALMIC SOLUTION 0.1 % azelastine hcl ophthalmic solution 0.05 % 4 LOMIDE OPHTHALMIC SOLUTION 0.5 % 4 Pepotastine besilate ophthalmic solution 1.5 % 5 CARDONIC OPHTHALMIC SOLUTION 0.05 % 4 Pepinastine hcl ophthalmic solution 0.05 % 4 Pepinastine hcl ophthalmic solution 0.05 % 5 CILOXAN OPHTHALMIC ONTIMENT 0.3 % 1 CILOXAN OPHTHALMIC INTIMENT 0.3 % 1 CILOXAN OPHTHALMIC SOLUTION 0.3 % 4 Perinastine hcl ophthalmic solution 0.3 % 4 Pepinastine in hcl ophthalmic solution 0.3 % 5 OS (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % 1 GENTAK OPHTHALMIC SOLUTION 0.3 % 5 OS (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % 5 OS (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % 5 OS (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC SOLUTION 0.3 % 5 OS (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC SOLUTION 0.3 % 5 OS (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC SOLUTION 0.3 % 5 OS (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years)	Drug Name	Tier	Notes
homatropine hbr ophthalmic solution 5 % ISOPTO HOMATROPINE OPHTHALMIC SOLUTION 2 % Sopto Hyposchie hcl ophthalmic solution 10 % 2.5 % 1 tropicamide ophthalmic solution 10 % 2.5 % 1 tropicamide ophthalmic solution 0.5 % 1 % 1 ** **MIOTICS - CHOLINESTERASE INHIBITORS*** PHOSPHOLINE IODIDE OPHTHALMIC SOLUTION 2 ** **MIOTICS - DIRECT ACTING*** ISOPTO CARBACHOL OPHTHALMIC SOLUTION 1.5 % 1 ** **OPHTHALMIC ANTIALLERGIC*** ALOCRIL OPHTHALMIC SOLUTION 2 % 3 ** ALOMIDE OPHTHALMIC SOLUTION 0.1 % 2 ** **ALOCRIL OPHTHALMIC SOLUTION 0.1 % 2 ** **ALOMIDE OPHTHALMIC SOLUTION 0.1 % 2 ** **Emabline ophthalmic solution 0.05 % 1 ** **Depotastine besilate ophthalmic solution 1.5 % 3 PA **Cormolyn sodium ophthalmic solution 0.05 % 1 ** **Emabline OPHTHALMIC SOLUTION 0.05 % 1 ** **CPHTHALMIC ANTIBIOTICS*** **Dacitracin ophthalmic solution 0.05 % 1 ** **OPHTHALMIC ANTIBIOTICS*** **Dacitracin ophthalmic solution 0.3 % 1 ** **OPHTHALMIC ONTMENT 0.3 % 2 ** **ciprofloxacin hcl ophthalmic intend 50 unitlym 2 ** **CILOXAN OPHTHALMIC OINTMENT 0.3 % 1 ** **gentamicin sulfate ophthalmic solution 0.3 % 1 ** **gentamicin sulfate ophthalmic intend 0.3 % 1 ** **gentamicin sulfate ophthalmic solution 0.3 % 1 ** **MIOTICS - CHOLING MB	cyclopentolate hcl ophthalmic solution 1 %, 2 %	1	
ISOPTO HOMATROPINE OPHTHALMIC SOLUTION 2 % SOPTO HYOSCINE OPHTHALMIC SOLUTION 0.25	HOMATROPAIRE OPHTHALMIC SOLUTION 5 %	1	
2 % ISOPTO HYOSCINE OPHTHALMIC SOLUTION 0.25 % phenylephrine hel ophthalmic solution 10 %, 2.5 % tropicamide ophthalmic solution 0.5 %, 1 % *MIOTICS - CHOLINESTERASE INHIBITORS*** PHOSPHOLINE IODIDE OPHTHALMIC SOLUTION RECONSTITUTED 0.125 % *MIOTICS - DIRECT ACTING*** ISOPTO CARBACHOL OPHTHALMIC SOLUTION 1.5 %, 3 % pilocarpine hel ophthalmic solution 1 %, 2 %, 4 % *OPHTHALMIC ANTIALLERGIC*** ALOCKIL OPHTHALMIC SOLUTION 2 % ALOMIDE OPHTHALMIC SOLUTION 0.1 % 2 acelastine hel ophthalmic solution 0.5 % bepotastine besilate ophthalmic solution 1.5 % cromolyn sodium ophthalmic solution 4 % EMADINE OPHTHALMIC SOLUTION 0.05 % 2 pinastine hel ophthalmic solution 0.05 % 3 PA CILOXAN OPHTHALMIC ANTIBIOTICS*** **OPHTHALMIC ANTIBIOTICS*** **OPHTHALMIC OINTMENT 0.3 % 2 ciprofloxacin hel ophthalmic solution 0.3 % 4 1 gentamicin sulfate ophthalmic solution 0.3 % 4 1 gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hel ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hel ophthalmic solution 0.3 % MITOSOL OPHTHALMIC SOLUTION 0.5 % 3 SO (SO Copay for members 1 year of age or younger per PPACA guidelines): AL (Max 1 Years) SO (SO Copay for members 1 year of age or younger per PPACA guidelines): AL (Max 1 Years) SO (SO Copay for members 1 year of age or younger per PPACA guidelines): AL (Max 1 Years) MITOSOL OPHTHALMIC SOLUTION 0.3 % MITOSOL OPHTHALMIC SOLUTION 0.3 % MITOSOL OPHTHALMIC SOLUTION 0.5 % 3 NA 1	homatropine hbr ophthalmic solution 5 %	1	
### Prenylephrine hol ophthalmic solution 10 %, 2.5 % 1	ISOPTO HOMATROPINE OPHTHALMIC SOLUTION 2 %	2	
tropicamide ophthalmic solution 0.5 %, 1 % *MIOTICS - CHOLINESTERASE INHIBITORS*** PHOSPHOLINE IODIDE OPHTHALMIC SOLUTION RECONSTITUTED 0.125 % *MIOTICS - DIRECT ACTING*** ISOPTO CARBACHOL OPHTHALMIC SOLUTION 1.5 %, 3 % pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 % *OPHTHALMIC ANTIALLERGIC*** ALOCRIL OPHTHALMIC SOLUTION 2 % 3 ALOMIDE OPHTHALMIC SOLUTION 0.1 % 2 peptastine hcl ophthalmic solution 0.15 % 3 PA cromolyn sodium ophthalmic solution 1.5 % 2 pepinastine hcl ophthalmic solution 0.05 % 4 pepinastine hcl ophthalmic solution 0.05 % 5 PA *OPHTHALMIC ANTIBIOTICS*** *OPHTHALMIC ANTIBIOTICS*** *OPHTHALMIC SOLUTION 0.05 % 2 pepinastine hcl ophthalmic solution 0.05 % 4 OPHTHALMIC ONTMENT 0.3 % 5 O (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % gentamicin sulfate ophthalmic solution 0.3 % I member of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC SOLUTION 0.5 % 3 O (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) MITOSOL OPHTHALMIC SOLUTION 0.3 % MITOSOL OPHTHALMIC SOLUTION 0.3 % MITOSOL OPHTHALMIC SOLUTION 0.3 % MITOSOL OPHTHALMIC SOLUTION 0.5 % MITOSOL OPHTHALMIC SOLUTION 0.5 % 3 O (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years)		2	
*MIOTICS - CHOLINESTERASE INHIBITORS*** PHOSPHOLINE IODIDE OPHTHALMIC SOLUTION RECONSTITUTED 0.125 % **MIOTICS - DIRECT ACTING*** ISOPTO CARBACHOL OPHTHALMIC SOLUTION 1.5 %, 3 % pilocarpine hol ophthalmic solution 1 %, 2 %, 4 % *OPHTHALMIC ANTIALLERGIC*** ALOCRIL OPHTHALMIC SOLUTION 2 % 3 ALOMIDE OPHTHALMIC SOLUTION 0.1 % 2 azelastine hol ophthalmic solution 0.05 % 1 bepotastine besilate ophthalmic solution 1.5 % 2 cromolyn sodium ophthalmic solution 4 % EMADINE OPHTHALMIC SOLUTION 0.05 % 2 epinastine hol ophthalmic solution 0.05 % 1 *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic solution 0.05 % 2 ciprofloxacin hol ophthalmic solution 0.3 % 1 *OPHTHALMIC OINTMENT 0.3 % 2 ciprofloxacin hol ophthalmic solution 0.3 % 1 *Qentamicin sulfate ophthalmic solution 0.5 % 3 *Qentamicin sulfate ophthalmic solution 0.5 %	phenylephrine hcl ophthalmic solution 10 %, 2.5 %	1	
INHIBITORS*** PHOSPHOLINE IODIDE OPHTHALMIC SOLUTION RECONSTITUTED 0.125 % *MIOTICS - DIRECT ACTING*** ISOPTO CARBACHOL OPHTHALMIC SOLUTION 1.5 %, 3 % pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 % 1 *OPHTHALMIC ANTIALLERGIC*** ALOCRIL OPHTHALMIC SOLUTION 2.7 ALOMIDE OPHTHALMIC SOLUTION 0.1 % 2 azelastine hcl ophthalmic solution 0.05 % 1 bepotastine besilate ophthalmic solution 1.5 % 3 PA cromolyn sodium ophthalmic solution 0.05 % 1 EMADINE OPHTHALMIC SOLUTION 0.05 % 2 epinastine hcl ophthalmic solution 0.05 % 1 *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic solution 0.05 % 2 ciprofloxacin hcl ophthalmic solution 0.3 % 1 erythromycin ophthalmic solution 0.3 % 1 gentamicin sulfate ophthalmic solution 0.3 % 1 gentamicin sulfate ophthalmic intment 5 mg/gm	tropicamide ophthalmic solution 0.5 %, 1 %	1	
*MIOTICS - DIRECT ACTING*** ISOPTO CARBACHOL OPHTHALMIC SOLUTION 1.5 %, 3 % 1 pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 % 1 *OPHTHALMIC ANTIALLERGIC*** ALOCRIL OPHTHALMIC SOLUTION 2 % 3 ALOMIDE OPHTHALMIC SOLUTION 0.1 % 2 azelastine hcl ophthalmic solution 0.05 % 1 bepotastine besilate ophthalmic solution 1.5 % 3 PA cromolyn sodium ophthalmic solution 4 % 1 EMADINE OPHTHALMIC SOLUTION 0.05 % 1 EMADINE OPHTHALMIC SOLUTION 0.05 % 2 epinastine hcl ophthalmic solution 0.05 % 1 *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic ointment 500 unit/gm 2 CILOXAN OPHTHALMIC OINTMENT 0.3 % 1 erythromycin ophthalmic solution 0.3 % 1 GENTAK OPHTHALMIC OINTMENT 0.3 % 1 gentamicin sulfate ophthalmic ointment 0.3 % 1 gentamicin sulfate ophthalmic solution 0.3 % 1 MITOSOL OPHTHALMIC KIT 0.2 MG MB moxifloxacin hcl ophthalmic solution 0.5 % 3 MITOSOL OPHTHALMIC KIT 0.2 MG MB moxifloxacin hcl ophthalmic solution 0.5 % 3 MITOSOL OPHTHALMIC KIT 0.2 MG MB moxifloxacin hcl ophthalmic solution 0.5 % 3			
ISOPTO CARBACHOL OPHTHALMIC SOLUTION 1.5 %, 3 % pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 % 1 *OPHTHALMIC ANTIALLERGIC*** ALOCRIL OPHTHALMIC SOLUTION 2 % 3 ALOMIDE OPHTHALMIC SOLUTION 0.1 % 2 azelastine hcl ophthalmic solution 0.05 % 1 bepotastine besilate ophthalmic solution 1.5 % 3 PA cromolyn sodium ophthalmic solution 4 % 1 EMADINE OPHTHALMIC SOLUTION 0.05 % 1 EMADINE OPHTHALMIC SOLUTION 0.05 % 1 *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic intrment 500 unit/gm 2 CILOXAN OPHTHALMIC OINTMENT 0.3 % 2 ciprofloxacin hcl ophthalmic solution 0.3 % 1 erythromycin ophthalmic ointment 5 mg/gm \$0 \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % 1 gentamicin sulfate ophthalmic solution 0.3 % 1 gentamicin sulfate ophthalmic solution 0.3 % 1 MITOSOL OPHTHALMIC KIT 0.2 MG MB moxifloxacin hcl ophthalmic Kit 0.2 MG MB moxifloxacin hcl ophthalmic solution 0.5 % 3		2	
1.5 %, 3 % pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 % *OPHTHALMIC ANTIALLERGIC*** ALOCRIL OPHTHALMIC SOLUTION 2 % ALOMIDE OPHTHALMIC SOLUTION 0.1 % azelastine hcl ophthalmic solution 0.05 % bepotastine besilate ophthalmic solution 1.5 % cromolyn sodium ophthalmic solution 4 % EMADINE OPHTHALMIC SOLUTION 0.05 % † EMADINE OPHTHALMIC SOLUTION 0.05 % † *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic solution 0.05 % ciprofloxacin hcl ophthalmic solution 0.3 % erythromycin ophthalmic solution 0.3 % GENTAK OPHTHALMIC OINTMENT 0.3 % gentamicin sulfate ophthalmic solution 0.3 % fentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % MB moxifloxacin hcl ophthalmic solution 0.5 % 3 ALOMIDE ANTIBLORITION A	*MIOTICS - DIRECT ACTING***		
*OPHTHALMIC ANTIALLERGIC*** ALOCRIL OPHTHALMIC SOLUTION 2 % ALOMIDE OPHTHALMIC SOLUTION 0.1 % azelastine hcl ophthalmic solution 0.05 % bepotastine besilate ophthalmic solution 1.5 % cromolyn sodium ophthalmic solution 4 % EMADINE OPHTHALMIC SOLUTION 0.05 % pinastine hcl ophthalmic solution 0.05 % *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic ointment 500 unit/gm CILOXAN OPHTHALMIC OINTMENT 0.3 % ciprofloxacin hcl ophthalmic solution 0.3 % 1 erythromycin ophthalmic ointment 5 mg/gm \$0 \$\$ (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % gentamicin sulfate ophthalmic ointment 0.3 % gentamicin sulfate ophthalmic solution 0.3 % I \$\text{MITOSOL OPHTHALMIC KIT 0.2 MG} \text{MB} \text{MB} moxifloxacin hcl ophthalmic solution 0.5 % 3		2	
ALOCRIL OPHTHALMIC SOLUTION 2 % ALOMIDE OPHTHALMIC SOLUTION 0.1 % azelastine hcl ophthalmic solution 0.05 % bepotastine besilate ophthalmic solution 1.5 % cromolyn sodium ophthalmic solution 4 % EMADINE OPHTHALMIC SOLUTION 0.05 % pinastine hcl ophthalmic solution 0.05 % *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic ointment 500 unit/gm CILOXAN OPHTHALMIC OINTMENT 0.3 % ciprofloxacin hcl ophthalmic solution 0.3 % 1 *O \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % gentamicin sulfate ophthalmic ointment 0.3 % gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3 *MB moxifloxacin hcl ophthalmic solution 0.5 % 3 **O ** **O **	pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 %	1	
ALOMIDE OPHTHALMIC SOLUTION 0.1 % azelastine hcl ophthalmic solution 0.05 % bepotastine besilate ophthalmic solution 1.5 % cromolyn sodium ophthalmic solution 4 % EMADINE OPHTHALMIC SOLUTION 0.05 % epinastine hcl ophthalmic solution 0.05 % *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic ointment 500 unit/gm CILOXAN OPHTHALMIC OINTMENT 0.3 % ciprofloxacin hcl ophthalmic solution 0.3 % 1 erythromycin ophthalmic ointment 5 mg/gm \$0 \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % gentamicin sulfate ophthalmic ointment 0.3 % gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3 PA PA PA PA PA PA PA PA PA	*OPHTHALMIC ANTIALLERGIC***	-	•
azelastine hcl ophthalmic solution 0.05 % bepotastine besilate ophthalmic solution 1.5 % cromolyn sodium ophthalmic solution 4 % EMADINE OPHTHALMIC SOLUTION 0.05 % epinastine hcl ophthalmic solution 0.05 % *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic ointment 500 unit/gm CILOXAN OPHTHALMIC OINTMENT 0.3 % ciprofloxacin hcl ophthalmic solution 0.3 % 1 erythromycin ophthalmic ointment 5 mg/gm \$0 \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % 1 gentamicin sulfate ophthalmic ointment 0.3 % gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3 PA 1 SO SO SO SO SO SO SO SO SO	ALOCRIL OPHTHALMIC SOLUTION 2 %	3	
bepotastine besilate ophthalmic solution 1.5 % cromolyn sodium ophthalmic solution 4 % EMADINE OPHTHALMIC SOLUTION 0.05 % epinastine hcl ophthalmic solution 0.05 % *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic ointment 500 unit/gm CILOXAN OPHTHALMIC OINTMENT 0.3 % ciprofloxacin hcl ophthalmic solution 0.3 % 1 erythromycin ophthalmic ointment 5 mg/gm \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % 1 gentamicin sulfate ophthalmic ointment 0.3 % gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3 PA 1 SO SO GENTAK OPHTHALMIC SILUTION 0.05 % MB MITOSOL OPHTHALMIC KIT 0.2 MG MB moxifloxacin hcl ophthalmic solution 0.5 % 3	ALOMIDE OPHTHALMIC SOLUTION 0.1 %	2	
cromolyn sodium ophthalmic solution 4 % EMADINE OPHTHALMIC SOLUTION 0.05 % epinastine hcl ophthalmic solution 0.05 % *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic ointment 500 unit/gm CILOXAN OPHTHALMIC OINTMENT 0.3 % ciprofloxacin hcl ophthalmic solution 0.3 % 1 erythromycin ophthalmic ointment 5 mg/gm \$0 \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % 1 gentamicin sulfate ophthalmic ointment 0.3 % 1 gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3	azelastine hcl ophthalmic solution 0.05 %	1	
epinastine hcl ophthalmic solution 0.05 % *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic ointment 500 unit/gm CILOXAN OPHTHALMIC OINTMENT 0.3 % ciprofloxacin hcl ophthalmic solution 0.3 % erythromycin ophthalmic ointment 5 mg/gm \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % 1 gentamicin sulfate ophthalmic ointment 0.3 % qentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3	bepotastine besilate ophthalmic solution 1.5 %	3	PA
epinastine hcl ophthalmic solution 0.05 % *OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic ointment 500 unit/gm CILOXAN OPHTHALMIC OINTMENT 0.3 % ciprofloxacin hcl ophthalmic solution 0.3 % 1 erythromycin ophthalmic ointment 5 mg/gm \$0 \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % 1 gentamicin sulfate ophthalmic ointment 0.3 % 1 gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3	cromolyn sodium ophthalmic solution 4 %	1	
*OPHTHALMIC ANTIBIOTICS*** bacitracin ophthalmic ointment 500 unit/gm CILOXAN OPHTHALMIC OINTMENT 0.3 % ciprofloxacin hcl ophthalmic solution 0.3 % erythromycin ophthalmic ointment 5 mg/gm \$0 \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % gentamicin sulfate ophthalmic ointment 0.3 % gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3	EMADINE OPHTHALMIC SOLUTION 0.05 %	2	
CILOXAN OPHTHALMIC OINTMENT 0.3 % ciprofloxacin hcl ophthalmic solution 0.3 % erythromycin ophthalmic ointment 5 mg/gm \$0 \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % gentamicin sulfate ophthalmic ointment 0.3 % gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3	epinastine hcl ophthalmic solution 0.05 %	1	
CILOXAN OPHTHALMIC OINTMENT 0.3 % ciprofloxacin hcl ophthalmic solution 0.3 % erythromycin ophthalmic ointment 5 mg/gm \$0 \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % gentamicin sulfate ophthalmic ointment 0.3 % gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3	*OPHTHALMIC ANTIBIOTICS***	•	•
ciprofloxacin hcl ophthalmic solution 0.3 % erythromycin ophthalmic ointment 5 mg/gm \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % gentamicin sulfate ophthalmic ointment 0.3 % gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3	bacitracin ophthalmic ointment 500 unit/gm	2	
erythromycin ophthalmic ointment 5 mg/gm \$0 \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % gentamicin sulfate ophthalmic ointment 0.3 % gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % \$0 (\$0 Copay for members 1 year of age or younger per PPACA guidelines); AL (Max 1 Years) 1 MITOSOL OPHTHALMIC KIT 0.3 % MB moxifloxacin hcl ophthalmic solution 0.5 %	CILOXAN OPHTHALMIC OINTMENT 0.3 %	2	
erythromycin ophthalmic ointment 5 mg/gm \$0 age or younger per PPACA guidelines); AL (Max 1 Years) GENTAK OPHTHALMIC OINTMENT 0.3 % gentamicin sulfate ophthalmic ointment 0.3 % gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3	ciprofloxacin hcl ophthalmic solution 0.3 %	1	
gentamicin sulfate ophthalmic ointment 0.3 % gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3	erythromycin ophthalmic ointment 5 mg/gm	\$0	age or younger per PPACA
gentamicin sulfate ophthalmic solution 0.3 % MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3	GENTAK OPHTHALMIC OINTMENT 0.3 %	1	
MITOSOL OPHTHALMIC KIT 0.2 MG moxifloxacin hcl ophthalmic solution 0.5 % 3	gentamicin sulfate ophthalmic ointment 0.3 %	1	
moxifloxacin hcl ophthalmic solution 0.5 % 3	gentamicin sulfate ophthalmic solution 0.3 %	1	
	MITOSOL OPHTHALMIC KIT 0.2 MG	MB	
ofloxacin ophthalmic solution 0.3 %	moxifloxacin hcl ophthalmic solution 0.5 %	3	
	ofloxacin ophthalmic solution 0.3 %	1	

MPC032520 191 Effective: 09/15/2025

Drug Name	Tier	Notes
tobramycin ophthalmic solution 0.3 %	1	
TOBREX OPHTHALMIC OINTMENT 0.3 %	3	
*OPHTHALMIC ANTIFUNGAL***		-
NATACYN OPHTHALMIC SUSPENSION 5 %	3	PA; QL (30 ML per 30 days)
*OPHTHALMIC ANTI-INFECTIVE COMBINATIONS***		
ak-poly-bac ophthalmic ointment 500-10000 unit/gm	1	
bacitracin-polymyxin b ophthalmic ointment 500-10000 unit/gm	1	
neomycin-bacitracin zn-polymyx ophthalmic ointment 5-400-10000	1	
neomycin-polymyxin-gramicidin ophthalmic solution 1.75-10000025	1	
NEO-POLYCIN OPHTHALMIC OINTMENT 3.5-400- 10000	1	
polymyxin b-trimethoprim ophthalmic solution 10000- 0.1 unit/ml-%	1	
*OPHTHALMIC ANTIVIRALS***		
trifluridine ophthalmic solution 1 %	1	
*OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS***		
brinzolamide ophthalmic suspension 1 %	3	
dorzolamide hcl ophthalmic solution 2 %	1	
*OPHTHALMIC IMMUNOMODULATORS***		
cyclosporine ophthalmic emulsion 0.05 %	3	QL (60 EA per 30 days)
*OPHTHALMIC LOCAL ANESTHETICS***		
proparacaine hcl ophthalmic solution 0.5 %	1	
*OPHTHALMIC NONSTEROIDAL ANTI- INFLAMMATORY AGENTS***		
bromfenac sodium ophthalmic solution 0.09 %	3	ST; QL (5 ML per 90 days)
diclofenac sodium ophthalmic solution 0.1 %	1	
flurbiprofen sodium ophthalmic solution 0.03 %	1	
ketorolac tromethamine ophthalmic solution 0.4 %, 0.5 %	1	
*OPHTHALMIC RHO KINASE INHIBITORS***		
RHOPRESSA OPHTHALMIC SOLUTION 0.02 %	2	ST
*OPHTHALMIC SELECTIVE ALPHA ADRENERGIC AGONISTS***		
apraclonidine hcl ophthalmic solution 0.5 %	1	

Drug Name	Tier	Notes
brimonidine tartrate ophthalmic solution 0.1 %	2	
brimonidine tartrate ophthalmic solution 0.15 %, 0.2 %	1	
*OPHTHALMIC STEROID COMBINATIONS***		
bacitra-neomycin-polymyxin-hc ophthalmic ointment 1 %	1	
BLEPHAMIDE OPHTHALMIC SUSPENSION 10-0.2 %	2	
BLEPHAMIDE S.O.P. OPHTHALMIC OINTMENT 10-0.2 %	2	
neomycin-polymyxin-dexameth ophthalmic ointment 3.5-10000-0.1	1	
neomycin-polymyxin-dexameth ophthalmic suspension 3.5-10000-0.1	1	
neomycin-polymyxin-hc ophthalmic suspension 3.5- 10000-1	3	
sulfacetamide-prednisolone ophthalmic solution 10- 0.23 %	1	
TOBRADEX OPHTHALMIC OINTMENT 0.3-0.1 %	2	
TOBRADEX ST OPHTHALMIC SUSPENSION 0.3-0.05 %	2	
tobramycin-dexamethasone ophthalmic suspension 0.3-0.1 %	1	
*OPHTHALMIC STEROIDS***		
ALREX OPHTHALMIC SUSPENSION 0.2 %	3	ST
dexamethasone sodium phosphate ophthalmic solution 0.1 %	1	
difluprednate ophthalmic emulsion 0.05 %	3	ST; QL (5 ML per 30 days)
DUREZOL OPHTHALMIC EMULSION 0.05 %	3	ST; QL (5 ML per 30 days)
fluorometholone ophthalmic suspension 0.1 %	1	
FML FORTE OPHTHALMIC SUSPENSION 0.25 %	2	
FML OPHTHALMIC OINTMENT 0.1 %	2	
LOTEMAX SM OPHTHALMIC GEL 0.38 %	2	ST
loteprednol etabonate ophthalmic gel 0.5 %	3	ST
loteprednol etabonate ophthalmic suspension 0.5 %	3	ST
MAXIDEX OPHTHALMIC SUSPENSION 0.1 %	3	
PRED MILD OPHTHALMIC SUSPENSION 0.12 %	2	
prednisolone acetate ophthalmic suspension 1 %	1	
prednisolone sodium phosphate ophthalmic solution 1 %	3	
VEXOL OPHTHALMIC SUSPENSION 1 %	3	
*OPHTHALMIC SULFONAMIDES***		

Drug Name	Tier	Notes	
sulfacetamide sodium ophthalmic solution 10 %	1		
*OPHTHALMIC SURGICAL AIDS - COMBINATIONS***			
OMIDRIA INTRAOCULAR SOLUTION 1-0.3 %	MB		
*PROSTAGLANDINS - OPHTHALMIC***			
latanoprost ophthalmic solution 0.005 %	1		
LUMIGAN OPHTHALMIC SOLUTION 0.01 %	2		
travoprost (bak free) ophthalmic solution 0.004 %	3		
*VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ANTAGONISTS***			
EYLEA HD INTRAVITREAL SOLUTION 8 MG/0.07ML	MB		
LUCENTIS INTRAOCULAR SOLUTION 0.3 MG/0.05ML, 0.5 MG/0.05ML	MB		
LUCENTIS INTRAVITREAL SOLUTION 0.3 MG/0.05ML, 0.5 MG/0.05ML	MB		
LUCENTIS INTRAVITREAL SOLUTION PREFILLED SYRINGE 0.3 MG/0.05ML, 0.5 MG/0.05ML	MB		
PAVBLU INTRAVITREAL SOLUTION 2 MG/0.05ML	MB		
PAVBLU INTRAVITREAL SOLUTION PREFILLED SYRINGE 2 MG/0.05ML	МВ		
OTIC AGENTS			
*OTIC AGENTS - MISCELLANEOUS***			
acetic acid otic solution 2 %	1		
acetic acid-aluminum acetate otic solution 2 %	1		
*OTIC ANALGESIC COMBINATIONS***			
antipyrine-benzocaine otic solution 5.4-1.4 %	1		
*OTIC ANTI-INFECTIVES***			
ofloxacin otic solution 0.3 %	1		
*OTIC STEROID-ANTI-INFECTIVE COMBINATIONS***			
CIPRO HC OTIC SUSPENSION 0.2-1 %	3	PA	
ciprofloxacin-dexamethasone otic suspension 0.3-0.1 %	3	ST; QL (7.5 ML per 30 days); AL (Max 12 Years)	
neomycin-polymyxin-hc otic solution 3.5-10000-1	1		
neomycin-polymyxin-hc otic suspension 3.5-10000-1	1		
*OTIC STEROIDS***			
fluocinolone acetonide otic oil 0.01 %	1		
hydrocortisone-acetic acid otic solution 1-2 %	1		

MPC032520 194 Effective: 09/15/2025

Drug Name	Tier	Notes	
OXYTOCICS			
*ABORTIFACIENTS/CERVICAL RIPENING - PROSTAGLANDINS***			
carboprost tromethamine intramuscular solution 250 mcg/ml	MB		
PREPIDIL VAGINAL GEL 0.5 MG/3GM	3		
*OXYTOCICS***			
methylergonovine maleate injection solution 0.2 mg/ml	3		
methylergonovine maleate oral tablet 0.2 mg	3		
oxytocin injection solution 10 unit/ml	MB		
PASSIVE IMMUNIZING AND TREATMENT AGENTS			
*ANTITOXINS-ANTIVENINS***			
ANAVIP INTRAVENOUS SOLUTION RECONSTITUTED	МВ		
CROFAB INTRAVENOUS SOLUTION RECONSTITUTED	МВ		
*ANTIVIRAL MONOCLONAL ANTIBODIES***			
BEYFORTUS INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 100 MG/ML, 50 MG/0.5ML	MB		
SYNAGIS INTRAMUSCULAR SOLUTION 100 MG/ML, 50 MG/0.5ML	МВ	РА	
*IMMUNE SERUMS***			
HYPERRHO S/D INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 1500 UNIT, 250 UNIT	МВ		
HYPERTET S/D INTRAMUSCULAR INJECTABLE 250 UNIT/ML	МВ		
kedrab intramuscular solution 150 unit/ml	MB		
MICRHOGAM ULTRA-FILTERED PLUS INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 250 UNIT	МВ		
RHOGAM ULTRA-FILTERED PLUS INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 1500 UNIT	МВ		
RHOPHYLAC INJECTION SOLUTION PREFILLED SYRINGE 1500 UNIT/2ML	MB		
WINRHO SDF INJECTION SOLUTION 1500 UNIT/1.3ML, 15000 UNIT/13ML, 2500 UNIT/2.2ML, 5000 UNIT/4.4ML	МВ		
PENICILLINS			
*AMINOPENICILLINS***			

MPC032520 195 Effective: 09/15/2025

Drug Name	Tier	Notes
amoxicillin oral capsule 250 mg, 500 mg	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
amoxicillin oral suspension reconstituted 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5ml	1	
amoxicillin oral tablet 500 mg	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
amoxicillin oral tablet 875 mg	1	
amoxicillin oral tablet chewable 125 mg, 250 mg	2	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
ampicillin oral capsule 250 mg	1	
ampicillin oral capsule 500 mg	2	
ampicillin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml	2	
*NATURAL PENICILLINS***		
BICILLIN L-A INTRAMUSCULAR SUSPENSION 600000 UNIT/ML	MB	
BICILLIN L-A INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 600000 UNIT/ML	МВ	
penicillin g procaine intramuscular suspension 600000 unit/ml	МВ	

MPC032520 196 Effective: 09/15/2025

Drug Name	Tier	Notes
penicillin v potassium oral solution reconstituted 125 mg/5ml, 250 mg/5ml	1	
penicillin v potassium oral tablet 250 mg, 500 mg	1	
PFIZERPEN INJECTION SOLUTION RECONSTITUTED 5000000 UNIT	МВ	
*PENICILLIN COMBINATIONS***		·
amoxicillin-pot clavulanate oral suspension reconstituted 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400- 57 mg/5ml, 600-42.9 mg/5ml	1	
amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg	1	
amoxicillin-pot clavulanate oral tablet chewable 200- 28.5 mg, 400-57 mg	2	
ampicillin-sulbactam sodium injection solution reconstituted 1.5 (1-0.5) gm	МВ	
BICILLIN C-R 900/300 INTRAMUSCULAR SUSPENSION 900000-300000 UNIT/2ML	МВ	
BICILLIN C-R INTRAMUSCULAR SUSPENSION 1200000 UNIT/2ML	MB	
ZOSYN INTRAVENOUS SOLUTION RECONSTITUTED 2.25 (2-0.25) GM	MB	
*PENICILLINASE-RESISTANT PENICILLINS***		
BACTOCILL IN DEXTROSE INTRAVENOUS SOLUTION 1 GM/50ML	MB	
dicloxacillin sodium oral capsule 250 mg, 500 mg	1	
PHARMACEUTICAL ADJUVANTS		
*PARENTERAL VEHICLES***		
saline bacteriostatic injection solution 0.9 %	1	
PROGESTINS		
*PROGESTINS***		
GALLIFREY ORAL TABLET 5 MG	1	
medroxyprogesterone acetate oral tablet 10 mg, 2.5 mg, 5 mg	1	
megestrol acetate oral suspension 625 mg/5ml	1	PA
norethindrone acetate oral tablet 5 mg	1	
progesterone intramuscular oil 50 mg/ml	MB	
progesterone micronized oral capsule 100 mg, 200 mg	1	
PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.		
*ALCOHOL DETERRENTS***		

MPC032520 197 Effective: 09/15/2025

Drug Name	Tier	Notes
acamprosate calcium oral tablet delayed release 333 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (180 EA per 30 days)
disulfiram oral tablet 250 mg	1	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*ANTI-CATAPLECTIC AGENTS***		
sodium oxybate oral solution 500 mg/ml	5	PA; LA; QL (540 ML per 30 days); AL (Min 7 Years); NDS
*BENZODIAZEPINES & TRICYCLIC AGENTS***		
chlordiazepoxide-amitriptyline oral tablet 10-25 mg, 5- 12.5 mg	2	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*CHOLINOMIMETICS - ACHE INHIBITORS***		
donepezil hcl oral tablet 10 mg	1	QL (30 EA per 30 days)
donepezil hcl oral tablet 5 mg	1	QL (60 EA per 30 days)
donepezil hcl oral tablet dispersible 10 mg, 5 mg	1	PA; QL (30 EA per 30 days)
EXELON ORAL SOLUTION 2 MG/ML	3	
galantamine hydrobromide er oral capsule extended release 24 hour 16 mg, 24 mg, 8 mg	1	
galantamine hydrobromide oral solution 4 mg/ml	2	
galantamine hydrobromide oral tablet 12 mg, 4 mg, 8 mg	1	
rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg	3	

MPC032520 198 Effective: 09/15/2025

Drug Name	Tier	Notes
*FIBROMYALGIA AGENT - SNRIS***		
SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG	3	PA; QL (60 EA per 30 days)
*MOVEMENT DISORDER DRUG THERAPY***		
AUSTEDO ORAL TABLET 12 MG	5	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost
		share is subject to applicable benefit plans.); QL (120 EA per 30 days); NDS; SP
		PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share.
AUSTEDO ORAL TABLET 6 MG, 9 MG	5	* High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days); NDS; SP
tetrabenazine oral tablet 12.5 mg	4	PA; QL (90 EA per 30 days); NDS; SP
tetrabenazine oral tablet 25 mg	4	PA; QL (120 EA per 30 days); NDS; SP
*MS AGENTS - PYRIMIDINE SYNTHESIS INHIBITORS***		
teriflunomide oral tablet 14 mg, 7 mg	1	QL (30 EA per 30 days); NDS; SP
*MULTIPLE SCLEROSIS AGENTS - ANTIMETABOLITES***		
MAVENCLAD (10 TABS) ORAL TABLET THERAPY PACK 10 MG	5	PA; DX (Diagnosis Validation Required); QL (20 EA per 326 days); NDS; SP
MAVENCLAD (4 TABS) ORAL TABLET THERAPY PACK 10 MG	5	PA; DX (Diagnosis Validation Required); QL (8 EA per 326 days); NDS; SP
MAVENCLAD (5 TABS) ORAL TABLET THERAPY PACK 10 MG	5	PA; DX (Diagnosis Validation Required); QL (10 EA per 326 days); NDS; SP
MAVENCLAD (6 TABS) ORAL TABLET THERAPY PACK 10 MG	5	PA; DX (Diagnosis Validation Required); QL (12 EA per 326 days); NDS; SP

MPC032520 199 Effective: 09/15/2025

Drug Name	Tier	Notes
MAVENCLAD (7 TABS) ORAL TABLET THERAPY PACK 10 MG	5	PA; DX (Diagnosis Validation Required); QL (14 EA per 326 days); NDS; SP
MAVENCLAD (8 TABS) ORAL TABLET THERAPY PACK 10 MG	5	PA; DX (Diagnosis Validation Required); QL (16 EA per 326 days); NDS; SP
MAVENCLAD (9 TABS) ORAL TABLET THERAPY PACK 10 MG	5	PA; DX (Diagnosis Validation Required); QL (18 EA per 326 days); NDS; SP
*MULTIPLE SCLEROSIS AGENTS - INTERFERONS***		
AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT 30 MCG/0.5ML	4	DX (Diagnosis Validation Required); QL (1 EA per 28 days); NDS; SP
AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT 30 MCG/0.5ML	4	DX (Diagnosis Validation Required); QL (1 EA per 28 days); NDS; SP
BETASERON SUBCUTANEOUS KIT 0.3 MG	5	
*MULTIPLE SCLEROSIS AGENTS - MONOCLONAL ANTIBODIES***		
BRIUMVI INTRAVENOUS SOLUTION 150 MG/6ML	4	PA; DX (Diagnosis Validation Required)
*MULTIPLE SCLEROSIS AGENTS - NRF2 PATHWAY ACTIVATORS***		
dimethyl fumarate oral capsule delayed release 120 mg, 240 mg	1	DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP
dimethyl fumarate starter pack oral 120 & 240 mg	1	QL (60 EA per 30 days); NDS; SP
dimethyl fumarate starter pack oral capsule delayed release therapy pack 120 & 240 mg	4	DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS; SP
*MULTIPLE SCLEROSIS AGENTS - POTASSIUM CHANNEL BLOCKERS***		
dalfampridine er oral tablet extended release 12 hour 10 mg	3	DX (Diagnosis Validation Required); QL (60 EA per 30 days); NDS
*MULTIPLE SCLEROSIS AGENTS***		
GLATOPA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML	4	DX (Diagnosis Validation Required); QL (30 ML per 30 days); NDS; SP
GLATOPA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 40 MG/ML	5	DX (Diagnosis Validation Required); QL (12 ML per 28 days); NDS; SP
*N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONISTS***		
memantine hcl er oral capsule extended release 24 hour 14 mg, 21 mg, 28 mg, 7 mg	3	ST; QL (30 EA per 30 days)
memantine hcl oral solution 2 mg/ml	1	
memantine hcl oral tablet 10 mg, 5 mg	1	QL (60 EA per 30 days)
*PHENOTHIAZINES & TRICYCLIC AGENTS***		

MPC032520 200 Effective: 09/15/2025

Drug Name	Tier	Notes
perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg	2	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*PSEUDOBULBAR AFFECT AGENT COMBINATIONS***		
NUEDEXTA ORAL CAPSULE 20-10 MG	5	PA; QL (60 EA per 30 days)
*PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.***		
ergoloid mesylates oral tablet 1 mg	2	
pimozide oral tablet 1 mg, 2 mg	3	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
*SMOKING DETERRENTS***		
bupropion hcl er (smoking det) oral tablet extended release 12 hour 150 mg	\$0	\$0 (\$0 dollar copayment per ACA guidelines. Limited to two 90 day courses per 365 days.); QL (360 EA per 365 days)
goodsense nicotine mouth/throat gum 2 mg	\$0	\$0 (\$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.); QL (4300 EA per 365 days)
nicotine polacrilex mouth/throat gum 2 mg, 4 mg	\$0	\$0 (\$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.); QL (4300 EA per 365 days)
nicotine polacrilex mouth/throat lozenge 2 mg, 4 mg	\$0	\$0 (\$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.); QL (3600 EA per 365 days)
nicotine transdermal kit 21-14-7 mg/24hr	\$0	\$0 (\$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.)

MPC032520 201 Effective: 09/15/2025

Drug Name	Tier	Notes
nicotine transdermal patch 24 hour 14 mg/24hr, 21 mg/24hr, 7 mg/24hr	\$0	\$0 (\$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.); QL (182 EA per 365 days)
NICOTROL INHALATION INHALER 10 MG	\$0	ST; \$0 (\$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.); QL (3024 EA per 365 days)
NICOTROL NS NASAL SOLUTION 10 MG/ML	\$0	ST; \$0 (\$0 dollar copayment per ACA guidelines. Limited to two 90 courses per 365 days.); QL (1440 ML per 365 days)
varenicline tartrate (starter) oral tablet therapy pack 0.5 mg x 11 & 1 mg x 42	\$0	QL (106 EA per 365 days)
varenicline tartrate oral tablet 0.5 mg, 1 mg	\$0	QL (360 EA per 365 days)
varenicline tartrate(continue) oral tablet 1 mg	\$0	QL (360 EA per 365 days)
*SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS***		
fingolimod hcl oral capsule 0.5 mg	3	
MAYZENT ORAL TABLET 0.25 MG	5	PA; DX (Diagnosis Validation Required); QL (120 EA per 30 days); NDS; SP
MAYZENT ORAL TABLET 1 MG, 2 MG	5	PA; DX (Diagnosis Validation Required); QL (30 EA per 30 days); NDS; SP
MAYZENT STARTER PACK ORAL TABLET THERAPY PACK 12 X 0.25 MG, 7 X 0.25 MG	5	PA; DX (Diagnosis Validation Required); QL (1 pack per 365 days); NDS; SP
TASCENSO ODT ORAL TABLET DISPERSIBLE 0.25 MG	3	
*THIENBENZODIAZEPINES & OPIOID ANTAGONISTS***	•	•
LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20- 10 MG, 5-10 MG	4	PA; BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (30 EA per 30 days)
RESPIRATORY AGENTS - MISC.		
*CFTR POTENTIATORS***		-
KALYDECO ORAL PACKET 13.4 MG	5	PA; QL (2 packets per 1 day); AL (Max 6 Years); NDS; SP

MPC032520 202 Effective: 09/15/2025

Drug Name	Tier	Notes
KALYDECO ORAL PACKET 25 MG, 50 MG, 75 MG	5	PA; QL (60 EA per 30 days); AL (Max 6 Years); NDS; SP
KALYDECO ORAL TABLET 150 MG	5	PA; QL (60 EA per 30 days); AL (Min 6 Years); NDS; SP
*CYSTIC FIBROSIS AGENT - COMBINATIONS***		
ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG	5	PA; QL (120 EA per 30 days); NDS; SP
SYMDEKO ORAL TABLET THERAPY PACK 100- 150 & 150 MG, 50-75 & 75 MG	5	PA; QL (60 EA per 30 days); AL (Min 6 Years and Max 12 Years); NDS; SP
TRIKAFTA ORAL TABLET THERAPY PACK 100- 50-75 & 150 MG, 50-25-37.5 & 75 MG	5	PA; QL (90 EA per 30 days); NDS; SP
TRIKAFTA ORAL THERAPY PACK 100-50-75 & 75 MG, 80-40-60 & 59.5 MG	5	PA; QL (2 packets per 1 day); NDS; SP
*HYDROLYTIC ENZYMES***		
PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML	5	LA; NDS
*PULMONARY FIBROSIS AGENTS - KINASE INHIBITORS***		
OFEV ORAL CAPSULE 100 MG, 150 MG	4	PA; QL (60 EA per 30 days); NDS; SP
SULFONAMIDES	-	
*SULFONAMIDES***		
sulfadiazine oral tablet 500 mg	1	
TETRACYCLINES		•
*GLYCYLCYCLINES***		
tigecycline intravenous solution reconstituted 50 mg	MB	
TYGACIL INTRAVENOUS SOLUTION RECONSTITUTED 50 MG	MB	
*TETRACYCLINES***		
demeclocycline hcl oral tablet 150 mg, 300 mg	3	
doxycycline hyclate oral capsule 100 mg, 50 mg	3	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)

MPC032520 203 Effective: 09/15/2025

Drug Name	Tier	Notes
doxycycline hyclate oral tablet 100 mg	3	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
doxycycline hyclate oral tablet 20 mg	1	
doxycycline monohydrate oral capsule 100 mg, 50 mg	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
doxycycline monohydrate oral suspension reconstituted 25 mg/5ml	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
MINOCIN INTRAVENOUS SOLUTION RECONSTITUTED 100 MG	MB	
minocycline hcl oral capsule 100 mg, 50 mg, 75 mg	1	
SEYSARA ORAL TABLET 100 MG	3	ST; NDS

Drug Name	Tier	Notes
tetracycline hcl oral capsule 250 mg, 500 mg	2	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
THYROID AGENTS		
*ANTITHYROID AGENTS***		
methimazole oral tablet 10 mg, 5 mg	1	
propylthiouracil oral tablet 50 mg	1	
*THYROID HORMONES***		
ARMOUR THYROID ORAL TABLET 120 MG, 15 MG, 180 MG, 240 MG, 30 MG, 300 MG, 60 MG, 90 MG	2	
EUTHYROX ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG	1	
LEVO-T ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG	1	
levothyroxine sodium oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg	1	
LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG	1	
liothyronine sodium oral tablet 25 mcg, 5 mcg, 50 mcg	1	
NATURE-THROID ORAL TABLET 113.75 MG, 130 MG, 146.25 MG, 16.25 MG, 162.5 MG, 195 MG, 260 MG, 32.5 MG, 325 MG, 48.75 MG, 65 MG, 81.25 MG, 97.5 MG	2	
NP THYROID ORAL TABLET 120 MG, 15 MG, 30 MG, 60 MG, 90 MG	1	
UNITHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG	1	
WESTHROID ORAL TABLET 130 MG, 16.25 MG, 195 MG, 260 MG, 32.5 MG, 325 MG, 65 MG, 97.5 MG	2	
TOXOIDS		
*TOXOID COMBINATIONS***		

MPC032520 205 Effective: 09/15/2025

Drug Name	Tier	Notes
ADACEL INTRAMUSCULAR SUSPENSION 5-2-15.5 LF-MCG/0.5	\$0	\$0 (\$0 Copay per PPACA guidelines.)
BOOSTRIX INTRAMUSCULAR SUSPENSION 5-2.5-18.5 , 5-2.5-18.5 LF-MCG/0.5	\$0	\$0 (\$0 Copay per PPACA guidelines.)
BOOSTRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 5-2.5-18.5 LF-MCG/0.5	\$0	\$0 (\$0 Copay per PPACA guidelines.)
tetanus-diphtheria toxoids td intramuscular suspension 2-2 lf/0.5ml	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ULCER DRUGS/ANTISPASMODICS/ANTICHOLINE RGICS		
*ANTICHOLINERGIC COMBINATIONS***		
chlordiazepoxide-clidinium oral capsule 5-2.5 mg	1	
*ANTISPASMODICS***		
BENTYL INTRAMUSCULAR SOLUTION 10 MG/ML	MB	
dicyclomine hcl oral capsule 10 mg	1	
dicyclomine hcl oral solution 10 mg/5ml	1	
dicyclomine hcl oral tablet 20 mg	1	
*BELLADONNA ALKALOIDS***		
hyoscyamine sulfate er oral tablet extended release 12 hour 0.375 mg	1	
hyoscyamine sulfate oral elixir 0.125 mg/5ml	1	
hyoscyamine sulfate oral solution 0.125 mg/ml	1	
hyoscyamine sulfate oral tablet 0.125 mg	1	
hyoscyamine sulfate oral tablet dispersible 0.125 mg	1	
hyoscyamine sulfate sublingual tablet sublingual 0.125 mg	1	
LEVSIN INJECTION SOLUTION 0.5 MG/ML	MB	
NULEV ORAL TABLET DISPERSIBLE 0.125 MG	1	
*H-2 ANTAGONISTS***		
cimetidine hcl oral solution 300 mg/5ml	1	
cimetidine oral tablet 300 mg, 400 mg, 800 mg	1	
famotidine oral suspension reconstituted 40 mg/5ml	1	
famotidine oral tablet 20 mg, 40 mg	1	
nizatidine oral capsule 150 mg, 300 mg	2	
ranitidine hcl injection solution 1000 mg/40ml, 150 mg/6ml, 50 mg/2ml	MB	
ranitidine hcl oral syrup 15 mg/ml, 150 mg/10ml, 75 mg/5ml	1	
ranitidine hcl oral tablet 150 mg, 300 mg	1	

Drug Name	Tier	Notes
*MISC. ANTI-ULCER***		
sucralfate oral suspension 1 gm/10ml	3	QL (1200 ML per 30 days); AL (Max 12 Years)
sucralfate oral tablet 1 gm	1	
*PROTON PUMP INHIBITORS***		
dexlansoprazole oral capsule delayed release 30 mg, 60 mg	3	PA; QL (30 EA per 30 days)
esomeprazole magnesium oral capsule delayed release 20 mg, 40 mg	1	QL (30 EA per 30 days)
lansoprazole oral capsule delayed release 15 mg, 30 mg	3	QL (60 EA per 30 days)
lansoprazole oral tablet dispersible 15 mg, 30 mg	3	PA
omeprazole magnesium oral capsule delayed release 20.6 (20 base) mg	1	QL (60 EA per 30 days)
omeprazole oral capsule delayed release 10 mg, 20 mg, 40 mg	1	QL (60 EA per 30 days)
pantoprazole sodium oral tablet delayed release 20 mg, 40 mg	1	QL (60 EA per 30 days)
PROTONIX INTRAVENOUS SOLUTION RECONSTITUTED 40 MG	МВ	
rabeprazole sodium oral tablet delayed release 20 mg	1	QL (60 EA per 30 days)
*QUATERNARY ANTICHOLINERGICS***		
glycopyrrolate injection solution 0.2 mg/ml, 0.4 mg/2ml, 1 mg/5ml, 4 mg/20ml	1	
glycopyrrolate oral tablet 1 mg, 2 mg	1	
propantheline bromide oral tablet 15 mg	2	
*ULCER DRUGS - PROSTAGLANDINS***		
misoprostol oral tablet 100 mcg, 200 mcg	1	
URINARY ANTISPASMODICS		
*URINARY ANTISPASMODIC - ANTIMUSCARINIC (ANTICHOLINERGIC)***		
fesoterodine fumarate er oral tablet extended release 24 hour 4 mg, 8 mg	3	ST; QL (30 EA per 30 days)
oxybutynin chloride er oral tablet extended release 24 hour 10 mg, 15 mg, 5 mg	1	
oxybutynin chloride oral solution 5 mg/5ml	1	
oxybutynin chloride oral syrup 5 mg/5ml	1	
oxybutynin chloride oral tablet 5 mg	1	
OXYTROL FOR WOMEN TRANSDERMAL PATCH TWICE WEEKLY 3.9 MG/24HR	3	PA; QL (8 EA per 28 days)
solifenacin succinate oral tablet 10 mg, 5 mg	1	QL (30 EA per 30 days)

MPC032520 207 Effective: 09/15/2025

Drug Name	Tier	Notes
tolterodine tartrate er oral capsule extended release 24 hour 2 mg, 4 mg	3	QL (30 EA per 30 days)
tolterodine tartrate oral tablet 1 mg, 2 mg	1	
trospium chloride er oral capsule extended release 24 hour 60 mg	3	ST
trospium chloride oral tablet 20 mg	3	
*URINARY ANTISPASMODICS - CHOLINERGIC AGONISTS***		
bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg	1	
*URINARY ANTISPASMODICS - DIRECT MUSCLE RELAXANTS***		
flavoxate hcl oral tablet 100 mg	1	
VACCINES		
*BACTERIAL VACCINES***		
CAPVAXIVE INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 0.5 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 1 Lifetime)
MENACTRA INTRAMUSCULAR INJECTABLE	1	\$0 (\$0 Copay per PPACA guidelines.)
MENACTRA INTRAMUSCULAR SOLUTION	\$0	\$0 (\$0 Copay per PPACA guidelines.)
MENOMUNE SUBCUTANEOUS INJECTABLE	1	\$0 (\$0 Copay per PPACA guidelines.)
MENQUADFI INTRAMUSCULAR SOLUTION 0.5 ML	\$0	\$0 (\$0 Copay for Preventative Services.)
MENVEO INTRAMUSCULAR SOLUTION	\$0	\$0 (\$0 Copay for Preventative Services.)
MENVEO INTRAMUSCULAR SOLUTION RECONSTITUTED	\$0	\$0 (\$0 Copay per PPACA guidelines.)
PENBRAYA INTRAMUSCULAR SUSPENSION RECONSTITUTED	\$0	\$0 (Zero Dollar Copay; PPACA Preventative Services)
PNEUMOVAX 23 INJECTION INJECTABLE 25 MCG/0.5ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
PNEUMOVAX 23 INJECTION SOLUTION 25 MCG/0.5ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
PNEUMOVAX 23 INJECTION SOLUTION PREFILLED SYRINGE 25 MCG/0.5ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
PREVNAR 13 INTRAMUSCULAR SUSPENSION	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
PREVNAR 20 INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 1 Lifetime)

MPC032520 208 Effective: 09/15/2025

Drug Name	Tier	Notes
TRUMENBA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML	\$0	\$0 (\$0 Copay for Preventative Services.)
VAXNEUVANCE INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.)
*MIXED VACCINE COMBINATIONS***		
COMVAX INTRAMUSCULAR SUSPENSION 7.5-5 MCG/0.5ML	1	\$0 (\$0 Copay per PPACA guidelines.)
*VIRAL VACCINE COMBINATIONS***	•	·
M-M-R II INJECTION SOLUTION RECONSTITUTED	\$0	\$0 (\$0 Copay per PPACA guidelines.)
M-M-R II SUBCUTANEOUS INJECTABLE	1	\$0 (\$0 Copay per PPACA guidelines.)
PROQUAD SUBCUTANEOUS INJECTABLE	1	\$0 (\$0 Copay per PPACA guidelines.)
TWINRIX INTRAMUSCULAR SUSPENSION 720-20	1	\$0 (\$0 Copay per PPACA guidelines.)
TWINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 720-20 ELU-MCG/ML	\$0	\$0 (\$0 Copay per PPACA guidelines.)
*VIRAL VACCINES***		
ABRYSVO INTRAMUSCULAR SOLUTION RECONSTITUTED 120 MCG/0.5ML	\$0	\$0 (\$0 Copay for Preventative Services.); AL (Min 60 Years)
AFLURIA INTRAMUSCULAR SUSPENSION	1	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
AFLURIA PRESERVATIVE FREE INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML	1	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
AFLURIA QUADRIVALENT INTRAMUSCULAR SUSPENSION	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
AFLURIA QUADRIVALENT INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
AREXVY INTRAMUSCULAR SUSPENSION RECONSTITUTED 120 MCG/0.5ML	\$0	\$0 (\$0 Copay for Preventative Services.); AL (Min 60 Years)
astrazeneca covid-19 vaccine intramuscular suspension 0.5 ml	1	\$0 (\$0 Copay per PPACA guidelines.)
COMIRNATY INTRAMUSCULAR SUSPENSION 30 MCG/0.3ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.3 ML per 21 days); AL (Min 12 Years)
ENGERIX-B INJECTION SUSPENSION 10 MCG/0.5ML, 20 MCG/ML	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ENGERIX-B INTRAMUSCULAR INJECTABLE 10 MCG/0.5ML, 20 MCG/ML	1	\$0 (\$0 Copay per PPACA guidelines.)
FLUAD QUADRIVALENT INTRAMUSCULAR PREFILLED SYRINGE 0.5 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.)
FLUARIX QUADRIVALENT INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)

MPC032520 209 Effective: 09/15/2025

Drug Name	Tier	Notes
FLUCELVAX INTRAMUSCULAR SUSPENSION	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days); NDS
FLUCELVAX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days); NDS
FLULAVAL INTRAMUSCULAR SUSPENSION	1	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
FLULAVAL QUADRIVALENT INTRAMUSCULAR SUSPENSION	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
FLULAVAL QUADRIVALENT INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
FLUMIST NASAL LIQUID	\$0	QL (0.5 mL per 180 days); AL (Min 2 Years and Max 49 Years)
FLUMIST QUADRIVALENT NASAL SUSPENSION	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (1 EA per 180 days); AL (Min 2 Years and Max 49 Years)
FLUZONE HIGH-DOSE QUADRIVALENT INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.7 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.7 ML per 180 days); AL (Min 65 Years)
FLUZONE INTRAMUSCULAR SUSPENSION	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
FLUZONE QUADRIVALENT INTRAMUSCULAR SUSPENSION, 0.5 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
FLUZONE QUADRIVALENT INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.25 ML, 0.5 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 180 days)
HAVRIX INTRAMUSCULAR SUSPENSION 1440 EL U/ML, 720 EL U/0.5ML	\$0	\$0 (\$0 Copay per PPACA guidelines.)
HAVRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 720 EL U/0.5ML	\$0	\$0 (\$0 Copay per PPACA guidelines.)
HEPLISAV-B INTRAMUSCULAR SOLUTION 20 MCG/0.5ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (1 ML per 1 day)
HEPLISAV-B INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 20 MCG/0.5ML	\$0	\$0 (\$0 Copay per PPACA guidelines.)
IPOL INJECTION INJECTABLE	\$0	\$0 (\$0 Copay per PPACA guidelines.)
janssen covid-19 vaccine intramuscular suspension 0.5 ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 56 days); AL (Min 18 Years)
MNEXSPIKE INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 10 MCG/0.2ML	\$0	AL (Min 12 Years)

MPC032520 210 Effective: 09/15/2025

Drug Name	Tier	Notes
moderna covid-19 bival booster intramuscular suspension 50 mcg/0.5ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 365 days); AL (Min 18 Years)
moderna covid-19 bivalent intramuscular suspension 50 mcg/0.5ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 365 days); AL (Min 18 Years)
moderna covid-19 vac (booster) intramuscular suspension 50 mcg/0.5ml, 50 mg/0.5ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 28 days); AL (Min 6 Years)
MODERNA COVID-19 VAC 6M-11Y INTRAMUSCULAR SUSPENSION 25 MCG/0.25ML	\$0	
moderna covid-19 vacc 6-11y intramuscular suspension 50 mcg/0.5ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 28 days); AL (Min 6 Years)
moderna covid-19 vacc 6m-5y intramuscular suspension 25 mcg/0.25ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.25 ML per 28 days); AL (Min 6 Years)
moderna covid-19 vaccine intramuscular suspension 100 mcg/0.5ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.5 ML per 28 days); AL (Min 12 Years)
novavax covid-19 vaccine intramuscular suspension prefilled syringe 5 mcg/0.5ml	\$0	QL (0.5 ML per 28 days); AL (Min 12 Years)
pfizer covid-19 vac bivalent intramuscular suspension 30 mcg/0.3ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.3 ML per 365 days); AL (Min 12 Years)
pfizer covid-19 vac-tris 5-11y intramuscular suspension 10 mcg/0.2ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.2 ML per 21 days); AL (Min 5 Years)
PFIZER COVID-19 VAC-TRIS 5-11Y INTRAMUSCULAR SUSPENSION 10 MCG/0.3ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 3 Years and Max 11 Years)
pfizer covid-19 vac-tris 6m-4y intramuscular suspension 3 mcg/0.2ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.2 ML per 21 days); AL (Min 6 Years)
pfizer covid-19 vac-tris 6m-4y intramuscular suspension 3 mcg/0.3ml	\$0	\$0 (\$0 Copay per PPACA guidelines.)
pfizer-biont covid-19 vac-tris intramuscular suspension 30 mcg/0.3ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.3 ML per 21 days); AL (Min 12 Years)
pfizer-biontech covid-19 vacc intramuscular suspension 30 mcg/0.3ml	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (0.3 ML per 21 days); AL (Min 12 Years)
RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5ML	\$0	\$0 (\$0 Copay per PPACA guidelines.)
SHINGRIX INTRAMUSCULAR SUSPENSION RECONSTITUTED 50 MCG/0.5ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); QL (2 vial per 1 Lifetime); AL (Min 50 Years)
SPIKEVAX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 50 MCG/0.5ML	\$0	QL (0.5 ML per 28 days)

MPC032520 211 Effective: 09/15/2025

Drug Name	Tier	Notes
VAQTA INTRAMUSCULAR SUSPENSION 25 UNIT/0.5ML, 50 UNIT/ML	\$0	\$0 (\$0 Copay per PPACA guidelines.)
VARIVAX INJECTION SUSPENSION RECONSTITUTED 1350 PFU/0.5ML	\$0	\$0 (\$0 Copay per PPACA guidelines.)
VARIVAX SUBCUTANEOUS INJECTABLE 1350 PFU/0.5ML	\$0	\$0 (\$0 Copay per PPACA guidelines.)
ZOSTAVAX SUBCUTANEOUS SUSPENSION RECONSTITUTED 19400 UNT/0.65ML	1	PA; \$0 (\$0 Copay per PPACA guidelines.); QL (1 EA per 1 Lifetime); AL (Min 60 Years)
VAGINAL AND RELATED PRODUCTS		
*IMIDAZOLE-RELATED ANTIFUNGALS***		
GYNAZOLE-1 VAGINAL CREAM 2 %	3	
terconazole vaginal cream 0.4 %, 0.8 %	1	
terconazole vaginal suppository 80 mg	1	
*SPERMICIDES***		
ENCARE VAGINAL SUPPOSITORY 100 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
OPTIONS CONCEPTROL VAGINAL GEL 4 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
OPTIONS GYNOL II CONTRACEPTIVE VAGINAL GEL 3 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
SHUR-SEAL CONTRACEPTIVE VAGINAL GEL 2 %	\$0	\$0 (\$0 Copay per PPACA guidelines.)
TODAY SPONGE VAGINAL 1000 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
VCF VAGINAL CONTRACEPTIVE VAGINAL FILM 28 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
VCF VAGINAL CONTRACEPTIVE VAGINAL FOAM 12.5 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
VCF VAGINAL CONTRACEPTIVE VAGINAL GEL 4 %	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Max 55 Years)
*VAGINAL ANTI-INFECTIVES***		
clindamycin phosphate vaginal cream 2 %	1	
metronidazole vaginal gel 0.75 %	1	STI (Formulary prescription drugs used for the prevention or treatment of sexually transmitted infections will be covered at zero cost share. Cost sharing applies for non-sexually transmitted infections. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost
		share is subject to applicable benefit plans.)
*VAGINAL ESTROGENS***		
estradiol vaginal cream 0.1 mg/gm	1	

MPC032520 212 Effective: 09/15/2025

Drug Name	Tier	Notes	
estradiol vaginal tablet 10 mcg	1		
ESTRING VAGINAL RING 7.5 MCG/24HR	3	QL (1 EA per 90 days)	
FEMRING VAGINAL RING 0.05 MG/24HR, 0.1 MG/24HR	3	QL (1 EA per 90 days)	
PREMARIN VAGINAL CREAM 0.625 MG/GM	2		
YUVAFEM VAGINAL TABLET 10 MCG	1		
*VAGINAL PROGESTINS***			
CRINONE VAGINAL GEL 8 %	3	PA	
VASOPRESSORS			
*ANAPHYLAXIS THERAPY AGENTS***			
epinephrine injection solution auto-injector 0.15 mg/0.3ml, 0.3 mg/0.3ml	1		
SYMJEPI INJECTION SOLUTION PREFILLED SYRINGE 0.15 MG/0.3ML, 0.3 MG/0.3ML	1		
*NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH) - AGENTS***			
droxidopa oral capsule 100 mg, 200 mg, 300 mg	5	PA	
*VASOPRESSORS***			
midodrine hcl oral tablet 10 mg, 2.5 mg, 5 mg	1		
phenylephrine hcl injection solution 10 mg/ml	MB		
VITAMINS			
*VITAMIN B-1***			
thiamine hcl injection solution 100 mg/ml	MB		
*VITAMIN B-6***			
pyridoxine hcl injection solution 100 mg/ml	MB		
*VITAMIN D***			
ergocalciferol oral capsule 1.25 mg (50000 ut)	1		
ergocalciferol oral solution 8000 unit/ml	1		
vitamin d (ergocalciferol) oral capsule 1.25 mg (50000 ut)	1		
*VITAMIN K***			
phytonadione oral tablet 5 mg	5		

MPC032520 213 Effective: 09/15/2025

Medical Benefit

Medical Benefit		1
Drug Name	Tier	Notes
ABRAXANE INTRAVENOUS SUSPENSION RECONSTITUTED 100 MG	МВ	PA; DX (Diagnosis Validation Required)
ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5ML	МВ	DX (Diagnosis Validation Required); NDS; SP
ALIMTA INTRAVENOUS SOLUTION RECONSTITUTED 100 MG, 500 MG	МВ	PA; DX (Diagnosis Validation Required)
ALIQOPA INTRAVENOUS SOLUTION RECONSTITUTED 60 MG	МВ	PA; DX (Diagnosis Validation Required)
amifostine intravenous solution reconstituted 500 mg	MB	PA
ANZEMET INTRAVENOUS SOLUTION 20 MG/ML	MB	PA
ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 300 MCG/ML	МВ	PA; NDS
azacitidine injection suspension reconstituted 100 mg	MB	DX (Diagnosis Validation Required)
AZEDRA DOSIMETRIC INTRAVENOUS SOLUTION 15 MCI/ML	МВ	PA; QL (1 EA per 30 days)
AZEDRA THERAPEUTIC INTRAVENOUS SOLUTION 15 MCI/ML	МВ	PA; QL (2 EA per 30 days)
BAVENCIO INTRAVENOUS SOLUTION 200 MG/10ML	МВ	PA; DX (Diagnosis Validation Required)
BD POSIFLUSH INTRAVENOUS SOLUTION 0.9 %	MB	
BELEODAQ INTRAVENOUS SOLUTION RECONSTITUTED 500 MG	MB	PA; DX (Diagnosis Validation Required)
BENLYSTA INTRAVENOUS SOLUTION RECONSTITUTED 120 MG, 400 MG	MB	PA; DX (Diagnosis Validation Required)
benztropine mesylate injection solution 1 mg/ml	МВ	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
BERINERT INTRAVENOUS KIT 500 UNIT	5	PA; QL (2 EA per 28 days); NDS; SP
BEXSERO INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML	MB	
BICNU INTRAVENOUS SOLUTION RECONSTITUTED 100 MG	MB	
BLINCYTO INTRAVENOUS SOLUTION RECONSTITUTED 35 MCG	MB	PA; DX (Diagnosis Validation Required)
BOTOX INJECTION SOLUTION RECONSTITUTED 100 UNIT	MB	PA
CEREBYX INJECTION SOLUTION 100 MG PE/2ML	MB	
,		

Drug Name	Tier	Notes
CERVARIX INTRAMUSCULAR SUSPENSION	МВ	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 19 Years and Max 26 Years)
CINRYZE INTRAVENOUS SOLUTION RECONSTITUTED 500 UNIT	5	PA; NDS; SP
CUBICIN INTRAVENOUS SOLUTION RECONSTITUTED 500 MG	МВ	
CUBICIN RF INTRAVENOUS SOLUTION RECONSTITUTED 500 MG	МВ	
CYRAMZA INTRAVENOUS SOLUTION 100 MG/10ML, 500 MG/50ML	МВ	PA; DX (Diagnosis Validation Required)
daptomycin intravenous solution reconstituted 500 mg	MB	
DEXFERRUM INJECTION SOLUTION 50 MG/ML	MB	
doripenem intravenous solution reconstituted 250 mg, 500 mg	МВ	
DYSPORT INTRAMUSCULAR SOLUTION RECONSTITUTED 300 UNIT, 500 UNIT	МВ	PA
ELIGARD SUBCUTANEOUS KIT 22.5 MG, 30 MG, 45 MG, 7.5 MG	МВ	DX (Diagnosis Validation Required)
ENTYVIO INTRAVENOUS SOLUTION RECONSTITUTED 300 MG	МВ	PA; NDS; SP
ertapenem sodium injection solution reconstituted 1 gm	МВ	
ERWINAZE INJECTION SOLUTION RECONSTITUTED 10000 UNIT	МВ	PA; DX (Diagnosis Validation Required)
ETHYOL INTRAVENOUS SOLUTION RECONSTITUTED 500 MG	MB	PA
EUFLEXXA INTRA-ARTICULAR SOLUTION PREFILLED SYRINGE 20 MG/2ML	МВ	PA; QL (6 ML per 180 days)
FLEBOGAMMA DIF INTRAVENOUS SOLUTION 0.5 GM/10ML, 10 GM/100ML, 10 GM/200ML, 2.5 GM/50ML, 20 GM/200ML, 20 GM/400ML, 5 GM/100ML, 5 GM/50ML	МВ	PA
fluphenazine hcl injection solution 2.5 mg/ml	МВ	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.)
FOSCAVIR INTRAVENOUS SOLUTION 24 MG/ML	MB	
GAMUNEX-C INJECTION SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 40 GM/400ML, 5 GM/50ML	MB	PA

MPC032520 215 Effective: 09/15/2025

Drug Name	Tier	Notes
GARDASIL 9 INTRAMUSCULAR SUSPENSION 0.5 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 9 Years and Max 45 Years)
GARDASIL 9 INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML	\$0	\$0 (\$0 Copay per PPACA guidelines.); AL (Min 9 Years and Max 45 Years)
GAZYVA INTRAVENOUS SOLUTION 1000 MG/40ML	MB	PA; DX (Diagnosis Validation Required)
heparin lock flush intravenous solution 2 unit/ml	MB	
heparin sod (porcine) in d5w intravenous solution 100 unit/ml	МВ	
heparin sodium flush intravenous kit 10-0.9 unit/ml-%, 100-0.9 unit/ml-%	МВ	
IMFINZI INTRAVENOUS SOLUTION 120 MG/2.4ML, 500 MG/10ML	МВ	PA; DX (Diagnosis Validation Required)
imipenem-cilastatin intravenous solution reconstituted 250 mg, 500 mg	МВ	
INFED INJECTION SOLUTION 50 MG/ML	MB	
INJECTAFER INTRAVENOUS SOLUTION 750 MG/15ML	МВ	
JELMYTO SOLUTION RECONSTITUTED 80 (2 X 40) MG	МВ	PA; DX (Diagnosis Validation Required); QL (17 EA per 1 day)
KALBITOR SUBCUTANEOUS SOLUTION 10 MG/ML	MB	PA
kcl (0.149%) in nacl intravenous solution 20-0.9 meq/l-%	4	
KENDALL SODIUM CHLORIDE FLUSH INTRAVENOUS SOLUTION 0.9 %	MB	
KEYTRUDA INTRAVENOUS SOLUTION 100 MG/4ML	MB	PA; DX (Diagnosis Validation Required)
KYPROLIS INTRAVENOUS SOLUTION RECONSTITUTED 10 MG, 30 MG, 60 MG	MB	PA; DX (Diagnosis Validation Required)
LARTRUVO INTRAVENOUS SOLUTION 500 MG/50ML	MB	PA; DX (Diagnosis Validation Required)
LUMOXITI INTRAVENOUS SOLUTION RECONSTITUTED 1 MG	МВ	PA; DX (Diagnosis Validation Required)
LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 3.75 MG	MB	DX (Diagnosis Validation Required)
LUPRON DEPOT (6-MONTH) INTRAMUSCULAR KIT 45 MG	MB	DX (Diagnosis Validation Required)
LUPRON DEPOT-PED (1-MONTH) INTRAMUSCULAR KIT 11.25 MG, 15 MG, 7.5 MG	MB	
LUPRON DEPOT-PED (3-MONTH) INTRAMUSCULAR KIT 11.25 MG	MB	
MARQIBO INTRAVENOUS SUSPENSION 5 MG/31ML	MB	PA; DX (Diagnosis Validation Required)

MPC032520 216 Effective: 09/15/2025

Drug Name	Tier	Notes
methyldopate hcl intravenous solution 250 mg/5ml	MB	
micafungin sodium intravenous solution reconstituted 100 mg	MB	
MONOJECT FLUSH SYRINGE INTRAVENOUS SOLUTION 0.9 %	МВ	
MONOJECT SODIUM CHLORIDE FLUSH INTRAVENOUS SOLUTION 0.9 %	МВ	
na ferric gluc cplx in sucrose intravenous solution 12.5 mg/ml	МВ	
normal saline flush intravenous solution 0.9 %	МВ	
OCREVUS INTRAVENOUS SOLUTION 300 MG/10ML	МВ	PA; DX (Diagnosis Validation Required); SP
ONPATTRO INTRAVENOUS SOLUTION 10 MG/5ML	MB	PA
OPDIVO INTRAVENOUS SOLUTION 100 MG/10ML, 240 MG/24ML, 40 MG/4ML	МВ	PA; DX (Diagnosis Validation Required)
ORENCIA INTRAVENOUS SOLUTION RECONSTITUTED 250 MG	МВ	PA; DX (Diagnosis Validation Required)
PERJETA INTRAVENOUS SOLUTION 420 MG/14ML	МВ	PA; DX (Diagnosis Validation Required)
potassium chloride in nacl intravenous solution 20-0.9 meq/l-%	МВ	
POTELIGEO INTRAVENOUS SOLUTION 20 MG/5ML	МВ	PA; DX (Diagnosis Validation Required)
procainamide hcl injection solution 100 mg/ml, 500 mg/ml	МВ	
PROVENGE INTRAVENOUS SUSPENSION	МВ	PA; DX (Diagnosis Validation Required)
romidepsin intravenous solution 27.5 mg/5.5ml	МВ	PA; DX (Diagnosis Validation Required)
saline flush intravenous solution 0.9 %	MB	
SALINE FLUSH ZR INTRAVENOUS SOLUTION 0.9 %	MB	
SANDOSTATIN LAR DEPOT INTRAMUSCULAR KIT 10 MG, 20 MG, 30 MG	МВ	
SKYLA INTRAUTERINE INTRAUTERINE DEVICE 13.5 MG	\$0	\$0 (\$0 Copay per PPACA guidelines.)
sodium chloride flush intravenous solution 0.9 %	MB	
sodium chloride intravenous solution 0.9 %	MB	
SWABFLUSH SALINE FLUSH INTRAVENOUS SOLUTION 0.9 %	MB	
TESTOPEL IMPLANT PELLET 75 MG	MB	PA; QL (6 EA per 90 days)
TRAZIMERA INTRAVENOUS SOLUTION RECONSTITUTED 420 MG	МВ	DX (Diagnosis Validation Required)
TRODELVY INTRAVENOUS SOLUTION RECONSTITUTED 180 MG	MB	PA; DX (Diagnosis Validation Required)

MPC032520 217 Effective: 09/15/2025

Drug Name	Tier	Notes
TYSABRI INTRAVENOUS CONCENTRATE 300 MG/15ML	MB	PA; DX (Diagnosis Validation Required); SP
UDENYCA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML	MB	PA; NDS; SP
VARIZIG INTRAMUSCULAR SOLUTION 125 UNIT/1.2ML	МВ	PA
VARIZIG INTRAMUSCULAR SOLUTION RECONSTITUTED 125 UNIT	МВ	PA
VENOFER INTRAVENOUS SOLUTION 20 MG/ML	MB	
VIVITROL INTRAMUSCULAR SUSPENSION RECONSTITUTED 380 MG	5	BH (Formulary prescription drugs used for the treatment of mental illness, behavioral health or substance use may be covered at zero share. * High Deductible Health Plan copays/coinsurances are subject to deductible first. Coverage at no cost share is subject to applicable benefit plans.); QL (1 EA per 28 days); NDS
XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED 150 MG	MB	PA; NDS; SP
YERVOY INTRAVENOUS SOLUTION 200 MG/40ML, 50 MG/10ML	MB	PA; DX (Diagnosis Validation Required)
ZALTRAP INTRAVENOUS SOLUTION 100 MG/4ML, 200 MG/8ML	MB	PA; DX (Diagnosis Validation Required)
ZIRABEV INTRAVENOUS SOLUTION 100 MG/4ML, 400 MG/16ML	MB	PA; DX (Diagnosis Validation Required)
ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG, 3.6 MG	MB	DX (Diagnosis Validation Required)
zoledronic acid intravenous concentrate 4 mg/5ml	MB	
zoledronic acid intravenous solution 5 mg/100ml	MB	